CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
11024230,110242305,5,F,,20200720,20150413,20200721,EXP,,CA-ABBVIE-15P-028-1372737-00,ABBVIE,,32,YR,,M,Y,53,KG,20200721,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction,110242305,OT,,,,,,,,,110242305,1,Product used for unknown indication
11721294,117212943,3,F,,20200831,20151111,20200915,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15386592,BRISTOL MYERS SQUIBB,"LAKHI N, GOVIND A. IMPLANON FAILURE IN PATIENTS ON ANTIRETROVIRAL MEDICATION: THE IMPORTANCE OF DISCLOSURE. JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE. 2010?36(3):181?2",33,YR,,F,Y,,,20200915,,MD,US,US,SUSTIVA,Drug interaction;Live birth;Maternal exposure during pregnancy;Pregnancy with implant contraceptive,,,,,117212943,1,200701,,,,117212943,1,HIV infection
11739131,117391318,8,F,,20200826,20151113,20200902,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-17476250,BRISTOL MYERS SQUIBB,SUSMAN ED. EFAVIRENZ TIED TO NEUROLOGICAL BIRTH DEFECTS. CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS. 2013,,,,,Y,,,20200902,,HP,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Pachygyria,117391318,CA,,,,,,,,,117391318,1,Product used for unknown indication
11748560,117485603,3,F,,20200710,20151117,20200720,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-18707349,BRISTOL MYERS SQUIBB,SUSMAN ED. EFAVIRENZ TIED TO NEUROLOGICAL BIRTH DEFECTS. CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS. 2013,,,N,,Y,,,20200720,,HP,FR,FR,SUSTIVA,Congenital cerebral cyst;Foetal exposure during pregnancy,117485603,OT,,,,,,,,,117485603,1,Product used for unknown indication
11853427,118534272,2,F,20010322,20200910,20151218,20200921,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-10850311,BRISTOL MYERS SQUIBB,,0,DY,,M,Y,3.24,KG,20200921,,HP,US,US,EFAVIRENZ.,Cystic fibrosis;Foetal exposure during pregnancy;Meconium ileus,118534272,OT,,,118534272,1,20000810,20000810,,,118534272,1,Product used for unknown indication
11858629,1185862910,10,F,,20200629,20151222,20200712,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2007-000002,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20200712,,MD,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Heart disease congenital,1185862910,CA,,,1185862910,1,20051201,20071211,,,1185862910,1,Product used for unknown indication
11858664,118586643,3,F,20010322,20200916,20151222,20200918,EXP,,US-009507513-01050823,MERCK,,1,DY,,M,Y,3.24,KG,20200918,,CN,US,US,SUSTIVA,Cystic fibrosis;Foetal exposure during pregnancy;Meconium ileus,118586643,OT,,,118586643,1,20001109,20000810,,,118586643,1,HIV infection
11937618,119376189,9,F,,20200722,20160122,20200728,EXP,,CA-009507513-1601CAN007640,MERCK,,54,YR,,M,Y,,,20200728,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,119376189,OT,,,,,,,,,119376189,1,Product used for unknown indication
11991033,1199103313,13,F,,20200706,20160202,20200715,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-004939,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20200715,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,1199103313,OT,,,,,,,,,1199103313,1,HIV infection
12476264,124762642,2,F,,20200820,20160617,20200902,EXP,,US-CIPLA LTD.-2016US07171,CIPLA,,,,,,Y,,,20200902,,HP,US,PE,EFAVIRENZ.,Adverse event;Virologic failure,124762642,OT,,,,,,,,,124762642,1,HIV infection
12476269,124762692,2,F,,20200820,20160617,20200903,EXP,,US-CIPLA LTD.-2016US06890,CIPLA,,,,,,Y,,,20200903,,HP,US,PE,EFAVIRENZ.,Kaposi's sarcoma AIDS related;Virologic failure,124762692,OT,,,,,,,,,124762692,1,HIV infection
12892681,128926812,2,F,,20200820,20161028,20200902,EXP,,GB-CIPLA LTD.-2016US20054,CIPLA,,,,,,Y,,,20200902,,HP,ES,GB,EFAVIRENZ.,Cardiac disorder,128926812,OT,,,,,,,,,128926812,1,HIV infection
12892747,128927472,2,F,,20200820,20161028,20200903,EXP,,GB-CIPLA LTD.-2016US20049,CIPLA,,,,,,Y,,,20200903,,HP,ES,GB,EFAVIRENZ.,Cardiac disorder,128927472,OT,,,,,,,,,128927472,1,HIV infection
12901876,129018762,2,F,,20200820,20161102,20200903,EXP,,GB-CIPLA LTD.-2016US20057,CIPLA,,,,,,Y,,,20200903,,HP,ES,GB,EFAVIRENZ.,Cardiac disorder,129018762,OT,,,,,,,,,129018762,1,HIV infection
12901926,129019262,2,F,,20200820,20161102,20200902,EXP,,GB-CIPLA LTD.-2016US20058,CIPLA,,,,,,Y,,,20200902,,HP,ES,GB,EFAVIRENZ.,Cardiac disorder,129019262,OT,,,,,,,,,129019262,2,HIV infection
12985056,129850566,6,F,,20200909,20161129,20200918,EXP,,CA-APOTEX-2016AP014805,APOTEX,,52,YR,,M,Y,,,20200918,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,129850566,CA,,,,,,,,,129850566,1,HIV infection
14301231,143012312,2,F,,20200917,20171219,20200928,EXP,,CA-APOTEX-2017AP022577,APOTEX,,,,,M,Y,,,20200928,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction,143012312,HO,,,,,,,,,143012312,1,Product used for unknown indication
14306973,143069738,8,F,,20200917,20171220,20200928,EXP,,CA-APOTEX-2017AP022582,APOTEX,,54,YR,,M,Y,,,20200928,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities,143069738,OT,,,,,,,,,143069738,1,Bipolar disorder
14307055,143070553,3,F,,20200720,20171220,20200728,EXP,,CA-APOTEX-2017AP022586,APOTEX,,,,,M,Y,,,20200728,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction,143070553,DE,,,,,,,,,143070553,1,Product used for unknown indication
14366162,143661622,2,F,,20200722,20180109,20200724,EXP,,CA-009507513-1801CAN001991,MERCK,,,,,,Y,,,20200724,,HP,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,143661622,OT,,,,,,,,,143661622,1,HIV infection
14485393,144853934,4,F,20180112,20180201,20180205,20200806,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-010659,BRISTOL MYERS SQUIBB,,21,YR,,F,Y,,,20200806,,HP,UG,UG,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Premature delivery,144853934,OT,,,144853934,1,20171206,,,,144853934,1,HIV infection
14608010,146080103,3,F,,20190905,20180307,20200727,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK038183,GLAXOSMITHKLINE,,52,YR,,M,Y,,,20200727,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,146080103,OT,,,,,,,,,146080103,1,HIV infection
14612446,146124463,3,F,,20190905,20180308,20200727,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2018GSK038183,VIIV,,52,YR,,M,Y,,,20200727,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,146124463,OT,,,,,,,,,146124463,1,HIV infection
14652614,146526145,5,F,,20200917,20180319,20200929,EXP,,CA-APOTEX-2018AP007741,APOTEX,,44,YR,,M,Y,,,20200929,,CN,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,146526145,OT,,,,,,,,,146526145,1,Psychotic disorder
14689574,146895746,6,F,,20200724,20180328,20200730,EXP,,IE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-007426,BRISTOL MYERS SQUIBB,"BRODERICK C, QUINLAN C, GULMANN C, O^KANE M. RECALCITRANT CUTANEOUS SARCOIDOSIS, WITH RESPONSE TO DAYLIGHT PHOTODYNAMIC THERAPY. AUTUMN MEETING OF THE IRISH ASSOCIATION OF DERMATOLOGISTS. 2016",37,YR,,F,Y,,,20200730,,HP,IE,IE,EFAVIRENZ.,Cushingoid;Drug ineffective;Intentional product use issue;Leukopenia;Skin atrophy,146895746,OT,,,,,,,,,146895746,1,Sarcoidosis
14854194,148541943,3,F,,20180509,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-039831,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Placental disorder;Stillbirth,148541943,OT,,,,,,,,,148541943,1,HIV infection
14854269,148542693,3,F,,20180509,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041218,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Placental disorder;Stillbirth,148542693,OT,,,,,,,,,148542693,1,HIV infection
14854271,148542713,3,F,,20180509,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041223,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Stillbirth,148542713,OT,,,,,,,,,148542713,1,HIV infection
14854272,148542723,3,F,,20180509,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041222,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Stillbirth,148542723,OT,,,,,,,,,148542723,1,HIV infection
14854273,148542733,3,F,,20180509,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041221,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Placental disorder;Stillbirth,148542733,OT,,,,,,,,,148542733,1,HIV infection
14854274,148542743,3,F,,20180509,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041219,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Placental disorder;Stillbirth,148542743,OT,,,,,,,,,148542743,1,HIV infection
14854276,148542763,3,F,,20180509,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041220,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Placental disorder;Stillbirth,148542763,OT,,,,,,,,,148542763,1,HIV infection
14854352,148543523,3,F,,20180509,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041224,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Stillbirth,148543523,OT,,,,,,,,,148543523,1,HIV infection
14854415,148544153,3,F,,20180509,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041225,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Stillbirth,148544153,OT,,,,,,,,,148544153,1,HIV infection
14854423,148544233,3,F,,20180509,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041226,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Stillbirth,148544233,OT,,,,,,,,,148544233,1,HIV infection
14854441,148544413,3,F,,20180509,20180507,20200806,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041227,BRISTOL MYERS SQUIBB,"ZASH R, JENGELA M, ROBERTS D, SOUDA S, DISEKO M, MORGAN S ET AL. PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV?INFECTED WOMEN. INTERNATIONAL ANTIVIRAL SOCIETY. 2018?26(SUPPL 1):373S",,,,F,Y,,,20200806,,HP,US,BW,EFAVIRENZ.,Intentional product use issue;Maternal exposure during pregnancy;Stillbirth,148544413,OT,,,,,,,,,148544413,1,HIV infection
14931261,149312617,7,F,,20200612,20180524,20200817,EXP,,CA-ROCHE-2126762,ROCHE,,52,YR,,M,Y,,,20200817,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,149312617,OT,,,,,,,,,149312617,1,HIV infection
15017775,150177751,1,I,20171024,20180611,20180615,20180615,EXP,,BY-PFIZER INC-2018240162,PFIZER,,42,YR,,M,Y,60,KG,20180615,,MD,BY,BY,EFAVIRENZ.,Hypoacusis,150177751,DS,,,150177751,1,20170928,20171220,,,,,
15036119,150361191,1,I,20171024,20180612,20180620,20180620,EXP,,PHHY2018BY023631,NOVARTIS,,42,YR,,M,Y,132.3,KG,20180620,,CN,JP,BY,EFAVIRENZ.,Hypoacusis;Incorrect product administration duration,150361191,DS,,,150361191,1,20170928,20171220,,,150361191,1,Product used for unknown indication
15058934,150589342,2,F,,20200629,20180625,20200708,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2018111756,VIIV,,52,YR,,M,Y,,,20200708,,HP,COUNTRY NOT SPECIFIED,PT,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective for unapproved indication;Drug interaction;Genotype drug resistance test positive;Infection,150589342,OT,,,,,,,,,150589342,1,HIV infection
15112110,151121106,6,F,20171006,20200831,20180705,20200903,EXP,,GB-GILEAD-2018-0347708,GILEAD,,,,N,M,Y,,,20200903,,MD,GB,GB,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18;Ultrasound antenatal screen,151121106,CA,,,151121106,1,20171006,20180205,,,151121106,1,HIV infection
15123625,1512362526,26,F,20180205,20200814,20180710,20200827,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-060524,BRISTOL MYERS SQUIBB,,43,YR,,F,Y,,,20200827,,HP,GB,GB,EFAVIRENZ.,Abortion spontaneous;Intentional product use issue;Maternal exposure during pregnancy,1512362526,OT,,,1512362526,1,20171006,20180205,,,1512362526,1,HIV infection
15123626,1512362620,20,F,20171006,20200814,20180710,20200827,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-063878,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20200827,,HP,GB,GB,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,1512362620,CA,,,1512362620,1,20171006,,,,1512362620,1,Product used for unknown indication
15214568,152145684,4,F,2005,20200910,20180730,20200917,EXP,,FR-VIIV HEALTHCARE LIMITED-B0561595A,VIIV,,25,YR,,F,Y,,,20200917,,HP,FR,FR,EFAVIRENZ.,Abortion induced;Exposure during pregnancy;Folate deficiency;Insomnia;Vertigo,152145684,OT,,,152145684,1,20050908,20050908,,,152145684,1,HIV infection
15248149,152481499,9,F,20050813,20200918,20180807,20200929,EXP,,"FR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-002639",BOEHRINGER INGELHEIM,,25,YR,A,F,Y,56,KG,20200929,,HP,FR,FR,EFAVIRENZ.;SUSTIVA,Abortion induced;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,152481499,OT,,,152481499,1,20050908,20050908,,,152481499,1,HIV infection
15362898,153628982,2,F,,20180827,20180907,20200806,PER,,ID-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-081902,BRISTOL MYERS SQUIBB,"IKHSAN M, YUWAAFII M. GRAVES DISEASE AS MANIFESTATION OF IMMUNE RECONSTITUTION SYNDROME IN A PREGNANT PATIENT WITH HIV/AIDS RECEIVING ANTIRETROVIRAL THERAPY. ENDOCRINE PRACTICE. 2018?24(1):270?1",36,YR,,F,Y,,,20200806,,HP,ID,US,EFAVIRENZ.,Basedow's disease;Immune reconstitution inflammatory syndrome;Intentional product use issue;Maternal exposure during pregnancy;Normal newborn,153628982,OT,,,,,,,,,153628982,1,HIV infection
15463860,154638604,4,F,2018,20200630,20181004,20200701,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2018GSK177825,VIIV,,6,WK,,,Y,,,20200701,,MD,ZA,ZA,EFAVIRENZ.,Umbilical hernia,154638604,CA,,,154638604,1,20180628,20200326,,,154638604,1,HIV infection
15480679,154806795,5,F,20050813,20200918,20181010,20200926,EXP,,PHHY2009FR075290,NOVARTIS,,25,YR,,F,Y,56,KG,20200926,,CN,FR,FR,EFAVIRENZ.;SUSTIVA,Exposure during pregnancy;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,154806795,HO,,,154806795,1,20050513,20050908,,,154806795,1,HIV infection
15626751,1562675110,10,F,,20200704,20181116,20200707,EXP,,CA-ABBVIE-18S-028-2552613-00,ABBVIE,,54,YR,,M,Y,,,20200707,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,1562675110,DE,,,,,,,,,1562675110,1,HIV infection
15645863,156458632,2,F,2011,20200713,20181121,20200904,PER,,US-GILEAD-2018-0375758,GILEAD,,,,A,M,Y,75.74,KG,20200904,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;Osteopenia;Pain,156458632,OT,,,156458632,1,201102,20120519,,,156458632,1,HIV infection
15651977,156519773,3,F,2017,20200715,20181123,20200831,EXP,,US-GILEAD-2018-0375835,GILEAD,,,,A,M,Y,117.01,KG,20200831,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Foot fracture;Osteoporosis;Pain,156519773,OT,,,156519773,1,2001,2012,,,156519773,1,HIV infection
15651984,156519842,2,F,20110114,20200716,20181123,20200828,EXP,,US-GILEAD-2018-0375837,GILEAD,,50,YR,A,F,Y,81.63,KG,20200828,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Depression;Economic problem;Emotional distress;Foot fracture;Glomerular filtration rate abnormal;Osteopenia;Osteoporosis;Pain,156519842,OT,,,156519842,1,2003,2017,,,156519842,1,HIV infection
15652130,156521302,2,F,20130513,20200712,20181123,20200717,EXP,,US-GILEAD-2018-0376062,GILEAD,,45,YR,A,F,Y,47.62,KG,20200717,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Osteopenia;Osteoporosis;Pain,156521302,OT,,,156521302,1,2011,2013,,,156521302,1,HIV infection
15652140,156521402,2,F,20161101,20200811,20181123,20200902,EXP,,US-GILEAD-2018-0376073,GILEAD,,33,YR,A,M,Y,97.51,KG,20200902,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Diarrhoea;Economic problem;Emotional distress;Pain;Pollakiuria,156521402,OT,,,156521402,1,2006,2006,,,156521402,1,Product used for unknown indication
15652214,156522142,2,F,20160401,20200813,20181123,20200904,PER,,US-GILEAD-2018-0376074,GILEAD,,54,YR,A,F,Y,107.48,KG,20200904,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Loss of personal independence in daily activities;Osteopenia;Pain,,,,,156522142,1,2001,2004,,,156522142,1,HIV infection
15656869,156568692,2,F,2014,20200715,20181126,20200824,PER,,US-GILEAD-2018-0376047,GILEAD,,61,YR,A,F,Y,120.64,KG,20200824,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Chronic kidney disease;Economic problem;Emotional distress;Pain;Renal pain,156568692,OT,,,156568692,1,2004,2013,,,156568692,1,HIV infection
15661445,156614453,3,F,2018,20200715,20181127,20200831,EXP,,US-GILEAD-2018-0376064,GILEAD,,38,YR,A,M,Y,,,20200831,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Pain,156614453,DE,,,156614453,1,20111221,20120120,,,156614453,1,HIV infection
15661710,156617104,4,F,2010,20200720,20181127,20200914,PER,,US-GILEAD-2018-0376139,GILEAD,,,,A,M,Y,89.8,KG,20200914,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Off label use;Pain,156617104,OT,,,156617104,1,2010,2013,,,156617104,1,Product used for unknown indication
15758795,157587952,2,F,,20200706,20181225,20200708,EXP,,PHHY2018PT192603,NOVARTIS,"FERRO F, FALCAO P, PIRES D, LUIS R, FREITAS F, MONTIRO P ET AL.. PRESENTACAO ENDOSCOPICA DE MYCOBACTERIUM SIMIAE. PULMONOLOGY. 2018?24 (4):82",30,YR,,M,Y,,,20200708,,HP,PT,PT,EFAVIRENZ.,Product use in unapproved indication;Seizure,157587952,OT,,,,,,,,,157587952,1,Mycobacterial infection
15897393,158973932,2,F,20090119,20200715,20190131,20200831,EXP,,US-GILEAD-2019-0387829,GILEAD,,58,YR,A,M,Y,72.56,KG,20200831,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;Fear;Osteopenia;Osteoporosis;Pain;Stress,158973932,OT,,,158973932,1,2001,200705,,,158973932,1,HIV infection
15902280,159022802,2,F,2016,20200709,20190201,20200824,PER,,US-GILEAD-2019-0387827,GILEAD,,47,YR,A,M,Y,72.56,KG,20200824,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Economic problem;Emotional distress;Fatigue;Pain;Protein urine present;Quality of life decreased;Renal failure,159022802,OT,,,159022802,1,200805,2015,,,159022802,1,HIV infection
15920730,159207302,2,F,201310,20200715,20190205,20200729,EXP,,US-GILEAD-2019-0387816,GILEAD,,61,YR,A,M,Y,,,20200729,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Economic problem;Emotional distress;Loss of libido;Loss of personal independence in daily activities;Osteopenia;Pain;Renal impairment,159207302,OT,,,159207302,1,201310,201510,,,159207302,1,HIV infection
15923667,159236674,4,F,20051019,20200915,20190206,20200922,EXP,,FR-AUROBINDO-AUR-APL-2019-006030,AUROBINDO,,36,YR,,F,Y,82,KG,20200922,,CN,FR,FR,SUSTIVA,Abdominal pain;Chills;Diarrhoea;Eyelid oedema;Lip oedema;Pyrexia;Rash;Thrombocytopenia,159236674,HO,,,159236674,1,20051201,20051202,,,159236674,1,Pyrexia
16009753,160097539,9,F,20181001,20200903,20190225,20200911,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-017261,BRISTOL MYERS SQUIBB,"ZASH R, HOLMES L, DISEKO M, JACOBSON DL, BRUMMEL S, MAYONDI G, ET AL. NEURAL?TUBE DEFECTS AND ANTIRETROVIRAL TREATMENT REGIMENS IN BOTSWANA. THE NEW ENGLAND JOURNAL OF MEDICINE. 2019",42,YR,,F,Y,,,20200911,,HP,BW,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,160097539,OT,,,,,,,,,160097539,1,HIV infection
16020890,1602089011,11,F,,20200806,20190301,20200818,EXP,,CA-AUROBINDO-AUR-APL-2019-010743,AUROBINDO,,54,YR,,M,Y,,,20200818,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,1602089011,OT,,,,,,,,,1602089011,1,HIV infection
16064851,160648518,8,F,2017,20200817,20190312,20200820,EXP,,US-ABBVIE-19K-163-2698768-00,ABBVIE,,71,YR,,M,Y,73.55,KG,20200819,,CN,US,US,SUSTIVA,Axillary mass;Axillary pain;Blood disorder;Cataract;Decreased appetite;Erectile dysfunction;Eye pruritus;Foot deformity;HIV infection;Hand deformity;Hypoacusis;Infection;Infectious thyroiditis;Mobility decreased;Nasopharyngitis;Neoplasm;Neoplasm skin;Pain;Psoriasis;Psoriatic arthropathy;Rhinitis;Skin discolouration;Subcutaneous abscess;Weight increased;Wound secretion,160648518,OT,,,160648518,1,20150504,201901,,,160648518,1,Psoriatic arthropathy
16080755,160807554,4,F,,20200805,20190316,20200813,EXP,,CA-AUROBINDO-AUR-APL-2019-013379,AUROBINDO,,44,YR,,M,Y,,,20200813,,HP,CA,CA,SUSTIVA,Anxiety,160807554,HO,,,,,,,,,160807554,1,Psychotic disorder
16081155,160811553,3,F,,20200909,20190316,20200915,EXP,,CA-AUROBINDO-AUR-APL-2019-013363,AUROBINDO,,54,YR,,M,Y,,,20200915,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,160811553,OT,,,,,,,,,160811553,1,HIV infection
16213513,162135134,4,F,2010,20200505,20190418,20200819,PER,,US-GILEAD-2019-0402870,GILEAD,,,,A,M,Y,64.4,KG,20200819,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Osteoporosis;Pain;Renal failure;Tooth loss,162135134,OT,,,162135134,1,200901,201901,,,162135134,1,HIV infection
16214079,162140793,3,F,201005,20200519,20190418,20200819,PER,,US-GILEAD-2019-0402864,GILEAD,,47,YR,A,M,Y,86.62,KG,20200819,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;Inflammation;Insomnia;Pain,162140793,OT,,,162140793,1,200401,200612,,,162140793,1,HIV infection
16272580,162725803,3,F,2016,20200519,20190503,20200824,EXP,,US-GILEAD-2019-0405402,GILEAD,,52,YR,A,M,Y,100.23,KG,20200823,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone density decreased;Bone loss;Economic problem;Emotional distress;Osteonecrosis;Osteopenia;Pain,162725803,OT,,,162725803,1,201109,201812,,,162725803,1,HIV infection
16288958,162889586,6,F,20050813,20200916,20190509,20200923,EXP,,FR-AUROBINDO-AUR-APL-2019-026163,AUROBINDO,,25,YR,,F,Y,56,KG,20200923,,CN,US,FR,SUSTIVA,Abortion induced;Exposure during pregnancy;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,162889586,HO,,,162889586,1,20050620,20050908,,,162889586,1,HIV infection
16321127,163211274,4,F,20040608,20200604,20190516,20200820,PER,,US-GILEAD-2019-0407768,GILEAD,,57,YR,A,M,Y,65.76,KG,20200820,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Osteopenia;Pain;Proteinuria,163211274,OT,,,163211274,1,200404,2005,,,163211274,1,HIV infection
16321491,163214912,2,F,20090501,20200729,20190516,20200831,PER,,US-GILEAD-2019-0407756,GILEAD,,40,YR,A,M,Y,217,KG,20200831,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone pain;Chronic kidney disease;Drug resistance;Economic problem;Emotional distress;Fanconi syndrome acquired;Gait disturbance;Pain;Renal impairment,163214912,OT,,,163214912,1,2001,20091017,,,163214912,1,HIV infection
16325122,163251222,2,F,20120922,20200627,20190517,20200819,EXP,,US-GILEAD-2019-0407763,GILEAD,,43,YR,A,M,Y,,,20200819,,CN,US,US,EFAVIRENZ.;SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Economic problem;Emotional distress;End stage renal disease;Glomerular filtration rate decreased;Pain,163251222,OT,,,163251222,1,2005,,,,163251222,1,HIV infection
16326345,163263452,2,F,200211,20200814,20190517,20200904,EXP,,US-GILEAD-2019-0407770,GILEAD,,39,YR,A,F,Y,62.59,KG,20200904,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Economic problem;Emotional distress;Fatigue;Loss of personal independence in daily activities;Osteoporosis;Pain,163263452,OT,,,163263452,1,2003,20130104,,,163263452,1,HIV infection
16333019,163330192,2,F,2009,20200815,20190520,20200908,EXP,,US-GILEAD-2019-0407859,GILEAD,,44,YR,A,M,Y,56.69,KG,20200908,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Degenerative bone disease;Economic problem;Emotional distress;Osteoporosis;Pain,163330192,OT,,,163330192,1,20071214,20120913,,,163330192,1,HIV infection
16333090,163330902,2,F,20120412,20200714,20190520,20200723,PER,,US-GILEAD-2019-0407953,GILEAD,,42,YR,A,M,Y,111.11,KG,20200723,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;Pain;Proteinuria;Renal disorder;Renal impairment,163330902,OT,,,163330902,1,2007,20160407,,,163330902,1,HIV infection
16333242,163332422,2,F,2015,20200811,20190520,20200831,PER,,US-GILEAD-2019-0407824,GILEAD,,39,YR,A,F,Y,65.76,KG,20200831,,CN,US,US,EFAVIRENZ.;SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Depression;Economic problem;Emotional distress;Exercise tolerance decreased;Fatigue;General physical health deterioration;Pain;Quality of life decreased;Renal failure,163332422,OT,,,163332422,1,2010,20120202,,,163332422,1,HIV infection
16334713,163347134,4,F,2008,20200904,20190520,20200925,EXP,,US-GILEAD-2019-0408522,GILEAD,,,,A,M,Y,75.7,KG,20200925,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Economic problem;Emotional distress;Femoral neck fracture;Osteomalacia;Osteopenia;Osteoporosis;Osteoporotic fracture;Pain;Tooth loss,163347134,OT,,,163347134,1,200402,201303,,,163347134,1,HIV infection
16340936,163409362,2,F,2016,20200729,20190522,20200831,EXP,,US-GILEAD-2019-0407997,GILEAD,,,,A,F,Y,69.84,KG,20200831,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Economic problem;Emotional distress;Fear;Femur fracture;General physical health deterioration;Hand fracture;Hip fracture;Osteoporosis;Pain;Post-traumatic stress disorder;Quality of life decreased;Radius fracture;Tibia fracture;Wheelchair user,163409362,OT,,,163409362,1,2009,2015,,,163409362,1,HIV infection
16342541,163425412,2,F,2011,20200611,20190522,20200821,EXP,,US-GILEAD-2019-0407993,GILEAD,,59,YR,A,F,Y,78.91,KG,20200821,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone loss;Depression;Economic problem;Emotional distress;General physical health deterioration;Hip arthroplasty;Osteopenia;Osteoporosis;Pain;Quality of life decreased,163425412,OT,,,163425412,1,2004,20161012,,,163425412,1,HIV infection
16350708,163507083,3,F,201503,20200427,20190524,20200807,EXP,,US-GILEAD-2019-0409332,GILEAD,,44,YR,A,M,Y,,,20200807,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Osteoporosis;Pain;Renal failure;Spinal fracture,163507083,HO,,,163507083,1,2009,2011,,,163507083,1,HIV infection
16428713,164287133,3,F,,20200630,20190613,20200707,EXP,,MY-GILEAD-2019-0413166,GILEAD,"KOH K, IBRAHIM N, ONG S. PARADOXICAL WORSENING OF CHEST RADIOGRAPHS SECONDARY TO IMMUNE RECONSTITUTION SYNDROME (IRIS) IN A PATIENT WITH ADVANCED HIV INFECTION AND RHODOCOCCUS PNEUMONIA. MED J MALAYSIA. 2020?75:164?166",38,YR,A,M,Y,,,20200707,,MD,MY,MY,EFAVIRENZ.,Chest X-ray abnormal;Immune reconstitution inflammatory syndrome;Pneumonia bacterial,164287133,OT,,,,,,,,,164287133,1,HIV infection
16430786,164307864,4,F,2005,20200422,20190614,20200828,EXP,,US-GILEAD-2019-0413028,GILEAD,,,,A,M,Y,,,20200828,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Economic problem;Emotional distress;Osteonecrosis;Pain;Renal cyst;Tooth loss,164307864,OT,,,164307864,1,2005,2010,,,164307864,1,HIV infection
16439860,164398602,2,F,,20200722,20190617,20200730,EXP,,CA-009507513-1906CAN005466,MERCK,,,,,M,Y,,,20200730,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,164398602,DE,,,,,,,,,164398602,1,Product used for unknown indication
16475912,164759124,4,F,1996,20200901,20190625,20200909,EXP,,IT-MYLANLABS-2019M1058328,MYLAN,"LANZAFAME M, LATTUADA E, RIZZARDO S, PIACENTINI D, CHIESI S, MAZZI R.. DOLUTEGRAVIR MONOTHERAPY^S VIROLOGICAL EFFICACY IN A HIGHLY TREATMENT?EXPERIENCED PATIENT.. AIDS RESEARCH AND HUMAN RETROVIRUSES.. 2019",74,YR,,F,Y,,,20200909,,HP,IT,IT,EFAVIRENZ.,Drug resistance;Genotype drug resistance test negative;Treatment failure;Treatment noncompliance;Virologic failure,164759124,OT,,,164759124,1,2005,2009,,,164759124,1,HIV infection
16549483,165494833,3,F,,20200807,20190710,20200818,EXP,,CA-AUROBINDO-AUR-APL-2019-037892,AUROBINDO,,54,YR,,M,Y,,,20200818,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,165494833,OT,,,,,,,,,165494833,1,Product used for unknown indication
16580930,165809306,6,F,,20200821,20190716,20200828,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2019AMR117290,VIIV,,,,,M,Y,100,KG,20200828,,MD,BR,BR,EFAVIRENZ.,Arthritis infective;Back pain;C-reactive protein;CD4 lymphocytes increased;Colitis microscopic;Condition aggravated;Diarrhoea;Gait disturbance;Joint effusion;Joint swelling;Malaise;Neuritis;Neurosyphilis;Oedema peripheral;Pain;Pericardial effusion;Pleural effusion;Psoriatic arthropathy;Rheumatic disorder;Spinal deformity;White blood cell disorder;Wound secretion,165809306,OT,,,165809306,1,201902,,,,165809306,1,HIV infection
16580959,165809596,6,F,,20200821,20190716,20200828,EXP,,BR-GLAXOSMITHKLINE-BR2019AMR117290,GLAXOSMITHKLINE,,,,,M,Y,100,KG,20200828,,MD,BR,BR,EFAVIRENZ.,Arthritis infective;Back pain;C-reactive protein;CD4 lymphocytes increased;Colitis microscopic;Condition aggravated;Diarrhoea;Gait disturbance;Joint effusion;Joint swelling;Malaise;Neuritis;Neurosyphilis;Oedema peripheral;Pain;Pericardial effusion;Pleural effusion;Psoriatic arthropathy;Rheumatic disorder;Spinal deformity;White blood cell disorder;Wound secretion,165809596,HO,,,165809596,1,201902,,,,165809596,1,HIV infection
16596270,165962703,3,F,20120805,20200918,20190719,20200928,EXP,,US-GILEAD-2019-0418471,GILEAD,,42,YR,A,M,Y,79.37,KG,20200928,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Nephrolithiasis;Pain;Proteinuria;Renal failure,165962703,OT,,,165962703,1,2010,2019,,,165962703,1,HIV infection
16608959,166089596,6,F,2009,20200904,20190722,20200925,EXP,,US-GILEAD-2019-0419331,GILEAD,,,,A,M,Y,97.51,KG,20200925,,LW,US,US,SUSTIVA,Anxiety;Blood creatinine increased;Bone density decreased;Bone loss;Coma;Dental caries;Depression;Emotional distress;Fracture;Gastric disorder;Glomerular filtration rate abnormal;Illness;Oesophageal disorder;Osteonecrosis;Osteoporosis;Pain;Protein total abnormal;Renal disorder;Tooth loss,166089596,OT,,,166089596,1,2009,2019,,,166089596,1,HIV infection
16622566,166225663,3,F,,20200914,20190723,20200928,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-069006,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,,,20200928,,CN,CA,CA,SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,166225663,OT,,,,,,,,,166225663,1,HIV infection
16634649,166346493,3,F,20181001,20200903,20190726,20200914,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2019022219,MACLEODS,,,,,,Y,,,20200914,,HP,US,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,166346493,OT,,,,,,,,,166346493,1,HIV infection
16635444,166354443,3,F,,20200731,20190726,20200812,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2019022220,MACLEODS,,,,,,Y,,,20200812,,HP,US,BW,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele,166354443,CA,,,,,,,,,166354443,1,Product used for unknown indication
16662141,166621418,8,F,2012,20200818,20190802,20200821,EXP,,PHHY2019AT170861,NOVARTIS,SCHALK H. DUALE ART IM NEBENWIRKUNGSMANAGEMENT. JATROS INFEKTIOLOGIE AND GASTROENTEROLOGIE?HEPATOLOGIE. 2019?2:22,69,YR,,M,Y,90,KG,20200821,,HP,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dizziness;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,166621418,OT,,,166621418,1,20031107,20040423,,,166621418,1,Antiretroviral therapy
16666980,166669803,3,F,200501,20200904,20190805,20200925,EXP,,US-GILEAD-2019-0421690,GILEAD,,40,YR,A,M,Y,83.9,KG,20200925,,CN,US,US,EFAVIRENZ.,Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;Pain,166669803,OT,,,166669803,1,200601,201001,,,166669803,1,HIV infection
16672048,166720485,5,F,20120420,20200924,20190806,20200928,EXP,,US-GILEAD-2019-0421735,GILEAD,,53,YR,A,M,Y,70.3,KG,20200928,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Economic problem;Emotional distress;Osteoporosis;Pain;Tooth loss,166720485,OT,,,166720485,1,20080826,20080831,,,166720485,1,HIV infection
16676304,166763043,3,F,2008,20200320,20190807,20200825,EXP,,US-GILEAD-2019-0421721,GILEAD,,46,YR,A,M,Y,81.63,KG,20200825,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Depression;Economic problem;Emotional distress;Loss of personal independence in daily activities;Osteonecrosis;Osteoporosis;Pain;Renal failure;Tooth loss,166763043,HO,,,166763043,1,200912,201907,,,166763043,1,HIV infection
16721263,167212632,2,F,201901,20200909,20190820,20200916,EXP,,US-ABBVIE-19K-163-2849740-00,ABBVIE,,65,YR,,M,Y,95.34,KG,20200916,,CN,US,US,SUSTIVA,Aphasia;Blood creatinine increased;Disorientation;Fall;Feeling abnormal;Incoherent;Infection;Nasopharyngitis;Pyrexia;Transient ischaemic attack;Tremor,167212632,HO,,,167212632,1,201701,201904,,,167212632,1,Psoriatic arthropathy
16758574,167585743,3,F,2013,20200520,20190830,20200831,EXP,,US-GILEAD-2019-0425696,GILEAD,,56,YR,A,M,Y,,,20200831,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Blood creatinine increased;Bone loss;Dental caries;Economic problem;Emotional distress;Oral disorder;Osteoporotic fracture;Pain,167585743,OT,,,167585743,1,20060615,2019,,,167585743,1,HIV infection
16774600,167746003,3,F,20180209,20200928,20190905,20200930,EXP,,US-GILEAD-2019-0425686,GILEAD,,54,YR,A,M,Y,72.56,KG,20200930,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Depression;Economic problem;Emotional distress;Hip fracture;Multiple injuries;Osteoporosis;Pain;Upper limb fracture,167746003,HO,,,167746003,1,201807,201901,,,167746003,1,HIV infection
16779164,167791643,3,F,201404,20200903,20190906,20200923,EXP,,US-GILEAD-2019-0426574,GILEAD,,47,YR,A,M,Y,108,KG,20200923,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Multiple fractures;Osteonecrosis;Pain;Renal failure,167791643,OT,,,167791643,1,20110609,201404,,,167791643,1,HIV infection
16779436,167794363,3,F,20151012,20200520,20190906,20200814,EXP,,US-GILEAD-2019-0426527,GILEAD,,53,YR,A,F,Y,,,20200814,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density abnormal;Bone density decreased;Bone loss;Chronic kidney disease;Economic problem;Emotional distress;Osteonecrosis;Pain;Tooth loss,167794363,OT,,,167794363,1,201505,201805,,,167794363,1,HIV infection
16785564,167855643,3,F,2013,20200615,20190909,20200831,EXP,,US-GILEAD-2019-0426593,GILEAD,,44,YR,A,F,Y,108.84,KG,20200831,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density abnormal;Bone density decreased;Bone loss;Economic problem;Emotional distress;Osteonecrosis;Osteoporosis;Pain,167855643,OT,,,167855643,1,2005,2006,,,167855643,1,HIV infection
16789078,167890786,6,F,2012,20200831,20190910,20200909,EXP,,US-GILEAD-2019-0426612,GILEAD,,48,YR,A,M,Y,123.36,KG,20200909,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Osteoporosis;Pain;Renal failure,167890786,OT,,,167890786,1,2012,2019,,,167890786,1,HIV infection
16806891,168068919,9,F,2001,20200831,20190913,20200911,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-086812,BRISTOL MYERS SQUIBB,"LOPEZ ASPIROZ E, CABRERA FIGUEROA SE, VALVERDE MERINO MP, CARRACEDO ALVAREZ A. INDIVIDUALIZED PROTEASE INHIBITOR MONOTHERAPY: THE ROLE OF PHARMACOKINETICS AND PHARMACOGENETICS IN AN AGED AND HEAVILY TREATED HIV?INFECTED PATIENT. CLINICAL DRUG INVESTIGATION. 2019?39 (11):1125?31",38,YR,,M,Y,,,20200911,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,168068919,OT,,,168068919,1,2001,2001,,,168068919,1,HIV infection
16824274,168242746,6,F,20060216,20200820,20190918,20200831,EXP,,FR-MYLANLABS-2019M1087495,MYLAN,,,,N,,Y,,,20200831,,CN,US,FR,EFAVIRENZ.,Brain herniation;Encephalocele;Foetal exposure during pregnancy;Spina bifida;Spinocerebellar disorder,168242746,CA,,,168242746,1,20050704,20050908,,,168242746,1,HIV infection
16824384,168243846,6,F,20070403,20200911,20190918,20200917,EXP,,FR-GILEAD-2019-0427918,GILEAD,,0,YR,N,M,Y,3.23,KG,20200917,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,168243846,CA,,,168243846,1,20070403,20070521,,,168243846,1,HIV infection
16829774,168297742,2,F,,20200703,20190919,20200713,EXP,,CA-TEVA-2019-CA-1109359,TEVA,,44,YR,,M,Y,,,20200713,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,168297742,HO,,,,,,,,,168297742,1,HIV infection
16832947,168329473,3,F,20150625,20200831,20190920,20200915,EXP,,US-GILEAD-2019-0428480,GILEAD,,38,YR,A,F,Y,63.49,KG,20200915,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Economic problem;Emotional distress;Pain;Renal failure,168329473,OT,,,168329473,1,200610,201705,,,168329473,1,HIV infection
16835292,168352928,8,F,,20200911,20190920,20200925,EXP,,FR-GLAXOSMITHKLINE-FR2019169921,GLAXOSMITHKLINE,,,,,M,Y,3.23,KG,20200925,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,168352928,CA,,,168352928,1,20070403,20070521,,,168352928,1,HIV infection
16835297,168352978,8,F,,20200911,20190920,20200925,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2019169921,VIIV,,,,,M,Y,3.23,KG,20200925,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,168352978,CA,,,168352978,1,20070403,20070521,,,168352978,1,HIV infection
16837681,168376812,2,F,201109,20200715,20190923,20200828,EXP,,US-GILEAD-2019-0429593,GILEAD,,67,YR,E,M,Y,,,20200828,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Decreased activity;Economic problem;Emotional distress;Insomnia;Loss of personal independence in daily activities;Osteopenia;Osteoporosis;Pain;Quality of life decreased,168376812,OT,,,168376812,1,2001,20080110,,,168376812,1,HIV infection
16837827,168378273,3,F,201607,20200722,20190923,20200730,PER,,US-GILEAD-2019-0429625,GILEAD,,64,YR,,M,Y,,,20200730,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Injury;Pain;Renal failure,168378273,DE,,,168378273,1,20150702,201507,,,168378273,1,HIV infection
16840765,168407653,3,F,201805,20200715,20190923,20200805,PER,,US-GILEAD-2019-0429232,GILEAD,,47,YR,A,M,Y,81.63,KG,20200805,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Blood creatinine increased;Decreased activity;Drug ineffective;Economic problem;Emotional distress;Fatigue;Loss of personal independence in daily activities;Pain;Pollakiuria;Quality of life decreased;Renal impairment,168407653,OT,,,168407653,1,2001,2011,,,168407653,1,HIV infection
16844259,168442592,2,F,20190822,20200715,20190924,20200804,PER,,US-GILEAD-2019-0429219,GILEAD,,54,YR,A,F,Y,58.96,KG,20200804,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;Osteopenia;Pain,,,,,168442592,1,2001,2018,,,168442592,1,HIV infection
16844386,168443862,2,F,20160122,20200709,20190924,20200828,EXP,,US-GILEAD-2019-0429662,GILEAD,,60,YR,A,M,Y,72.56,KG,20200828,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Emotional distress;Loss of personal independence in daily activities;Pain;Quality of life decreased,168443862,HO,,,168443862,1,2001,201901,,,168443862,1,HIV infection
16844478,168444782,2,F,2012,20200813,20190924,20200904,EXP,,US-GILEAD-2019-0429687,GILEAD,,,,A,M,Y,65.76,KG,20200904,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Decreased activity;Depression;Economic problem;Emotional distress;End stage renal disease;Insomnia;Loss of personal independence in daily activities;Osteoporosis;Pain;Quality of life decreased;Renal disorder;Renal failure;Renal impairment,168444782,OT,,,168444782,1,2001,2008,,,168444782,1,HIV infection
16844534,168445343,3,F,2017,20200708,20190924,20200915,EXP,,US-GILEAD-2019-0429756,GILEAD,,43,YR,A,M,Y,,,20200915,,CN,US,US,SUSTIVA,Acute kidney injury;Anaemia of chronic disease;Anhedonia;Anxiety;Asthenia;Decreased activity;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Impaired work ability;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal failure;Sluggishness,168445343,OT,,,168445343,1,2009,20140912,,,168445343,1,HIV infection
16845382,168453822,2,F,201503,20200818,20190924,20200904,EXP,,US-GILEAD-2019-0429703,GILEAD,,51,YR,A,M,Y,84.81,KG,20200904,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Decreased activity;Depression;Emotional distress;Fatigue;Mobility decreased;Osteoporosis;Pain;Quality of life decreased;Renal impairment,168453822,OT,,,168453822,1,2002,20181002,,,168453822,1,HIV infection
16845626,168456262,2,F,200404,20200710,20190924,20200828,EXP,,US-GILEAD-2019-0429615,GILEAD,,41,YR,A,M,Y,68.03,KG,20200828,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Fatigue;Pain;Quality of life decreased;Renal failure;Renal transplant,168456262,OT,,,168456262,1,2001,2017,,,168456262,1,HIV infection
16847030,168470302,2,F,20150409,20200703,20190924,20200820,EXP,,US-GILEAD-2019-0429491,GILEAD,,64,YR,A,F,Y,49.89,KG,20200820,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Decreased activity;Emotional distress;End stage renal disease;Fatigue;Loss of personal independence in daily activities;Mobility decreased;Osteopenia;Osteoporosis;Pain;Quality of life decreased,168470302,OT,,,168470302,1,20170601,2017,,,168470302,1,HIV infection
16848787,168487872,2,F,2005,20200812,20190925,20200904,EXP,,US-GILEAD-2019-0429707,GILEAD,,,,A,M,Y,92.97,KG,20200904,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;End stage renal disease;Fatigue;Loss of personal independence in daily activities;Pain;Renal failure,168487872,OT,,,168487872,1,2001,200602,,,168487872,1,HIV infection
16849240,168492402,2,F,20130510,20200613,20190925,20200820,EXP,,US-GILEAD-2019-0429708,GILEAD,,38,YR,A,F,Y,44.54,KG,20200820,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Arthritis;Decreased activity;Depression;Emotional distress;End stage renal disease;Fatigue;Loss of personal independence in daily activities;Multiple fractures;Osteonecrosis;Osteoporosis;Pain;Proteinuria;Quality of life decreased;Renal transplant;Spinal osteoarthritis,168492402,OT,,,168492402,1,20111013,20130131,,,168492402,1,HIV infection
16850098,168500982,2,F,2005,20200629,20190925,20200827,EXP,,US-GILEAD-2019-0429508,GILEAD,,41,YR,A,M,Y,77.1,KG,20200827,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Bone density decreased;Bone loss;Bone pain;Carpal tunnel syndrome;Decreased activity;Depression;Economic problem;Emotional distress;Grip strength decreased;Loss of personal independence in daily activities;Nephropathy;Osteopenia;Osteoporosis;Pain;Plantar fasciitis;Quality of life decreased;Tendonitis,168500982,OT,,,168500982,1,2001,2008,,,168500982,1,HIV infection
16850183,168501832,2,F,20160227,20200707,20190925,20200806,EXP,,US-GILEAD-2019-0429207,GILEAD,,35,YR,A,F,Y,,,20200806,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Chronic kidney disease;Economic problem;Emotional distress;Multiple injuries;Pain;Renal failure,168501832,HO,,,168501832,1,20150817,20161102,,,168501832,1,HIV infection
16850212,168502122,2,F,2017,20200814,20190925,20200904,EXP,,US-GILEAD-2019-0429610,GILEAD,,49,YR,A,M,Y,103.4,KG,20200904,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Arthralgia;Decreased activity;Depression;Dysstasia;Economic problem;Emotional distress;Fibula fracture;Gait disturbance;Impaired work ability;Loss of personal independence in daily activities;Musculoskeletal chest pain;Osteoporosis;Pain;Pain in extremity;Quality of life decreased;Rib fracture;Spinal fracture;Spinal pain,168502122,OT,,,168502122,1,2015,2016,,,168502122,1,HIV infection
16851521,168515213,3,F,2015,20200715,20190925,20200821,EXP,,US-GILEAD-2019-0429645,GILEAD,,25,YR,A,M,Y,135,KG,20200821,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Depressed mood;Economic problem;Emotional distress;Fatigue;Gait disturbance;Impaired work ability;Loss of personal independence in daily activities;Pain;Panic attack;Peripheral swelling;Quality of life decreased;Renal failure,168515213,OT,,,168515213,1,2005,2011,,,168515213,1,HIV infection
16851962,168519622,2,F,2010,20200716,20190925,20200828,EXP,,US-GILEAD-2019-0429428,GILEAD,,45,YR,A,F,Y,,,20200828,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Clavicle fracture;Decreased activity;Disturbance in attention;Economic problem;Emotional distress;Fatigue;Femoral neck fracture;Fine motor skill dysfunction;Foot fracture;Forearm fracture;Hip fracture;Loss of employment;Loss of personal independence in daily activities;Mobility decreased;Osteopenia;Osteoporosis;Pain;Personal relationship issue;Quality of life decreased;Renal failure;Rib fracture;Social problem;Upper limb fracture,168519622,OT,,,168519622,1,2003,2015,,,168519622,1,HIV infection
16852615,168526153,3,F,2006,20200715,20190925,20200902,EXP,,US-GILEAD-2019-0429663,GILEAD,,49,YR,A,F,Y,102.04,KG,20200902,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Dysstasia;Economic problem;Emotional distress;Fear;Gait disturbance;Insomnia;Loss of personal independence in daily activities;Mobility decreased;Osteoporosis;Pain;Quality of life decreased,168526153,OT,,,168526153,1,2004,201304,,,168526153,1,HIV infection
16852781,168527813,3,F,2017,20200320,20190925,20200831,EXP,,US-GILEAD-2019-0429286,GILEAD,,58,YR,A,M,Y,,,20200831,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease-mineral and bone disorder;Decreased activity;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Loss of personal independence in daily activities;Mobility decreased;Pain;Quality of life decreased,168527813,OT,,,168527813,1,200908,201403,,,168527813,1,HIV infection
16853159,168531592,2,F,200412,20200715,20190925,20200824,EXP,,US-GILEAD-2019-0429655,GILEAD,,66,YR,E,M,Y,58.96,KG,20200824,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Economic problem;Emotional distress;Fear;Foot fracture;Loss of personal independence in daily activities;Lower limb fracture;Osteopenia;Osteoporosis;Pain;Quality of life decreased;Renal impairment;Upper limb fracture,168531592,OT,,,168531592,1,20041115,20080926,,,168531592,1,HIV infection
16853616,1685361610,10,F,,20200928,20190926,20200929,EXP,,FR-ABBVIE-19K-056-2935895-00,ABBVIE,,11,YR,,M,Y,,,20200929,,CN,COUNTRY NOT SPECIFIED,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,1685361610,CA,,,1685361610,4,20070510,20070521,,,1685361610,1,Maternal exposure timing unspecified
16854037,168540373,3,F,2015,20200712,20190926,20200717,PER,,US-GILEAD-2019-0429745,GILEAD,,,,E,M,Y,214,KG,20200717,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Fatigue;Loss of personal independence in daily activities;Pain;Renal failure;Vitamin D deficiency,168540373,OT,,,168540373,1,2012,2018,,,168540373,1,HIV infection
16854308,168543082,2,F,201402,20200714,20190926,20200723,EXP,,US-GILEAD-2019-0429572,GILEAD,,67,YR,E,F,Y,,,20200723,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Pain,168543082,DE,,,168543082,1,20080702,2019,,,168543082,1,HIV infection
16854788,168547882,2,F,2018,20200716,20190926,20200831,EXP,,US-GILEAD-2019-0429794,GILEAD,,43,YR,A,M,Y,,,20200831,,CN,US,US,EFAVIRENZ.;SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Economic problem;Emotional distress;Fatigue;Loss of personal independence in daily activities;Pain;Quality of life decreased,168547882,OT,,,168547882,1,2004,2009,,,168547882,1,HIV infection
16855068,168550683,3,F,20150902,20200701,20190926,20200819,PER,,US-GILEAD-2019-0429433,GILEAD,,,,,M,Y,108.84,KG,20200819,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Economic problem;Emotional distress;Fatigue;Fear;Osteopenia;Pain;Quality of life decreased;Renal failure,168550683,OT,,,168550683,1,20081218,20170823,,,168550683,1,HIV infection
16856415,168564153,3,F,2009,20200715,20190926,20200826,EXP,,US-GILEAD-2019-0429606,GILEAD,,56,YR,A,M,Y,70.3,KG,20200826,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Economic problem;Emotional distress;End stage renal disease;Fatigue;Fear;Impaired work ability;Loss of personal independence in daily activities;Mobility decreased;Pain;Quality of life decreased;Renal failure;Spinal compression fracture,168564153,OT,,,168564153,1,2006,200906,,,168564153,1,HIV infection
16856450,168564502,2,F,201004,20200708,20190926,20200827,EXP,,US-GILEAD-2019-0429605,GILEAD,,,,,M,Y,,,20200827,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Hyperthyroidism;Hyperuricaemia;Impaired work ability;Nephropathy;Pain;Proteinuria;Renal disorder;Renal failure,168564502,HO,,,168564502,1,2010,2017,,,168564502,1,HIV infection
16856453,168564532,2,F,201308,20200722,20190926,20200729,EXP,,US-GILEAD-2019-0429244,GILEAD,,71,YR,E,F,Y,85.26,KG,20200729,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Fatigue;Fracture;Gait disturbance;Loss of personal independence in daily activities;Lower limb fracture;Osteopenia;Osteoporosis;Pain;Quality of life decreased;Renal failure;Tibia fracture,168564532,OT,,,168564532,1,2009,20141107,,,168564532,1,HIV infection
16856482,168564822,2,F,2019,20200710,20190926,20200831,EXP,,US-GILEAD-2019-0429730,GILEAD,,60,YR,A,M,Y,,,20200831,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Blood creatinine increased;Chronic kidney disease;Economic problem;Emotional distress;Fatigue;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal impairment;Urinary tract infection,168564822,OT,,,168564822,1,2014,201903,,,168564822,1,HIV infection
16856671,168566712,2,F,2018,20200705,20190926,20200830,EXP,,US-GILEAD-2019-0429735,GILEAD,,42,YR,A,M,Y,93.88,KG,20200830,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Decreased activity;Economic problem;Emotional distress;End stage renal disease;Fatigue;Loss of personal independence in daily activities;Pain;Quality of life decreased,168566712,OT,,,168566712,1,2004,2009,,,168566712,1,HIV infection
16856872,168568722,2,F,2017,20200708,20190926,20200827,EXP,,US-GILEAD-2019-0429524,GILEAD,,51,YR,A,M,Y,65.3,KG,20200827,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Economic problem;Emotional distress;Fear-related avoidance of activities;Gait disturbance;Osteoporosis;Pain;Quality of life decreased,168568722,OT,,,168568722,1,20100907,20130514,,,168568722,1,HIV infection
16857423,168574232,2,F,2010,20200814,20190926,20200903,EXP,,US-GILEAD-2019-0429293,GILEAD,,42,YR,A,F,Y,176.87,KG,20200903,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Arthropathy;Bone density decreased;Economic problem;Emotional distress;Gait disturbance;Loss of personal independence in daily activities;Mobility decreased;Osteoporosis;Pain,168574232,OT,,,168574232,1,2009,2016,,,168574232,1,HIV infection
16858117,168581172,2,F,201309,20200715,20190926,20200825,EXP,,US-GILEAD-2019-0429577,GILEAD,,70,YR,E,F,Y,,,20200825,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Decreased activity;Economic problem;Emotional distress;End stage renal disease;Fatigue;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal disorder;Renal failure,168581172,OT,,,168581172,1,2006,201309,,,168581172,1,HIV infection
16858241,168582412,2,F,2017,20200810,20190926,20200827,EXP,,US-GILEAD-2019-0429239,GILEAD,,,,A,M,Y,72.56,KG,20200827,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Decreased appetite;Economic problem;Emotional distress;Fear-related avoidance of activities;Gait disturbance;Loss of personal independence in daily activities;Osteoporosis;Pain;Pain in extremity;Quality of life decreased;Weight decreased,168582412,OT,,,168582412,1,2004,2018,,,168582412,1,HIV infection
16858570,168585703,3,F,2018,20200814,20190926,20200904,PER,,US-GILEAD-2019-0429731,GILEAD,,,,A,M,Y,94.79,KG,20200904,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone density decreased;Economic problem;Emotional distress;Fear-related avoidance of activities;Gait disturbance;Hepatic enzyme increased;Loss of personal independence in daily activities;Pain;Quality of life decreased,168585703,OT,,,168585703,1,2005,2007,,,168585703,1,HIV infection
16858956,168589562,2,F,,20200721,20190926,20200831,EXP,,US-GILEAD-2019-0429204,GILEAD,,,,A,F,Y,47.62,KG,20200831,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;Fatigue;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal failure;Renal pain,168589562,OT,,,168589562,1,2004,2015,,,168589562,1,HIV infection
16858997,168589973,3,F,20070531,20200716,20190926,20200828,PER,,US-GILEAD-2019-0429671,GILEAD,,43,YR,A,M,Y,,,20200828,,CN,US,US,SUSTIVA,Anaemia of chronic disease;Anhedonia;Anxiety;Decreased activity;Economic problem;Emotional distress;End stage renal disease;Fatigue;Pain;Quality of life decreased,168589973,OT,,,168589973,1,20070409,200806,,,168589973,1,HIV infection
16859196,168591962,2,F,2009,20200727,20190926,20200806,EXP,,US-GILEAD-2019-0429411,GILEAD,,,,A,M,Y,69.39,KG,20200806,,CN,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Decreased activity;Economic problem;Emotional distress;Fear;Loss of personal independence in daily activities;Osteopenia;Osteoporosis;Pain;Quality of life decreased;Renal impairment;Upper limb fracture;Wrist fracture,168591962,OT,,,168591962,1,20051024,2018,,,168591962,1,HIV infection
16860051,168600513,3,F,2014,20200615,20190927,20200929,EXP,,US-GILEAD-2019-0429732,GILEAD,,,,A,M,Y,77,KG,20200929,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Decreased activity;Economic problem;Emotional distress;Osteoporosis;Quality of life decreased,168600513,OT,,,168600513,1,20100826,20140605,,,168600513,1,HIV infection
16860358,168603582,2,F,2014,20200715,20190927,20200818,EXP,,US-GILEAD-2019-0429584,GILEAD,,,,,M,Y,90.7,KG,20200818,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Economic problem;Emotional distress;Multiple injuries;Pain;Renal failure;Suicidal ideation,168603582,OT,,,168603582,1,2015,2017,,,168603582,1,HIV infection
16860421,168604212,2,F,2011,20200716,20190927,20200827,PER,,US-GILEAD-2019-0429722,GILEAD,,37,YR,A,M,Y,86.17,KG,20200827,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Blood urine present;Decreased activity;Depression;Economic problem;Emotional distress;Fear;Joint noise;Loss of personal independence in daily activities;Osteopenia;Pain;Quality of life decreased,,,,,168604212,1,20090819,20120919,,,168604212,1,HIV infection
16860533,168605332,2,F,201310,20200915,20190927,20200923,EXP,,US-GILEAD-2019-0429643,GILEAD,,29,YR,A,F,Y,72.56,KG,20200923,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;Pain;Quality of life decreased,168605332,OT,,,168605332,1,200907,201102,,,168605332,1,HIV infection
16860704,168607043,3,F,2010,20200914,20190927,20200918,EXP,,US-GILEAD-2019-0429650,GILEAD,,,,A,M,Y,78.01,KG,20200918,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Decreased activity;Economic problem;Emotional distress;Fatigue;Gait disturbance;Osteoporosis;Pain;Quality of life decreased;Renal failure,168607043,OT,,,168607043,1,2004,,,,168607043,1,HIV infection
16860718,168607182,2,F,201006,20200922,20190927,20200928,EXP,,US-GILEAD-2019-0429656,GILEAD,,22,YR,A,M,Y,106.58,KG,20200928,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Decreased activity;Economic problem;Emotional distress;End stage renal disease;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal failure;Renal transplant,168607182,OT,,,168607182,1,2007,2010,,,168607182,1,HIV infection
16861811,168618112,2,F,201011,20200703,20190927,20200831,EXP,,US-GILEAD-2019-0429413,GILEAD,,55,YR,A,M,Y,45.35,KG,20200831,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Economic problem;Emotional distress;Fatigue;Loss of personal independence in daily activities;Pain;Quality of life decreased,168618112,HO,,,168618112,1,2009,20191009,,,168618112,1,HIV infection
16862172,168621722,2,F,20160323,20200709,20190927,20200826,EXP,,US-GILEAD-2019-0429742,GILEAD,,51,YR,A,F,Y,,,20200826,,CN,US,US,SUSTIVA,Abnormal dreams;Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Depression;Economic problem;Emotional distress;End stage renal disease;Multiple injuries;Pain;Renal failure;Somnambulism,168621722,OT,,,168621722,1,201304,201603,,,168621722,1,HIV infection
16862241,168622412,2,F,,20200708,20190927,20200824,EXP,,US-GILEAD-2019-0429714,GILEAD,,39,YR,A,M,Y,71.2,KG,20200824,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;End stage renal disease;Fatigue;Fear-related avoidance of activities;Impaired work ability;Loss of personal independence in daily activities;Mobility decreased;Myocardial infarction;Osteopenia;Pain;Quality of life decreased;Renal failure,168622412,OT,,,168622412,1,2011,2018,,,168622412,1,HIV infection
16863042,168630422,2,F,2007,20200731,20190927,20200831,EXP,,US-GILEAD-2019-0429241,GILEAD,,53,YR,A,M,Y,84.81,KG,20200831,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Economic problem;Emotional distress;End stage renal disease;Pain,168630422,OT,,,168630422,1,200607,2011,,,168630422,1,HIV infection
16863190,168631902,2,F,20160309,20200714,20190927,20200724,EXP,,US-GILEAD-2019-0429518,GILEAD,,57,YR,A,M,Y,,,20200724,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;Fatigue;Fear;Loss of personal independence in daily activities;Mobility decreased;Pain;Quality of life decreased,168631902,HO,,,168631902,1,20131118,20160510,,,168631902,1,HIV infection
16863363,168633632,2,F,2005,20200713,20190927,20200723,EXP,,US-GILEAD-2019-0429499,GILEAD,,51,YR,A,M,Y,81.63,KG,20200723,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Decreased activity;Depression;Economic problem;Emotional distress;Fear;Loss of personal independence in daily activities;Nephropathy;Osteopenia;Osteoporosis;Pain;Quality of life decreased;Renal failure,168633632,OT,,,168633632,1,2004,2016,,,168633632,1,HIV infection
16867931,168679314,4,F,1996,20200904,20190930,20200908,EXP,,ES-ROCHE-2412643,ROCHE,"LOPEZ ASPIROZ E, CABRERA FIGUEROA SE, VALVERDE MERINO MP, CARRACEDO ALVAREZ A INDIVIDUALIZED PROTEASE INHIBITOR MONOTHERAPY: THE ROLE OF PHARMACOKINETICS AND PHARMACOGENETICS IN AN AGED AND HEAVILY TREATED HIV?INFECTED PATIENT. CLINICAL DRUG INVESTIGATION 2019?39:1125?1131.",38,YR,,M,Y,,,20200908,,HP,ES,ES,EFAVIRENZ.,Asthenia;Bone metabolism disorder;Chronic kidney disease;Dyslipidaemia;Fanconi syndrome;Fatigue;Hypophosphataemia;Lipodystrophy acquired;Musculoskeletal pain;Musculoskeletal toxicity;Myalgia;Neurotoxicity;Overdose;Pathological fracture;Proteinuria;Renal glycosuria;Renal impairment;Virologic failure,168679314,OT,,,168679314,1,1996,1997,,,168679314,1,Antiretroviral therapy
16896724,168967243,3,F,200311,20200915,20191008,20200922,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-007833,BRISTOL MYERS SQUIBB,,36,YR,,F,Y,82,KG,20200922,,HP,FR,FR,SUSTIVA,Abdominal pain;Chills;Diarrhoea;Eyelid oedema;Lip oedema;Pyrexia;Rash;Thrombocytopenia,168967243,HO,,,168967243,1,20051201,20051202,,,168967243,1,Pyrexia
16908146,169081462,2,F,20190929,20200721,20191011,20200727,EXP,,US-GILEAD-2019-0432211,GILEAD,,60,YR,A,M,Y,99.7,KG,20200727,,CN,US,US,SUSTIVA,Abnormal dreams;Atrial fibrillation;Burn oral cavity;Burning sensation;Emotional disorder;Feeling hot;Flushing;Genital burning sensation;Genital rash;Gingival bleeding;Hypertension;Mental disorder;Myocardial infarction;Nervous system disorder;Nightmare;Oral disorder;Poisoning;Poor dental condition;Skin burning sensation,169081462,OT,,,169081462,2,201901,,,,169081462,1,HIV test positive
16939274,169392743,3,F,,20200710,20191021,20200718,EXP,,NG-AUROBINDO-AUR-APL-2019-067617,AUROBINDO,,7,YR,,M,Y,,,20200718,,HP,DE,DE,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified,169392743,OT,,,,,,,,,169392743,1,HIV infection
16939753,169397532,2,F,,20200706,20191021,20200716,EXP,,DE-AUROBINDO-AUR-APL-2019-067618,AUROBINDO,,42,YR,,M,Y,,,20200717,,HP,NG,DE,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified,169397532,OT,,,,,,,,,169397532,1,HIV infection
16969122,169691224,4,F,20160101,20200520,20191029,20200916,EXP,,US-GILEAD-2019-0434689,GILEAD,,57,YR,A,M,Y,113.38,KG,20200916,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone loss;Depression;Economic problem;Emotional distress;Intervertebral disc degeneration;Liver disorder;Nerve compression;Osteonecrosis;Osteoporosis;Osteoporotic fracture;Pain;Renal disorder,169691224,OT,,,169691224,1,200101,201601,,,169691224,1,HIV infection
16978043,169780435,5,F,2006,20200919,20191031,20200925,EXP,,US-GILEAD-2019-0434706,GILEAD,,,,A,M,Y,,,20200925,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone density decreased;Bone loss;Economic problem;Emotional distress;Foot fracture;Fracture;Osteoporosis;Osteoporotic fracture;Pain,169780435,OT,,,169780435,1,2002,2005,,,169780435,1,HIV infection
17000237,170002372,2,F,,20191029,20191106,20200807,EXP,,NVSC2019ZA023705,NOVARTIS,,,,N,,Y,,,20200807,,HP,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL 600 MG/200 MG/245 MG FILM,Meningomyelocele,170002372,CA,,,,,,,,,170002372,1,Foetal exposure during pregnancy
17042336,170423362,2,F,,20200722,20191118,20200731,EXP,,CA-009507513-1911CAN004576,MERCK,,44,YR,,M,Y,,,20200731,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,170423362,HO,,,,,,,,,170423362,1,HIV infection
17075955,170759555,5,F,20130717,20200904,20191126,20200924,EXP,,US-GILEAD-2019-0439498,GILEAD,,55,YR,A,M,Y,70.3,KG,20200924,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Foot fracture;Osteoporosis;Pain;Renal failure;Renal tubular necrosis,170759555,HO,,,170759555,1,20130612,20130719,,,170759555,1,HIV infection
17084668,170846683,3,F,20181001,20200810,20191127,20200820,EXP,,"BW-LANNETT COMPANY, INC.-BW-2019LAN001043",LANNETT,,0,DY,,,Y,,,20200820,,HP,BW,BW,EFAVIRENZ.,Arnold-Chiari malformation;Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele;Stillbirth,170846683,OT,,,,,,,,,170846683,1,HIV infection
17097939,170979393,3,F,2015,20200615,20191202,20200819,EXP,,US-GILEAD-2019-0440104,GILEAD,,,,A,M,Y,,,20200819,,CN,US,US,SUSTIVA,Arthralgia;Bone density decreased;Bone loss;Fracture;Hip arthroplasty;Joint arthroplasty;Osteonecrosis;Osteoporosis;Tooth loss,170979393,OT,,,170979393,1,2008,2019,,,170979393,1,HIV infection
17110907,171109073,3,F,1998,20200518,20191204,20200818,EXP,,US-GILEAD-2019-0440237,GILEAD,,,,A,F,Y,,,20200818,,LW,US,US,SUSTIVA,Back disorder;Bone density decreased;Bone loss;Intervertebral disc degeneration;Multiple fractures;Osteonecrosis;Osteoporosis;Tooth loss;Upper limb fracture,171109073,OT,,,171109073,1,2005,200612,,,171109073,1,HIV infection
17149728,171497282,2,F,2004,20200731,20191213,20200831,EXP,,US-GILEAD-2019-0442009,GILEAD,,,,A,F,Y,52.15,KG,20200831,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;End stage renal disease;Pain;Quality of life decreased;Renal failure;Skeletal injury;Tooth injury,171497282,OT,,,171497282,1,2009,2017,,,171497282,1,HIV infection
17150292,171502922,2,F,20141202,20200615,20191213,20200821,EXP,,US-GILEAD-2019-0442021,GILEAD,,47,YR,A,M,Y,102.04,KG,20200821,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Economic problem;Emotional distress;Glomerular filtration rate decreased;Pain,171502922,OT,,,171502922,1,2001,2018,,,171502922,1,Product used for unknown indication
17214260,172142604,4,F,1996,20200909,20191230,20200917,EXP,,ES-MYLANLABS-2019M1127115,MYLAN,"ASPIROZ EL, CABRERA FIGUEROA SE, VALVERDE MERINO MP, ALVAREZ AC.. INDIVIDUALIZED PROTEASE INHIBITOR MONOTHERAPY: THE ROLE OF PHARMACOKINETICS AND PHARMACOGENETICS IN AN AGED AND HEAVILY TREATED HIV?INFECTED PATIENT.. CLINICAL DRUG INVESTIGATION. 2019?39:1125?31",38,YR,,M,Y,,,20200917,,HP,CL,ES,EFAVIRENZ.,Asthenia;Bone metabolism disorder;Bone pain;Chronic kidney disease;Drug abuse;Dyslipidaemia;Fanconi syndrome acquired;Fatigue;Glycosuria;Hypophosphataemia;Intentional product misuse;Lipodystrophy acquired;Medication error;Musculoskeletal pain;Musculoskeletal toxicity;Myalgia;Nephropathy toxic;Neurotoxicity;Overdose;Pathological fracture;Proteinuria;Renal impairment;Virologic failure,172142604,OT,,,172142604,1,1997,2001,,,172142604,1,Antiretroviral therapy
17244297,172442976,6,F,2006,20200724,20200107,20200826,EXP,,US-GILEAD-2019-0444758,GILEAD,,54,YR,A,M,Y,81.63,KG,20200826,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density abnormal;Bone density decreased;Depression;Economic problem;Emotional distress;Fracture;Osteopenia;Osteoporosis;Pain;Renal failure;Tooth loss,172442976,OT,,,172442976,1,200604,201701,,,172442976,1,HIV infection
17244308,172443082,2,F,2014,20200403,20200107,20200824,EXP,,US-GILEAD-2019-0444842,GILEAD,,52,YR,A,F,Y,70.3,KG,20200824,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;Osteopenia;Osteoporosis;Pain,172443082,OT,,,172443082,1,20121011,20150409,,,172443082,1,HIV infection
17244336,172443362,2,F,20161103,20200403,20200107,20200826,PER,,US-GILEAD-2019-0444847,GILEAD,,49,YR,A,M,Y,68.93,KG,20200826,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Economic problem;Emotional distress;Osteopenia;Pain,,,,,172443362,1,20030819,20060826,,,172443362,1,HIV infection
17244339,172443392,2,F,20190222,20200417,20200107,20200811,EXP,,US-GILEAD-2019-0444878,GILEAD,,57,YR,A,M,Y,85.26,KG,20200811,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;Osteopenia;Osteoporosis;Pain,172443392,OT,,,172443392,1,2003,201407,,,172443392,1,HIV infection
17244361,172443613,3,F,2016,20200910,20200107,20200924,EXP,,US-GILEAD-2019-0444939,GILEAD,,57,YR,A,F,Y,86.17,KG,20200924,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Hand fracture;Pain;Tooth loss,172443613,OT,,,172443613,1,2005,201908,,,172443613,1,HIV infection
17244379,172443793,3,F,2007,20200514,20200107,20200904,EXP,,US-GILEAD-2020-0445051,GILEAD,,59,YR,A,M,Y,140.59,KG,20200904,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Economic problem;Emotional distress;Foot fracture;Fracture;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Tooth loss,172443793,OT,,,172443793,1,2004,2009,,,172443793,1,HIV infection
17244440,172444404,4,F,2017,20200911,20200107,20200925,EXP,,US-GILEAD-2020-0445067,GILEAD,,40,YR,A,M,Y,77.1,KG,20200925,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Fracture;Hand fracture;Pain;Renal failure;Rib fracture;Spinal fracture;Tooth loss,172444404,OT,,,172444404,1,2008,201803,,,172444404,1,HIV infection
17261017,172610173,3,F,1989,20200819,20200113,20200825,EXP,,US-GILEAD-2020-0445884,GILEAD,,53,YR,A,M,Y,63.49,KG,20200825,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back injury;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Hip arthroplasty;Hyperparathyroidism;Intervertebral disc degeneration;Nephrolithiasis;Osteoarthritis;Osteopenia;Pain;Renal arteriosclerosis;Renal failure;Renal transplant;Vitamin D decreased,172610173,OT,,,172610173,1,2010,2018,,,172610173,1,HIV infection
17261513,172615134,4,F,20100713,20200903,20200113,20200923,EXP,,US-GILEAD-2020-0446117,GILEAD,,47,YR,A,M,Y,76.64,KG,20200923,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;New onset diabetes after transplantation;Osteonecrosis;Osteopenia;Pain;Renal transplant;Renal tubular disorder;Tooth loss,172615134,OT,,,172615134,1,200712,201411,,,172615134,1,HIV infection
17283524,172835243,3,F,20051025,20200822,20200117,20200916,EXP,,US-GILEAD-2020-0447082,GILEAD,,52,YR,A,M,Y,89.8,KG,20200916,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Pain;Renal failure;Renal transplant;Tooth loss,172835243,OT,,,172835243,1,2005,20140407,,,172835243,1,HIV infection
17346840,173468402,2,F,200705,20200825,20200130,20200909,EXP,,US-GILEAD-2020-0448756,GILEAD,,40,YR,A,F,Y,87.53,KG,20200909,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Economic problem;Emotional distress;End stage renal disease;Pain,173468402,OT,,,173468402,1,2003,20100601,,,173468402,1,HIV infection
17348937,173489372,2,F,201505,20200830,20200130,20200922,EXP,,US-GILEAD-2020-0448801,GILEAD,,45,YR,A,M,Y,50.8,KG,20200922,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Body height decreased;Bone density decreased;Decreased activity;Depression;Economic problem;Emotional distress;Muscular weakness;Musculoskeletal stiffness;Osteopenia;Osteoporosis;Pain;Pain in extremity;Spinal compression fracture;Spinal pain,173489372,OT,,,173489372,1,201309,201605,,,173489372,1,HIV infection
17349167,173491672,2,F,20101014,20200828,20200130,20200914,EXP,,US-GILEAD-2020-0448797,GILEAD,,36,YR,A,M,Y,79.37,KG,20200914,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Economic problem;Emotional distress;End stage renal disease;Pain,173491672,OT,,,173491672,1,2001,20170802,,,173491672,1,HIV infection
17350590,173505902,2,F,20111227,20200730,20200130,20200820,EXP,,US-GILEAD-2020-0448729,GILEAD,,39,YR,A,M,Y,,,20200820,,CN,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;Osteopenia;Pain,173505902,OT,,,173505902,1,2010,2015,,,173505902,1,HIV infection
17350813,173508132,2,F,2007,20200830,20200130,20200917,EXP,,US-GILEAD-2020-0448710,GILEAD,,,,A,M,Y,99.7,KG,20200917,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Comminuted fracture;Depression;Economic problem;Emotional distress;Osteopenia;Osteoporosis;Pain,173508132,OT,,,173508132,1,2006,2009,,,173508132,1,HIV infection
17353136,173531362,2,F,201310,20200914,20200131,20200918,EXP,,US-GILEAD-2020-0448717,GILEAD,,48,YR,A,M,Y,68.03,KG,20200918,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Economic problem;Emotional distress;End stage renal disease;Pain;Renal failure,173531362,OT,,,173531362,1,2011,20130321,,,173531362,1,HIV infection
17353538,173535382,2,F,20170515,20200803,20200131,20200827,EXP,,US-GILEAD-2020-0448725,GILEAD,,,,,F,Y,,,20200827,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Osteoporosis;Pain,173535382,OT,,,173535382,1,2006,201801,,,173535382,1,HIV infection
17353625,173536252,2,F,201206,20200831,20200131,20200921,EXP,,US-GILEAD-2020-0448749,GILEAD,,46,YR,A,M,Y,52.15,KG,20200921,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Clavicle fracture;Economic problem;Emotional distress;Osteoporosis;Pain,173536252,OT,,,173536252,2,2010,201005,,,173536252,1,HIV infection
17354354,173543543,3,F,201306,20200803,20200131,20200831,PER,,US-GILEAD-2020-0448785,GILEAD,,62,YR,A,M,Y,67,KG,20200831,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Economic problem;Emotional distress;End stage renal disease;Osteopenia;Pain;Renal disorder,173543543,OT,,,173543543,1,2013,20100323,,,173543543,1,HIV infection
17355530,173555302,2,F,20131005,20200827,20200131,20200917,EXP,,US-GILEAD-2020-0448761,GILEAD,,44,YR,A,M,Y,77.1,KG,20200917,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;Pain,173555302,OT,,,173555302,1,20111213,20140812,,,173555302,1,HIV infection
17359915,173599152,2,F,20141007,20200923,20200203,20200929,EXP,,US-GILEAD-2020-0448758,GILEAD,,53,YR,A,F,Y,158,KG,20200929,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Economic problem;Emotional distress;Gait inability;Osteopenia;Osteoporosis;Pain,173599152,OT,,,173599152,1,2009,20170221,,,173599152,1,HIV infection
17359956,173599563,3,F,2009,20200916,20200203,20200925,PER,,US-GILEAD-2020-0448795,GILEAD,,,,E,M,Y,99.77,KG,20200925,,CN,US,US,EFAVIRENZ.;SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Pain;Renal failure,173599563,HO,,,173599563,1,2004,20090312,,,173599563,1,HIV infection
17360065,173600652,2,F,201410,20200831,20200203,20200916,PER,,US-GILEAD-2020-0448747,GILEAD,,64,YR,A,M,Y,94.33,KG,20200916,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;Pain;Renal failure,173600652,OT,,,173600652,1,2004,2019,,,173600652,1,HIV infection
17360333,173603332,2,F,201902,20200818,20200203,20200904,PER,,US-GILEAD-2020-0448768,GILEAD,,57,YR,A,M,Y,63.49,KG,20200904,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Economic problem;Emotional distress;Pain;Renal failure,173603332,OT,,,173603332,1,2015,201905,,,173603332,1,HIV infection
17360688,173606882,2,F,2016,20200831,20200203,20200915,EXP,,US-GILEAD-2020-0448770,GILEAD,,,,A,F,Y,81.63,KG,20200915,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Fall;Multiple fractures;Osteoporosis;Pain,173606882,OT,,,173606882,1,2008,201612,,,173606882,1,HIV infection
17360997,173609972,2,F,2013,20200830,20200203,20200923,EXP,,US-GILEAD-2020-0448773,GILEAD,,27,YR,A,F,Y,68.04,KG,20200923,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Crying;Depression;Economic problem;Emotional distress;End stage renal disease;Helplessness;Pain;Renal atrophy;Renal impairment;Restlessness;Suicidal ideation;Thrombosis,173609972,OT,,,173609972,1,2009,20110210,,,173609972,1,HIV infection
17362144,173621442,2,F,2017,20200831,20200203,20200916,EXP,,US-GILEAD-2020-0448814,GILEAD,,,,A,F,Y,98,KG,20200916,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Death;Economic problem;Emotional distress;Foot fracture;Gait disturbance;Osteoporosis;Pain;Upper limb fracture,173621442,DE,,,173621442,1,2004,201605,,,173621442,1,HIV infection
17371124,173711243,3,F,,20200911,20200205,20200923,EXP,,FR-MACLEODS PHARMACEUTICALS US LTD-MAC2020024999,MACLEODS,,,,,,Y,,,20200923,,HP,US,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,173711243,OT,,,173711243,1,20070403,20070521,,,173711243,1,Product used for unknown indication
17408367,174083674,4,F,20140604,20200520,20200212,20200821,EXP,,US-GILEAD-2020-0450628,GILEAD,,60,YR,A,M,Y,90.7,KG,20200821,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Osteopenia;Osteoporosis;Pain;Upper limb fracture;Wrist fracture,174083674,HO,,,174083674,1,20130102,20160316,,,174083674,1,HIV infection
17412129,174121295,5,F,2014,20200810,20200213,20200904,EXP,,US-GILEAD-2020-0450637,GILEAD,,51,YR,A,M,Y,86.2,KG,20200904,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone density decreased;Economic problem;Emotional distress;Joint destruction;Mobility decreased;Osteopenia;Pain;Spinal osteoarthritis,174121295,OT,,,174121295,1,201312,20170412,,,174121295,1,HIV infection
17412233,174122336,6,F,2015,20200521,20200213,20200924,EXP,,US-GILEAD-2020-0450638,GILEAD,,57,YR,A,M,Y,81.6,KG,20200924,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Economic problem;Emotional distress;Fracture;Osteopenia;Osteoporosis;Pain;Renal failure;Suicidal ideation,174122336,OT,,,174122336,1,201505,201508,,,174122336,1,HIV infection
17427715,174277152,2,F,,20200711,20200218,20200716,EXP,,BR-AUROBINDO-AUR-APL-2020-009000,AUROBINDO,,,,,F,Y,2.8,KG,20200716,,MD,BR,BR,EFAVIRENZ.,Diastasis recti abdominis;Foetal exposure during pregnancy;Vaginal prolapse,174277152,CA,,,174277152,2,20121128,20121128,,,174277152,1,Product used for unknown indication
17427792,174277923,3,F,,20200714,20200218,20200715,EXP,,NVSC2020CH038861,NOVARTIS,,46,YR,,F,Y,,,20200715,,HP,CH,CH,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,174277923,OT,,,174277923,1,20151203,20151204,,,174277923,1,Premature labour
17441515,174415153,3,F,20110601,20200903,20200220,20200923,EXP,,US-GILEAD-2020-0451447,GILEAD,,43,YR,A,M,Y,126.08,KG,20200923,,CN,US,US,SUSTIVA,Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Fracture;Osteoporosis;Pain;Renal failure;Tooth loss,174415153,OT,,,174415153,1,2006,201912,,,174415153,1,HIV infection
17461679,174616791,1,I,2012,20200213,20200226,20200226,EXP,,"BR-LANNETT COMPANY, INC.-BR-2020LAN000063",LANNETT,,,,,F,Y,2.88,KG,20200226,,HP,BR,BR,EFAVIRENZ.,Diastasis recti abdominis;Foetal exposure during pregnancy;Genital prolapse,174616791,CA,,,,,,,,,174616791,1,Product used for unknown indication
17463940,174639401,1,I,,20200213,20200226,20200226,EXP,,BR-MACLEODS PHARMACEUTICALS US LTD-MAC2020025278,MACLEODS,,,,,,Y,,,20200226,,HP,US,BR,EFAVIRENZ.,Diastasis recti abdominis;Foetal exposure during pregnancy;Prolapse,174639401,CA,,,174639401,1,20120521,20120521,,,174639401,1,Product used for unknown indication
17484391,174843914,4,F,200909,20200904,20200302,20200918,EXP,,US-GILEAD-2020-0452915,GILEAD,,51,YR,A,M,Y,88.44,KG,20200918,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Osteopenia;Osteoporosis;Pain;Renal impairment;Tooth fracture;Tooth loss,174843914,OT,,,174843914,1,2007,2010,,,174843914,1,HIV infection
17486133,174861333,3,F,,20200725,20200303,20200806,EXP,,BR-MACLEODS PHARMACEUTICALS US LTD-MAC2020025401,MACLEODS,,,,,,Y,,,20200806,,HP,US,BR,Lamivudine+ Efavirenz + Tenofovir,Foetal exposure during pregnancy;Talipes,174861333,OT,,,174861333,1,20150302,,,,174861333,1,Product used for unknown indication
17497427,174974272,2,F,20180301,20200723,20200304,20200728,EXP,,ZA-GILEAD-2020-0453451,GILEAD,,,,A,F,Y,,,20200728,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,174974272,OT,,,174974272,1,20170625,,,,174974272,1,HIV infection
17497526,174975265,5,F,2006,20200904,20200304,20200928,EXP,,US-GILEAD-2020-0452918,GILEAD,,46,YR,A,M,Y,70.75,KG,20200928,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Pain;Renal failure,174975265,HO,,,174975265,1,2006,201808,,,174975265,1,HIV infection
17523420,175234203,3,F,20161220,20200903,20200310,20200924,EXP,,US-GILEAD-2020-0454098,GILEAD,,55,YR,A,M,Y,72.56,KG,20200924,,LW,US,US,SUSTIVA,Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Pain;Renal failure,175234203,OT,,,175234203,1,20090824,20141119,,,175234203,1,HIV infection
17548280,175482804,4,F,1996,20200829,20200317,20200905,EXP,,ES-AUROBINDO-AUR-APL-2020-012619,AUROBINDO,,38,YR,,M,Y,,,20200905,,HP,CL,ES,EFAVIRENZ.,Asthenia;Bone metabolism disorder;Chronic kidney disease;Dyslipidaemia;Fanconi syndrome acquired;Fatigue;Glycosuria;Hypophosphataemia;Lipodystrophy acquired;Musculoskeletal pain;Musculoskeletal toxicity;Myalgia;Neurotoxicity;Overdose;Pathological fracture;Proteinuria;Renal impairment;Virologic failure,175482804,OT,,,175482804,1,2001,2001,,,175482804,1,HIV infection
17549433,175494334,4,F,,20200801,20200317,20200807,EXP,,NG-VIIV HEALTHCARE LIMITED-NG2020GSK046275,VIIV,,,,,,Y,,,20200807,,CN,US,NG,EFAVIRENZ.,Congenital hydrocephalus;Foetal exposure during pregnancy;Hydranencephaly,175494334,CA,,,,,,,,,175494334,1,HIV infection
17549495,175494954,4,F,,20200801,20200317,20200807,EXP,,NG-GLAXOSMITHKLINE-NG2020GSK046275,GLAXOSMITHKLINE,,,,,,Y,,,20200807,,CN,US,NG,EFAVIRENZ.,Congenital hydrocephalus;Foetal exposure during pregnancy;Hydranencephaly,175494954,OT,,,,,,,,,175494954,1,HIV infection
17559291,175592913,3,F,20180701,20200731,20200319,20200810,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-022163,BRISTOL MYERS SQUIBB,,,,,,Y,,,20200810,,HP,NG,NG,EFAVIRENZ.,Congenital hydrocephalus;Foetal exposure during pregnancy;Hydranencephaly,175592913,OT,,,,,,,,,175592913,1,Product used for unknown indication
17564646,175646462,2,F,20180701,20200731,20200320,20200806,EXP,,NG-HETERO-HET2020NG00332,HETERO,,,,,,Y,,,20200806,,HP,NG,NG,EFAVIRENZ.,Foetal exposure during pregnancy;Hydranencephaly,175646462,CA,,,,,,,,,175646462,1,HIV infection
17568633,175686332,2,F,,20200724,20200321,20200805,EXP,,NG-MACLEODS PHARMACEUTICALS US LTD-MAC2020025775,MACLEODS,,,,,,Y,,,20200805,,HP,US,NG,EFAVIRENZ.,Foetal exposure during pregnancy;Hydranencephaly,175686332,OT,,,,,,,,,175686332,1,Product used for unknown indication
17568636,175686362,2,F,20180715,20200801,20200321,20200813,EXP,,NG-MACLEODS PHARMACEUTICALS US LTD-MAC2020025774,MACLEODS,,,,,,Y,,,20200813,,HP,US,NG,EFAVIRENZ.,Abortion induced;Maternal exposure during pregnancy,175686362,OT,,,,,,,,,175686362,1,HIV infection
17570075,175700753,3,F,,20200731,20200323,20200807,EXP,,NG-AUROBINDO-AUR-APL-2020-013909,AUROBINDO,,,,,F,Y,,,20200807,,MD,NG,NG,EFAVIRENZ.,Congenital hydrocephalus;Foetal exposure during pregnancy,175700753,OT,,,,,,,,,175700753,1,Product used for unknown indication
17571317,175713173,3,F,2018,20200810,20200323,20200820,EXP,,"NG-LANNETT COMPANY, INC.-NG-2020LAN000086",LANNETT,,43,YR,,F,Y,,,20200820,,HP,NG,NG,EFAVIRENZ.,Hydranencephaly;Hydrocephalus;Maternal exposure during pregnancy,175713173,CA,,,,,,,,,175713173,1,Product used for unknown indication
17572197,175721973,3,F,201301,20200818,20200323,20200904,EXP,,US-GILEAD-2020-0455841,GILEAD,,47,YR,A,M,Y,,,20200904,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;End stage renal disease;Pain;Renal failure,175721973,OT,,,175721973,1,2013,201301,,,175721973,1,HIV infection
17574124,175741242,2,F,20101027,20200911,20200323,20200917,EXP,,US-GILEAD-2020-0456084,GILEAD,,,,,F,Y,95.24,KG,20200917,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Disability;Economic problem;Emotional distress;Osteopenia;Osteoporosis;Pain;Vitamin D deficiency,175741242,OT,,,175741242,1,2010,201603,,,175741242,1,HIV infection
17574294,175742943,3,F,,20200731,20200324,20200812,EXP,,NG-AUROBINDO-AUR-APL-2020-015307,AUROBINDO,,43,YR,,F,Y,,,20200812,,MD,NG,NG,EFAVIRENZ.,Abortion induced;Exposure during pregnancy,175742943,OT,,,,,,,,,175742943,1,Product used for unknown indication
17574846,175748462,2,F,2010,20200831,20200324,20200910,PER,,US-GILEAD-2020-0455882,GILEAD,,,,A,F,Y,126.53,KG,20200910,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;Nephropathy;Pain;Renal failure,175748462,OT,,,175748462,1,2010,2010,,,175748462,1,HIV infection
17574921,175749212,2,F,2018,20200828,20200324,20200911,EXP,,US-GILEAD-2020-0455870,GILEAD,,57,YR,A,M,Y,,,20200911,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Foot fracture;Osteopenia;Osteoporosis;Pain,175749212,OT,,,175749212,1,2006,2017,,,175749212,1,HIV infection
17575000,175750002,2,F,201712,20200901,20200324,20200918,EXP,,US-GILEAD-2020-0455867,GILEAD,,69,YR,E,M,Y,70.3,KG,20200918,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Fracture;Hepatic cirrhosis;Osteoporosis;Pain,175750002,OT,,,175750002,1,2006,2016,,,175750002,1,HIV infection
17575701,175757012,2,F,2009,20200829,20200324,20200915,EXP,,US-GILEAD-2020-0456183,GILEAD,,,,A,M,Y,88.4,KG,20200915,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Pain,175757012,OT,,,175757012,1,2013,2015,,,175757012,1,HIV infection
17576667,175766672,2,F,2012,20200827,20200324,20200917,EXP,,US-GILEAD-2020-0455896,GILEAD,,,,A,F,Y,111.11,KG,20200917,,CN,US,US,EFAVIRENZ.,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Osteoporosis;Pain,175766672,OT,,,175766672,1,2010,2018,,,175766672,1,HIV infection
17576959,175769592,2,F,20090604,20200722,20200324,20200730,EXP,,US-GILEAD-2020-0455949,GILEAD,,62,YR,A,M,Y,,,20200730,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;Hip fracture;Osteoporosis;Pain,175769592,OT,,,175769592,1,2001,20120423,,,175769592,1,HIV infection
17577037,175770372,2,F,201004,20200826,20200324,20200915,EXP,,US-GILEAD-2020-0456126,GILEAD,,44,YR,A,M,Y,77,KG,20200915,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Bone density decreased;Economic problem;Emotional distress;Osteoporosis;Pain;Renal impairment;Tibia fracture,175770372,OT,,,175770372,1,2004,2014,,,175770372,1,HIV infection
17577194,175771943,3,F,2014,20200730,20200324,20200914,EXP,,US-GILEAD-2020-0455942,GILEAD,,63,YR,A,M,Y,,,20200914,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Nephrolithiasis;Osteopenia;Pain,175771943,OT,,,175771943,1,20070427,2014,,,175771943,1,HIV infection
17579467,175794672,2,F,2017,20200830,20200325,20200918,EXP,,US-GILEAD-2020-0456157,GILEAD,,,,A,M,Y,68.03,KG,20200918,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Decreased activity;Depression;Economic problem;Emotional distress;Hip arthroplasty;Osteoporosis;Pain,175794672,OT,,,175794672,1,20100802,20170729,,,175794672,1,HIV infection
17579634,175796343,3,F,201711,20200831,20200325,20200910,PER,,US-GILEAD-2020-0455880,GILEAD,,44,YR,A,F,Y,162.36,KG,20200910,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Pain,175796343,OT,,,175796343,1,201205,201711,,,175796343,1,HIV infection
17579753,175797532,2,F,200109,20200828,20200325,20200917,EXP,,US-GILEAD-2020-0456111,GILEAD,,27,YR,A,F,Y,140.59,KG,20200917,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Dyspnoea;Economic problem;Emotional distress;Gait disturbance;Pain,175797532,OT,,,175797532,2,2004,,,,175797532,1,HIV infection
17579788,175797882,2,F,201603,20200911,20200325,20200918,EXP,,US-GILEAD-2020-0455851,GILEAD,,71,YR,E,M,Y,69,KG,20200918,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Pain,175797882,OT,,,175797882,1,2006,2013,,,175797882,1,HIV infection
17580644,175806442,2,F,2012,20200823,20200325,20200911,EXP,,US-GILEAD-2020-0456171,GILEAD,,,,A,M,Y,81.63,KG,20200911,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Economic problem;Emotional distress;End stage renal disease;Pain;Renal failure,175806442,OT,,,175806442,1,2010,2012,,,175806442,1,HIV infection
17581216,175812163,3,F,201201,20200819,20200325,20200826,EXP,,US-GILEAD-2020-0455861,GILEAD,,42,YR,A,M,Y,86.17,KG,20200826,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Fanconi syndrome acquired;Gait disturbance;Pain,175812163,OT,,,175812163,1,201001,201304,,,175812163,1,HIV infection
17584141,175841412,2,F,,20200803,20200326,20200817,EXP,,NG-CIPLA LTD.-2020NG02102,CIPLA,,,,,,Y,,,20200817,,HP,NG,NG,EFAVIRENZ.,Exposure during pregnancy,175841412,OT,,,,,,,,,175841412,1,HIV infection
17584738,175847382,2,F,201207,20200831,20200326,20200910,EXP,,US-GILEAD-2020-0456102,GILEAD,,64,YR,,M,Y,95,KG,20200910,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Economic problem;Emotional distress;Joint injury;Osteopenia;Osteoporosis;Pain;Renal impairment,175847382,OT,,,175847382,1,2004,20050729,,,175847382,1,HIV infection
17620198,176201982,2,F,20191115,20200720,20200403,20200722,EXP,,CN-GLAXOSMITHKLINE-CN2020APC055904,GLAXOSMITHKLINE,,28,YR,,M,Y,66,KG,20200722,,HP,CN,CN,EFAVIRENZ TABLETS,Drug eruption;Drug-induced liver injury;Hepatic failure;Liver injury;Pyrexia;Rash,176201982,HO,,,176201982,1,20191031,20191225,,,176201982,1,Acquired immunodeficiency syndrome
17620215,176202152,2,F,20191115,20200720,20200403,20200722,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020APC055904,VIIV,,28,YR,,M,Y,66,KG,20200722,,HP,CN,CN,EFAVIRENZ TABLETS,Drug eruption;Drug-induced liver injury;Hepatic failure;Liver injury;Pyrexia;Rash,176202152,OT,,,176202152,1,20191031,20191225,,,176202152,1,Acquired immunodeficiency syndrome
17663074,176630742,2,F,2010,20200420,20200413,20200717,EXP,,US-NAPPMUNDI-USA-2020-0151656,PURDUE,,,,,F,Y,110,KG,20200717,,MD,US,US,SUSTIVA,Anxiety;Arthralgia;Back pain;Bone deformity;Death;Depression;Dizziness;Drug dependence;Drug hypersensitivity;Drug ineffective;Dry mouth;Epilepsy;Fall;Fatigue;Gait disturbance;Headache;Hypotonia;Illness;Intervertebral disc degeneration;Kyphosis;Movement disorder;Mydriasis;Nausea;Off label use;Osteomyelitis;Pain;Pain in extremity;Pruritus;Reflexes abnormal;Scar;Sleep disorder;Somnolence;Swelling;Tenderness;Vomiting,176630742,OT,,,176630742,1,2010,20181028,,,176630742,1,Pain
17669637,176696372,2,F,2006,20200811,20200415,20200904,EXP,,US-GILEAD-2020-0458875,GILEAD,,,,A,M,Y,,,20200904,,LW,US,US,SUSTIVA,Chronic kidney disease;Economic problem;Emotional distress;Pain,176696372,OT,,,176696372,1,2008,2015,,,176696372,1,Product used for unknown indication
17670190,176701903,3,F,201805,20200817,20200415,20200914,PER,,US-GILEAD-2020-0458892,GILEAD,,59,YR,A,M,Y,,,20200914,,LW,US,US,EFAVIRENZ.,Bone density decreased;Economic problem;Emotional distress;Pain,,,,,176701903,1,200511,201805,,,176701903,1,HIV infection
17678730,176787303,3,F,201205,20200828,20200417,20200904,PER,,US-GILEAD-2020-0459240,GILEAD,,41,YR,A,M,Y,72.11,KG,20200904,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Dysuria;Economic problem;Emotional distress;Mobility decreased;Nephrolithiasis;Pain;Unevaluable event,176787303,OT,,,176787303,1,201209,201604,,,176787303,1,HIV infection
17678746,176787462,2,F,20100506,20200831,20200417,20200911,PER,,US-GILEAD-2020-0459248,GILEAD,,28,YR,A,M,Y,74.83,KG,20200911,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Bone density decreased;Depression;Disturbance in attention;Economic problem;Emotional distress;Fear;Loss of personal independence in daily activities;Osteopenia;Pain;Renal disorder;Sexual dysfunction,,,,,176787462,1,2001,20100929,,,176787462,1,HIV infection
17679133,176791332,2,F,2011,20200828,20200417,20200914,PER,,US-GILEAD-2020-0459235,GILEAD,,48,YR,A,M,Y,81.63,KG,20200914,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Economic problem;Emotional distress;Osteopenia;Pain;Renal failure,176791332,OT,,,176791332,1,200601,201003,,,176791332,1,HIV infection
17679923,176799232,2,F,2012,20200828,20200417,20200924,EXP,,US-GILEAD-2020-0459255,GILEAD,,46,YR,A,M,Y,77.1,KG,20200924,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Osteopenia;Osteoporosis;Pain;Spinal compression fracture;Tibia fracture;Tooth disorder;Tooth loss;Wrist fracture,176799232,OT,,,176799232,1,201203,201812,,,176799232,1,HIV infection
17681702,176817022,2,F,2013,20200831,20200417,20200910,EXP,,US-GILEAD-2020-0459245,GILEAD,,,,A,M,Y,68.03,KG,20200910,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Economic problem;Emotional distress;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Proteinuria,176817022,OT,,,176817022,1,201008,201602,,,176817022,1,HIV infection
17684543,176845432,2,F,,20200824,20200420,20200831,EXP,,CA-ROCHE-2583703,ROCHE,,52,YR,,M,Y,,,20200901,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,176845432,OT,,,,,,,,,176845432,1,HIV infection
17703788,177037883,3,F,201804,20200904,20200424,20200925,EXP,,US-GILEAD-2020-0460165,GILEAD,,57,YR,A,M,Y,78.01,KG,20200925,,CN,US,US,SUSTIVA,Anxiety;Arthralgia;Blood creatinine increased;Bone density decreased;Bone loss;Chronic kidney disease;Depression;Dizziness;Economic problem;Emotional distress;Fracture;Nausea;Osteomalacia;Osteonecrosis;Osteoporosis;Pain;Pathological fracture,177037883,OT,,,177037883,1,2005,201904,,,177037883,1,HIV infection
17705704,177057042,2,F,20141026,20200729,20200424,20200828,EXP,,US-GILEAD-2020-0460888,GILEAD,,52,YR,A,M,Y,,,20200828,,LW,US,US,SUSTIVA,Chronic kidney disease;Nephrolithiasis;Renal failure;Skeletal injury,177057042,OT,,,177057042,1,2015,,,,177057042,1,HIV infection
17709935,177099352,2,F,,20200729,20200427,20200828,EXP,,US-GILEAD-2020-0460866,GILEAD,,,,A,M,Y,,,20200828,,LW,US,US,SUSTIVA,Arthralgia;Back pain;Bone density decreased;Bone loss;Fracture;Osteonecrosis;Renal injury,177099352,OT,,,177099352,1,201304,2019,,,177099352,1,HIV infection
17727228,177272285,5,F,20150102,20200916,20200430,20200925,EXP,,US-GILEAD-2020-0460881,GILEAD,,65,YR,E,F,Y,61.22,KG,20200925,,LW,US,US,SUSTIVA,Acute kidney injury;Blood creatinine increased;Chronic kidney disease;Economic problem;Emotional distress;Fanconi syndrome acquired;Pain;Renal failure,177272285,OT,,,177272285,1,20150904,20151021,,,177272285,1,HIV infection
17758738,177587385,5,F,,20200903,20200507,20200911,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-018592,BRISTOL MYERS SQUIBB,"ZASH R, HOLMES L, DISEKO M, JACOBSON DL, BRUMMEL S, MAYONDI G, ET AL. NEURAL?TUBE DEFECTS AND ANTIRETROVIRAL TREATMENT REGIMENS IN BOTSWANA. THE NEW ENGLAND JOURNAL OF MEDICINE. 2019",,,,,Y,,,20200911,,HP,BW,BW,EFAVIRENZ.,Arnold-Chiari malformation;Congenital hydrocephalus;Foetal exposure during pregnancy;Meningomyelocele,177587385,OT,,,,,,,,,177587385,1,Product used for unknown indication
17759277,177592772,2,F,,20200824,20200508,20200828,EXP,,CA-ROCHE-2485311,ROCHE,,45,YR,,M,Y,,,20200828,,HP,CA,CA,EFAVIRENZ.,Multiple-drug resistance,177592772,OT,,,,,,,,,177592772,1,HIV infection
17893955,178939553,3,F,,20200728,20200615,20200805,EXP,,FR-AUROBINDO-AUR-APL-2020-028781,AUROBINDO,M. GREGOIRE. DRUG?DRUG INTERACTIONS IN ELDERLY PATIENTS LIVING WITH HIV. LA LETTRE DE L^LNFECTIOLOGUE. 2019?5:212?7,64,YR,,F,Y,,,20200805,,MD,FR,FR,Efavirenz+Emtricitabine+Tenofovir,Cushing's syndrome;Drug interaction,178939553,OT,,,,,,,,,178939553,1,HIV infection
17908695,179086952,2,F,201912,20200701,20200617,20200714,EXP,,ZA-JNJFOC-20200613811,JOHNSON AND JOHNSON,,34,YR,,F,Y,,,20200714,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL,Contraindicated product administered;Drug ineffective;Hypoxia;Pulmonary embolism,179086952,HO,,,179086952,1,201901,,,,179086952,1,Product used for unknown indication
17919994,179199942,2,F,2005,20200624,20200620,20200703,EXP,,PT-AUROBINDO-AUR-APL-2020-029718,AUROBINDO,,41,YR,,F,Y,,,20200703,,CN,US,PT,EFAVIRENZ.,Drug intolerance;Drug resistance;Fatigue;Hepatic cirrhosis;Hypertension;Nausea;Vomiting,179199942,OT,,,179199942,1,2005,2008,,,179199942,1,Antiretroviral therapy
17927768,179277682,2,F,2005,20200626,20200622,20200703,EXP,PT-EMA-DD-20200610-BHARDWAJ_R-142802,"PT-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-12-030005",BOEHRINGER INGELHEIM,,41,YR,,F,Y,,,20200703,,MD,PT,PT,EFAVIRENZ.,Drug intolerance;Drug resistance;Fatigue;Hepatic cirrhosis;Hypertension;Nausea;Vomiting,179277682,OT,,,179277682,1,2003,2005,,,179277682,1,Product used for unknown indication
17930673,179306732,2,F,,20200612,20200623,20200827,EXP,,CA-ROCHE-2621256,ROCHE,,52,YR,,M,Y,,,20200827,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,179306732,OT,,,,,,,,,179306732,1,HIV infection
17938178,179381782,2,F,2005,20200629,20200624,20200709,EXP,PT-EMA-DD-20200610-BHARDWAJ_R-142802,PT-MYLANLABS-2020M1057301,MYLAN,,41,YR,,F,Y,,,20200709,,CN,US,PT,EFAVIRENZ.,Drug intolerance;Drug resistance;Fatigue;Hepatic cirrhosis;Hypertension;Nausea;Vomiting,179381782,OT,,,179381782,1,20050710,2008,,,179381782,1,Antiretroviral therapy
17945682,179456822,2,F,,20200703,20200625,20200709,EXP,,NVSC2020CZ177777,NOVARTIS,"SUCHOPAR J, PRKES M, SUCHOPAR S. LEKOVE INTERAKCE V UROLOGII NA CO SI DAT POZOR. UROLOGIE PRO PRAXI. 2020?21(2):80?6",16,YR,,M,Y,,,20200709,,HP,CZ,CZ,EFAVIRENZ.,Priapism,179456822,HO,,,,,,,,,179456822,1,Benign prostatic hyperplasia
17945994,179459942,2,F,,20200908,20200626,20200915,EXP,E2B_02979508,CA-ACCORD-186584,ACCORD,,,,,M,Y,,,20200915,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction,179459942,HO,,,,,,,,,179459942,1,Product used for unknown indication
17954859,179548592,2,F,,20200807,20200629,20200817,EXP,,CA-AUROBINDO-AUR-APL-2020-030609,AUROBINDO,,54,YR,,M,Y,,,20200817,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,179548592,OT,,,,,,,,,179548592,1,HIV infection
17964473,179644732,2,F,2005,20200701,20200630,20200703,EXP,PT-EMA-DD-20200610-BHARDWAJ_R-142802,PT-ROCHE-2630671,ROCHE,,41,YR,,F,Y,,,20200703,,MD,PT,PT,EFAVIRENZ.,Drug intolerance;Drug resistance;Fatigue;Hepatic cirrhosis;Hypertension;Nausea;Vomiting,179644732,OT,,,179644732,1,200804,200805,,,179644732,1,Product used for unknown indication
17969704,179697041,1,I,201912,20200610,20200701,20200701,EXP,FR-AFSSAPS-AN20200672,FR-VIIV HEALTHCARE LIMITED-FR2020098065,VIIV,,45,YR,,M,Y,,,20200701,,MD,FR,FR,EFAVIRENZ.,Congestive cardiomyopathy,179697041,HO,,,179697041,1,20181018,20160210,,,179697041,1,HIV infection
17969930,179699301,1,I,,20200629,20200701,20200701,EXP,,US-GILEAD-2020-0477732,GILEAD,,,,A,M,Y,,,20200701,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;HIV infection,179699301,OT,,,,,,,,,179699301,1,Prophylaxis against HIV infection
17976726,179767261,1,I,202003,20200624,20200703,20200703,EXP,,GB-AUROBINDO-AUR-APL-2020-031587,AUROBINDO,,,,A,F,Y,,,20200703,,CN,GB,GB,Efavirenz 600mg,Abdominal pain upper;COVID-19;Cough;Diarrhoea;Dyspnoea;Pyrexia;Tremor,179767261,OT,,,,,,,,,179767261,1,Product used for unknown indication
17977458,179774581,1,I,202003,20200624,20200703,20200703,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-050445,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20200703,,CN,GB,GB,EFAVIRENZ.,Abdominal pain upper;COVID-19;Cough;Diarrhoea;Dyspnoea;Pyrexia;Tremor,179774581,OT,,,,,,,,,179774581,1,Product used for unknown indication
17977642,179776421,1,I,2005,20200624,20200703,20200703,EXP,,PT-AUROBINDO-AUR-APL-2020-031581,AUROBINDO,,41,YR,,F,Y,,,20200703,,CN,US,PT,EFAVIRENZ.,Drug intolerance;Drug resistance;Fatigue;Hepatic cirrhosis;Hypertension;Nausea;Vomiting,179776421,OT,,,179776421,1,2005,2008,,,179776421,1,Antiretroviral therapy
17982046,179820461,1,I,,20180725,20200706,20200706,EXP,,PT-AUROBINDO-AUR-APL-2018-039458,AUROBINDO,,52,YR,,M,Y,,,20200706,,HP,PT,PT,Efavirenz+Emtricitabine+Tenofovir  Film  coated Tablets,Drug ineffective for unapproved indication;Drug interaction;Genotype drug resistance test positive;Virologic failure,179820461,OT,,,179820461,4,201206,,,,179820461,1,Hepatitis B
17982071,179820711,1,I,,20200629,20200706,20200706,EXP,,BW-AUROBINDO-AUR-APL-2020-032148,AUROBINDO,,25,YR,,F,Y,,,20200706,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179820711,OT,,,,,,,,,179820711,1,HIV infection
17982074,179820741,1,I,,20200629,20200706,20200706,EXP,,BW-AUROBINDO-AUR-APL-2020-032147,AUROBINDO,,23,YR,,F,Y,,,20200706,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Viral mutation identified,179820741,OT,,,,,,,,,179820741,1,HIV infection
17982077,179820771,1,I,,20200629,20200706,20200706,EXP,,BW-AUROBINDO-AUR-APL-2020-032150,AUROBINDO,,40,YR,,F,Y,,,20200706,,HP,US,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179820771,OT,,,,,,,,,179820771,1,HIV infection
17982088,179820881,1,I,,20200629,20200706,20200706,EXP,,BW-AUROBINDO-AUR-APL-2020-032160,AUROBINDO,,40,YR,,F,Y,,,20200706,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179820881,OT,,,,,,,,,179820881,1,HIV infection
17982091,179820911,1,I,,20200629,20200706,20200706,EXP,,BW-AUROBINDO-AUR-APL-2020-032170,AUROBINDO,,29,YR,,F,Y,,,20200706,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179820911,OT,,,,,,,,,179820911,1,HIV infection
17982291,179822913,3,F,,20200725,20200706,20200801,EXP,,FR-AUROBINDO-AUR-APL-2020-032078,AUROBINDO,,,,,,Y,,,20200801,,HP,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Pachygyria,179822913,OT,,,,,,,,,179822913,1,Product used for unknown indication
17985085,179850851,1,I,,20200629,20200706,20200706,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2020EME116192,VIIV,,,,,M,Y,,,20200706,,CN,GB,GB,EFAVIRENZ.,Feeling abnormal;Hospitalisation;Lung cancer metastatic;Lung neoplasm malignant,179850851,HO,,,,,,,,,179850851,1,Product used for unknown indication
17985108,179851081,1,I,,20200629,20200706,20200706,EXP,,GB-GLAXOSMITHKLINE-GB2020EME116192,GLAXOSMITHKLINE,,,,,M,Y,,,20200706,,CN,GB,GB,EFAVIRENZ.,Feeling abnormal;Hospitalisation;Lung cancer metastatic;Lung neoplasm malignant,179851081,HO,,,,,,,,,179851081,1,Product used for unknown indication
17986460,179864601,1,I,,20200629,20200707,20200707,EXP,,BW-AUROBINDO-AUR-APL-2020-032152,AUROBINDO,,25,YR,,F,Y,,,20200707,,HP,US,BW,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Viral mutation identified,179864601,OT,,,,,,,,,179864601,1,HIV infection
17986465,179864651,1,I,,20200629,20200707,20200707,EXP,,BW-AUROBINDO-AUR-APL-2020-032154,AUROBINDO,,25,YR,,F,Y,,,20200707,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179864651,OT,,,,,,,,,179864651,1,HIV infection
17986481,179864811,1,I,,20200629,20200707,20200707,EXP,,BW-AUROBINDO-AUR-APL-2020-032158,AUROBINDO,,29,YR,,F,Y,,,20200707,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179864811,OT,,,,,,,,,179864811,1,HIV infection
17986484,179864841,1,I,,20200629,20200707,20200707,EXP,,BW-AUROBINDO-AUR-APL-2020-032171,AUROBINDO,,26,YR,,F,Y,,,20200707,,HP,BW,BW,EFAVIRENZ.,Exposure during pregnancy;Viral load increased,179864841,OT,,,,,,,,,179864841,1,HIV infection
17986504,179865041,1,I,,20200629,20200707,20200707,EXP,,BW-AUROBINDO-AUR-APL-2020-032174,AUROBINDO,,40,YR,,F,Y,,,20200707,,HP,BW,BW,EFAVIRENZ.,Exposure during pregnancy;Viral load increased,179865041,OT,,,,,,,,,179865041,1,HIV infection
17987047,179870471,1,I,20200625,20200701,20200707,20200707,EXP,,ZA-ROCHE-2634859,ROCHE,,48,YR,,M,Y,89,KG,20200707,,PH,ZA,ZA,EFAVIRENZ.,Off label use;Renal failure,179870471,DE,,,179870471,1,20200625,,,,179870471,1,COVID-19 pneumonia
17987253,179872531,1,I,,20200629,20200707,20200707,EXP,,BW-AUROBINDO-AUR-APL-2020-032157,AUROBINDO,,27,YR,,F,Y,,,20200707,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179872531,OT,,,,,,,,,179872531,1,HIV infection
17987258,179872581,1,I,,20200629,20200707,20200707,EXP,,BW-AUROBINDO-AUR-APL-2020-032146,AUROBINDO,,27,YR,,F,Y,,,20200707,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Viral mutation identified,179872581,OT,,,,,,,,,179872581,1,HIV infection
17987332,179873321,1,I,,20200629,20200707,20200707,EXP,,BW-AUROBINDO-AUR-APL-2020-032149,AUROBINDO,,35,YR,,F,Y,,,20200707,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179873321,OT,,,,,,,,,179873321,1,HIV infection
17987710,179877101,1,I,,20200629,20200707,20200707,EXP,,BW-AUROBINDO-AUR-APL-2020-032161,AUROBINDO,,33,YR,,F,Y,,,20200707,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Viral mutation identified,179877101,OT,,,,,,,,,179877101,1,HIV infection
17989504,179895041,1,I,,20200625,20200707,20200707,EXP,,DE-MYLANLABS-2020M1061156,MYLAN,,7,YR,,M,Y,,,20200707,,HP,DE,NG,EFAVIRENZ.,Pathogen resistance,179895041,OT,,,,,,,,,179895041,1,HIV infection
17989513,179895131,1,I,,20200625,20200707,20200707,EXP,,DE-MYLANLABS-2020M1061150,MYLAN,,42,YR,,M,Y,,,20200707,,HP,DE,NG,EFAVIRENZ.,Pathogen resistance,179895131,OT,,,,,,,,,179895131,1,HIV infection
17990876,179908761,1,I,,20200626,20200707,20200707,EXP,,GB-MYLANLABS-2020M1060756,MYLAN,,,,,M,Y,,,20200707,,CN,GB,GB,EFAVIRENZ.,Life expectancy shortened;Lung neoplasm malignant;Malaise;Metastases to central nervous system,179908761,HO,,,,,,,,,179908761,1,Product used for unknown indication
17992095,179920951,1,I,,20200629,20200708,20200708,EXP,,BW-AUROBINDO-AUR-APL-2020-032153,AUROBINDO,,35,YR,,F,Y,,,20200708,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179920951,OT,,,,,,,,,179920951,1,HIV infection
17992102,179921021,1,I,,20200629,20200708,20200708,EXP,,BW-AUROBINDO-AUR-APL-2020-032167,AUROBINDO,,24,YR,,F,Y,,,20200708,,HP,BW,BW,EFAVIRENZ.,Exposure during pregnancy;Viral load increased,179921021,OT,,,,,,,,,179921021,1,HIV infection
17992107,179921071,1,I,,20200629,20200708,20200708,EXP,,BW-AUROBINDO-AUR-APL-2020-032175,AUROBINDO,,28,YR,,F,Y,,,20200708,,HP,BW,BW,EFAVIRENZ.,Exposure during pregnancy;Viral load increased,179921071,OT,,,,,,,,,179921071,1,HIV infection
17992294,179922942,2,F,,20200722,20200708,20200728,EXP,,FR-STRIDES ARCOLAB LIMITED-2020SP007632,STRIDES,,,,,,Y,,,20200728,,HP,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Pachygyria,179922942,OT,,,,,,,,,179922942,1,Product used for unknown indication
17993740,179937401,1,I,,20200629,20200708,20200708,EXP,,BW-AUROBINDO-AUR-APL-2020-032163,AUROBINDO,,26,YR,,F,Y,,,20200708,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179937401,OT,,,,,,,,,179937401,1,HIV infection
17996590,179965901,1,I,,20200629,20200709,20200709,EXP,,BW-AUROBINDO-AUR-APL-2020-032178,AUROBINDO,,20,YR,,F,Y,,,20200709,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Gene mutation,179965901,OT,,,,,,,,,179965901,1,HIV infection
17998241,179982412,2,F,20200607,20200706,20200708,20200716,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-053850,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20200716,,CN,GB,GB,EFAVIRENZ.,COVID-19,179982412,OT,,,,,,,,,179982412,1,Product used for unknown indication
17998484,179984841,1,I,,20200629,20200709,20200709,EXP,,BW-AUROBINDO-AUR-APL-2020-032145,AUROBINDO,,27,YR,,F,Y,,,20200709,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179984841,OT,,,,,,,,,179984841,1,HIV infection
17998486,179984861,1,I,,20200629,20200709,20200709,EXP,,BW-AUROBINDO-AUR-APL-2020-032165,AUROBINDO,,40,YR,,F,Y,,,20200709,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179984861,OT,,,,,,,,,179984861,1,HIV infection
17998489,179984891,1,I,,20200629,20200709,20200709,EXP,,BW-AUROBINDO-AUR-APL-2020-032164,AUROBINDO,,27,YR,,F,Y,,,20200709,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179984891,OT,,,,,,,,,179984891,1,HIV infection
17998495,179984951,1,I,,20200629,20200709,20200709,EXP,,BW-AUROBINDO-AUR-APL-2020-032162,AUROBINDO,,30,YR,,F,Y,,,20200709,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179984951,OT,,,,,,,,,179984951,1,HIV infection
17998503,179985031,1,I,,20200629,20200709,20200709,EXP,,BW-AUROBINDO-AUR-APL-2020-032172,AUROBINDO,,41,YR,,F,Y,,,20200709,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,179985031,OT,,,,,,,,,179985031,1,HIV infection
17998519,179985191,1,I,,20200629,20200709,20200709,EXP,,FR-HETERO-HET2020FR00755,HETERO,,,,I,,Y,,,20200709,,HP,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Pachygyria,179985191,CA,,,,,,,,,179985191,1,HIV infection
18001991,180019911,1,I,20200607,20200629,20200709,20200709,EXP,,GB-MYLANLABS-2020M1060950,MYLAN,,,,,F,Y,,,20200709,,CN,GB,GB,EFAVIRENZ.,Coronavirus infection,180019911,OT,,,,,,,,,180019911,1,Product used for unknown indication
18002066,180020661,1,I,,20200629,20200710,20200710,EXP,,BW-AUROBINDO-AUR-APL-2020-032156,AUROBINDO,,26,YR,,F,Y,,,20200710,,HP,BW,BW,EFAVIRENZ.,Blood HIV RNA increased;Exposure during pregnancy,180020661,OT,,,,,,,,,180020661,1,HIV infection
18002318,180023181,1,I,,20200706,20200709,20200709,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-053886,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20200709,,CN,GB,GB,EFAVIRENZ.,Life expectancy shortened;Lung neoplasm malignant;Malaise;Metastases to central nervous system,180023181,HO,,,,,,,,,180023181,1,Product used for unknown indication
18007582,180075821,1,I,,20200706,20200710,20200710,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-034172",BOEHRINGER INGELHEIM,,,,,,Y,,,20200710,,HP,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,180075821,OT,,,,,,,,,180075821,1,HIV infection
18012500,180125001,1,I,,20200703,20200713,20200713,EXP,,CA-TEVA-2020-CA-1798759,TEVA,,,,,M,Y,,,20200713,,CN,CA,CA,EFAVIRENZ.,Depression;Drug interaction,180125001,OT,,,,,,,,,180125001,1,Product used for unknown indication
18014650,180146501,1,I,,20200703,20200713,20200713,EXP,,CA-TEVA-2020-CA-1798842,TEVA,,,,,M,Y,,,20200713,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,180146501,DE,,,,,,,,,180146501,1,Product used for unknown indication
18015435,180154351,1,I,,20200703,20200713,20200713,EXP,,CA-TEVA-2020-CA-1798836,TEVA,,54,YR,,M,Y,,,20200713,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,180154351,OT,,,,,,,,,180154351,1,Bipolar disorder
18016136,180161361,1,I,,20200703,20200713,20200713,EXP,,CA-TEVA-2020-CA-1798833,TEVA,,54,YR,,M,Y,,,20200713,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,180161361,OT,,,,,,,,,180161361,1,Bipolar disorder
18018055,180180551,1,I,,20200703,20200713,20200713,EXP,,DE-AUROBINDO-AUR-APL-2020-034154,AUROBINDO,,42,YR,,M,Y,,,20200714,,HP,DE,DE,EFAVIRENZ.,Pathogen resistance,180180551,OT,,,,,,,,,180180551,1,HIV infection
18019221,180192211,1,I,200909,20200706,20200714,20200714,EXP,,ZA-GLAXOSMITHKLINE-ZA2020EME123755,GLAXOSMITHKLINE,,,,A,F,Y,,,20200714,,HP,ZA,ZA,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180192211,OT,,,180192211,1,2007,,,,180192211,1,HIV infection
18020882,180208821,1,I,2001,20200702,20200714,20200714,EXP,,DE-GLAXOSMITHKLINE-DE2020GSK120069,GLAXOSMITHKLINE,HAFNER J AND BOGNER J. 30 YEARS OF ANTIRETROVIRAL THERAPY: FROM DEATH SENTENCE TO CHRONIC ILLNESS. MMW FORTSCHRITTE DER MEDIZIN. 2020?162 (SUPPL 2):16?19,,,,M,Y,,,20200714,,MD,DE,DE,EFAVIRENZ.,Disease progression;General physical health deterioration;Impaired work ability;Limb deformity;Lipodystrophy acquired;Neck deformity;Pathogen resistance;Polyneuropathy chronic;Renal impairment,180208821,OT,,,180208821,1,198909,2015,,,180208821,1,HIV infection
18020905,180209051,1,I,2001,20200702,20200714,20200714,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2020GSK120069,VIIV,HAFNER J AND BOGNER J. 30 YEARS OF ANTIRETROVIRAL THERAPY: FROM DEATH SENTENCE TO CHRONIC ILLNESS. MMW FORTSCHRITTE DER MEDIZIN. 2020?162 (SUPPL 2):16?19,,,,M,Y,,,20200714,,MD,DE,DE,EFAVIRENZ.,Disease progression;General physical health deterioration;Impaired work ability;Limb deformity;Lipodystrophy acquired;Neck deformity;Pathogen resistance;Polyneuropathy chronic;Renal impairment,180209051,OT,,,180209051,1,198909,2015,,,180209051,1,HIV infection
18021000,180210001,1,I,,20200703,20200714,20200714,EXP,,DE-AUROBINDO-AUR-APL-2020-034155,AUROBINDO,,7,YR,,M,Y,,,20200714,,HP,DE,NG,EFAVIRENZ.,Pathogen resistance,180210001,OT,,,,,,,,,180210001,1,HIV infection
18021966,180219661,1,I,,20200707,20200715,20200715,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-054489,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20200715,,HP,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Pachygyria,180219661,CA,,,,,,,,,180219661,1,Product used for unknown indication
18022611,180226112,2,F,,20200826,20200715,20200903,EXP,,GB-AUROBINDO-AUR-APL-2020-034425,AUROBINDO,,,,,M,Y,,,20200903,,CN,GB,GB,EFAVIRENZ.,Feeling abnormal;Hospitalisation;Life expectancy shortened;Lung cancer metastatic;Lung neoplasm malignant;Malaise;Metastases to central nervous system,180226112,HO,,,,,,,,,180226112,1,Product used for unknown indication
18022832,180228321,1,I,202004,20200514,20200715,20200715,PER,,DE-HORMOSAN PHARMA GMBH-2020-02278,LUPIN,,44,YR,,M,Y,,,20200715,,HP,DE,DE,EFAVIRENZ.,Arthralgia;Back pain;Faeces soft;Fatigue;Muscle disorder;Myalgia;Pain in extremity;Rash,,,,,,,,,,,180228321,1,HIV infection
18024631,180246311,1,I,20200607,20200704,20200714,20200714,EXP,,GB-AUROBINDO-AUR-APL-2020-034387,AUROBINDO,,,,,F,Y,,,20200715,,CN,GB,GB,EFAVIRENZ.,Coronavirus infection,180246311,OT,,,,,,,,,180246311,1,Product used for unknown indication
18029816,180298161,1,I,200909,20200706,20200715,20200715,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2020EME123755,VIIV,,,,A,F,Y,,,20200715,,HP,ZA,ZA,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180298161,OT,,,180298161,1,2007,,,,180298161,1,HIV infection
18033126,180331261,1,I,,20200708,20200716,20200716,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK130228,GLAXOSMITHKLINE,,24,YR,,M,Y,,,20200716,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180331261,OT,,,,,,,,,180331261,1,HIV infection
18033133,180331331,1,I,,20200708,20200716,20200716,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK130228,VIIV,,24,YR,,M,Y,,,20200716,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180331331,OT,,,,,,,,,180331331,1,HIV infection
18033166,180331661,1,I,,20200708,20200716,20200716,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK130229,VIIV,,52,YR,,M,Y,,,20200716,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180331661,OT,,,,,,,,,180331661,1,HIV infection
18033167,180331671,1,I,,20200708,20200716,20200716,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK130229,GLAXOSMITHKLINE,,52,YR,,M,Y,,,20200716,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180331671,OT,,,,,,,,,180331671,1,HIV infection
18033949,180339491,1,I,,20200708,20200716,20200716,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK130232,GLAXOSMITHKLINE,,26,YR,,M,Y,,,20200716,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180339491,OT,,,,,,,,,180339491,1,HIV infection
18033950,180339501,1,I,,20200708,20200716,20200716,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK130232,VIIV,,26,YR,,M,Y,,,20200716,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180339501,OT,,,,,,,,,180339501,1,HIV infection
18034001,180340011,1,I,,20200708,20200716,20200716,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK130234,VIIV,,25,YR,,M,Y,,,20200716,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180340011,OT,,,,,,,,,180340011,1,HIV infection
18034002,180340021,1,I,,20200708,20200716,20200716,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK130234,GLAXOSMITHKLINE,,25,YR,,M,Y,,,20200716,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180340021,OT,,,,,,,,,180340021,1,HIV infection
18034167,180341671,1,I,,20200708,20200716,20200716,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK130239,VIIV,,41,YR,,M,Y,,,20200716,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180341671,OT,,,,,,,,,180341671,1,HIV infection
18034168,180341681,1,I,,20200708,20200716,20200716,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK130239,GLAXOSMITHKLINE,,41,YR,,M,Y,,,20200716,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,180341681,OT,,,,,,,,,180341681,1,HIV infection
18035690,180356902,2,F,,20200831,20200717,20200911,EXP,,US-LUPIN PHARMACEUTICALS INC.-2020-03391,LUPIN,,,,A,F,Y,,,20200911,,HP,KE,US,EFAVIRENZ.,Drug resistance;Exposure during pregnancy,180356902,OT,,,,,,,,,180356902,1,Prophylaxis against HIV infection
18037850,180378502,2,F,,20200831,20200717,20200911,EXP,,US-LUPIN PHARMACEUTICALS INC.-2020-03387,LUPIN,,,,A,F,Y,,,20200911,,HP,KE,US,EFAVIRENZ.,Drug resistance;Exposure during pregnancy,180378502,OT,,,,,,,,,180378502,1,Prophylaxis against HIV infection
18038179,180381791,1,I,202004,20200708,20200717,20200717,EXP,,GB-MYLANLABS-2020M1063433,MYLAN,,,,A,M,Y,,,20200717,,CN,GB,GB,EFAVIRENZ.,Coronavirus infection,180381791,OT,,,,,,,,,180381791,1,Product used for unknown indication
18038721,180387211,1,I,,20200707,20200717,20200717,EXP,,SG-LUPIN PHARMACEUTICALS INC.-2020-03425,LUPIN,,,,A,M,Y,,,20200717,,HP,SG,SG,EFAVIRENZ.,HIV infection;Retroviral rebound syndrome,180387211,OT,,,,,,,,,180387211,1,HIV infection
18038722,180387221,1,I,,20200707,20200717,20200717,EXP,,SG-LUPIN PHARMACEUTICALS INC.-2020-03426,LUPIN,,,,A,M,Y,,,20200717,,HP,SG,SG,EFAVIRENZ.,Drug resistance;HIV infection;Retroviral rebound syndrome,180387221,OT,,,,,,,,,180387221,1,HIV infection
18040288,180402881,1,I,20140609,20200713,20200717,20200717,EXP,,US-GILEAD-2020-0483314,GILEAD,,38,YR,A,M,Y,,,20200717,,CN,US,US,SUSTIVA,Chronic kidney disease;Pain,180402881,OT,,,180402881,1,200604,20181126,,,180402881,1,HIV infection
18045598,180455981,1,I,,20200710,20200720,20200720,EXP,,GB-MYLANLABS-2020M1064529,MYLAN,,,,,F,Y,,,20200720,,CN,GB,GB,EFAVIRENZ MYLAN,Hospitalisation,180455981,HO,,,,,,,,,180455981,1,Product used for unknown indication
18045782,180457821,1,I,,20200713,20200720,20200720,EXP,,CA-TEVA-2020-CA-1801616,TEVA,,52,YR,,M,Y,,,20200720,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,180457821,OT,,,,,,,,,180457821,1,HIV infection
18045984,180459842,2,F,,20200826,20200720,20200904,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-055026,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20200904,,CN,GB,GB,EFAVIRENZ.,Feeling abnormal;Hospitalisation;Lung cancer metastatic;Lung neoplasm malignant,180459842,HO,,,,,,,,,180459842,1,Product used for unknown indication
18047788,180477883,3,F,20191001,20200731,20200721,20200807,EXP,,ZA-AUROBINDO-AUR-APL-2020-036019,AUROBINDO,,20,YR,,F,Y,,,20200807,,HP,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Abortion induced;Maternal exposure during pregnancy,180477883,OT,,,180477883,1,20180710,,,,180477883,1,HIV infection
18047798,180477983,3,F,20200410,20200731,20200721,20200807,EXP,,ZA-AUROBINDO-AUR-APL-2020-036030,AUROBINDO,,30,YR,,F,Y,,,20200807,,HP,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Abortion induced;Maternal exposure during pregnancy,180477983,OT,,,180477983,1,20180510,,,,180477983,1,HIV infection
18050416,180504161,1,I,,20200713,20200721,20200721,EXP,,GB-MYLANLABS-2020M1064471,MYLAN,,,,,M,Y,,,20200721,,CN,GB,GB,EFAVIRENZ.,Feeling abnormal;Hospitalisation;Lung cancer metastatic;Lung neoplasm malignant,180504161,HO,,,,,,,,,180504161,1,Product used for unknown indication
18050425,180504251,1,I,,20200713,20200721,20200721,EXP,,FR-MYLANLABS-2020M1064473,MYLAN,,,,,,Y,,,20200721,,HP,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Pachygyria,180504251,CA,,,,,,,,,180504251,1,Product used for unknown indication
18052384,180523841,1,I,2001,20200714,20200722,20200722,EXP,,DE-AUROBINDO-AUR-APL-2020-035645,AUROBINDO,,,,,M,Y,,,20200722,,HP,DE,DE,EFAVIRENZ.,Disease progression;General physical health deterioration;Impaired work ability;Limb deformity;Lipodystrophy acquired;Neck deformity;Pathogen resistance;Polyneuropathy chronic;Renal impairment,180523841,OT,,,180523841,2,2002,2015,,,180523841,1,HIV infection
18052548,180525481,1,I,2012,20200713,20200722,20200722,EXP,,US-AUROBINDO-AUR-APL-2020-035573,AUROBINDO,,24,YR,,M,Y,,,20200722,,HP,US,US,EFAVIRENZ.,Hepatic failure;Hepatotoxicity,180525481,LT,,,180525481,1,2010,2013,,,180525481,1,HIV infection
18053271,180532711,1,I,2001,20200717,20200722,20200722,EXP,,DE-ROCHE-2644768,ROCHE,"HAFNER J, AND BOGNER J 30 YEARS OF ANTIRETROVIRAL THERAPY: FROM DEATH SENTENCE TO CHRONIC ILLNESS. MMW FORTSCHRITTE DER MEDIZIN 2020?162 (SUPPL 2):16?19.",,,,M,Y,,,20200722,,MD,DE,DE,EFAVIRENZ.,Disease progression;General physical health deterioration;Impaired work ability;Limb deformity;Lipodystrophy acquired;Neck deformity;Pathogen resistance;Polyneuropathy chronic;Renal impairment,180532711,OT,,,180532711,2,198909,2015,,,180532711,1,HIV infection
18057020,180570201,1,I,20090212,20200714,20200722,20200722,EXP,,US-GILEAD-2020-0484454,GILEAD,,33,YR,A,M,Y,88.44,KG,20200722,,CN,US,US,SUSTIVA,Bone density decreased;Chronic kidney disease;Emotional distress;Pain;Renal failure,180570201,OT,,,180570201,1,20040120,20050519,,,180570201,1,HIV infection
18061821,180618211,1,I,20120923,20200715,20200723,20200723,EXP,,US-GILEAD-2020-0484958,GILEAD,,23,YR,A,M,Y,72.56,KG,20200723,,CN,US,US,SUSTIVA,Chronic kidney disease;Emotional distress;Haematoma;Pain;Renal failure,180618211,HO,,,180618211,1,20100324,20130308,,,180618211,1,HIV infection
18063886,180638861,1,I,2012,20200713,20200724,20200724,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2020027417,MACLEODS,,,,,,Y,,,20200724,,CN,IN,US,EFAVIRENZ.,Hepatic failure;Hepatotoxicity,180638861,OT,,,180638861,1,2010,2013,,,180638861,1,HIV infection
18064001,180640011,1,I,,20200713,20200724,20200724,EXP,,UG-CIPLA LTD.-2020UG04953,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21: 232:1 TO 6",,,,,Y,,,20200724,,HP,UG,UG,EFAVIRENZ;LAMIVUDINE;TENOFOVIR,Hyperkalaemia;Hyperphosphataemia;Hypocalcaemia,180640011,OT,,,,,,,,,180640011,1,HIV infection WHO clinical stage II
18064080,180640801,1,I,,20200713,20200724,20200724,EXP,,UG-CIPLA LTD.-2020UG04954,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P.. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21(232):1 TO 6",,,,,Y,,,20200724,,HP,UG,UG,EFAVIRENZ;LAMIVUDINE;TENOFOVIR,Hyperkalaemia;Hyperphosphataemia;Hypocalcaemia,180640801,OT,,,,,,,,,180640801,1,HIV infection WHO clinical stage II
18065411,180654111,1,I,,20200720,20200724,20200724,EXP,,CA-BAUSCH-BL-2020-020959,BAUSCH AND LOMB,,54,YR,,M,Y,,,20200724,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,180654111,OT,,,,,,,,,180654111,1,Bipolar disorder
18065589,180655891,1,I,,20200714,20200724,20200724,EXP,E2B_02992182,CA-ACCORD-191476,ACCORD,,44,YR,,M,Y,,,20200724,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,180655891,HO,,,,,,,,,180655891,1,Depression
18065634,180656341,1,I,2012,20200713,20200724,20200724,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-056332,BRISTOL MYERS SQUIBB,"MODI AR, KOVAL CE, TAEGE AJ, MODARESI ESFEH J, EGHTESAD B, NARAYANAN MENON KV, ET AL. CORONAVIRUS DISEASE 2019 IN AN ORTHOTOPIC LIVER TRANSPLANT RECIPIENT LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS. TRANSPLANT INFECTIOUS DISEASE. 2020",24,YR,,M,Y,,,20200724,,MD,US,US,EFAVIRENZ.,Hepatic failure;Hepatotoxicity,180656341,LT,,,180656341,1,2010,2013,,,180656341,1,HIV infection
18067893,180678931,1,I,2001,20200718,20200724,20200724,EXP,,DE-MYLANLABS-2020M1066161,MYLAN,HAFNER J AND BOGNER J.. 30 YEARS OF ANTIRETROVIRAL THERAPY: FROM DEATH SENTENCE TO CHRONIC ILLNESS.. MMW FORTSCHRITTE DER MEDIZIN.. 2020?162 (SUPPL 2):16?19,,,,M,Y,,,20200724,,MD,DE,DE,EFAVIRENZ.,Disease progression;General physical health deterioration;Impaired work ability;Limb deformity;Lipodystrophy acquired;Neck deformity;Pathogen resistance;Polyneuropathy chronic;Renal impairment,180678931,OT,,,180678931,1,2002,2015,,,180678931,1,HIV infection
18069659,180696591,1,I,,20200720,20200726,20200726,EXP,,CA-BAUSCH-BL-2020-020961,BAUSCH AND LOMB,,54,YR,,M,Y,,,20200727,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,180696591,OT,,,,,,,,,180696591,1,Product used for unknown indication
18069660,180696601,1,I,,20200720,20200726,20200726,EXP,,CA-BAUSCH-BL-2020-020951,BAUSCH AND LOMB,,,,,M,Y,,,20200727,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,180696601,DE,,,,,,,,,180696601,1,Product used for unknown indication
18069661,180696611,1,I,,20200720,20200726,20200726,EXP,,CA-BAUSCH-BL-2020-020967,BAUSCH AND LOMB,,54,YR,,M,Y,,,20200727,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,180696611,OT,,,,,,,,,180696611,1,Bipolar disorder
18072196,180721961,1,I,,20200713,20200727,20200727,EXP,,UG-CIPLA LTD.-2020UG04960,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P.. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21: 232:1 TO 6",,,,,Y,,,20200727,,HP,UG,UG,EFAVIRENZ.,Hyperkalaemia,180721961,OT,,,,,,,,,180721961,1,HIV infection WHO clinical stage I
18072198,180721981,1,I,,20200713,20200727,20200727,EXP,,UG-CIPLA LTD.-2020UG04955,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21: 232:1 TO 6",,,,,Y,,,20200727,,HP,UG,UG,EFAVIRENZ.,Hyperkalaemia;Hyperphosphataemia;Hypocalcaemia,180721981,OT,,,,,,,,,180721981,1,HIV infection WHO clinical stage II
18072199,180721991,1,I,,20200713,20200727,20200727,EXP,,UG-CIPLA LTD.-2020UG04952,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P.. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21 (232):1 TO 6",,,,,Y,,,20200727,,HP,UG,UG,EFAVIRENZ.,Hyperkalaemia,180721991,OT,,,,,,,,,180721991,1,HIV infection WHO clinical stage I
18072200,180722001,1,I,,20200713,20200727,20200727,EXP,,UG-CIPLA LTD.-2020UG04963,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P.. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21 (232):1 TO 6",,,,,Y,,,20200727,,HP,UG,UG,EFAVIRENZ.,Hyperkalaemia,180722001,OT,,,,,,,,,180722001,1,HIV infection WHO clinical stage I
18072207,180722071,1,I,,20200713,20200727,20200727,EXP,US-MLMSERVICE-20200707-2366000-1,US-CIPLA LTD.-2020US04931,CIPLA,"MODI AR, KOVAL CE, TAEGE AJ, MODARESI EJ, EGHTESAD B,NARAYANAN MKV ET AL.. CORONAVIRUS DISEASE 2019 IN AN ORTHOTOPIC LIVER TRANSPLANT RECIPIENT LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS. TRANSPLANT INFECTIOUS DISEASE. 2020",,,,,Y,,,20200727,,MD,US,US,EFAVIRENZ.,Hepatic failure;Hepatotoxicity,180722071,LT,,,180722071,1,2010,2013,,,180722071,1,HIV infection
18072208,180722081,1,I,,20200713,20200727,20200727,EXP,,UG-CIPLA LTD.-2020UG04958,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21 (232):1 TO 6",,,,,Y,,,20200727,,HP,UG,UG,EFAVIRENZ.,Hyperkalaemia;Renal impairment,180722081,OT,,,,,,,,,180722081,1,HIV infection WHO clinical stage II
18072209,180722091,1,I,,20200713,20200727,20200727,EXP,,UG-CIPLA LTD.-2020UG04956,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21: 232:1 TO 6",,,,,Y,,,20200727,,HP,UG,UG,EFAVIRENZ.,Hyperkalaemia,180722091,OT,,,,,,,,,180722091,1,HIV infection WHO clinical stage III
18072215,180722151,1,I,,20200713,20200727,20200727,EXP,,UG-CIPLA LTD.-2020UG04990,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P.. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21 (232):1 TO 6",,,,,Y,,,20200727,,HP,UG,UG,EFAVIRENZ.,Hyperkalaemia,180722151,OT,,,,,,,,,180722151,1,HIV infection WHO clinical stage I
18073458,180734581,1,I,,20200714,20200727,20200727,EXP,,UG-LUPIN PHARMACEUTICALS INC.-2020-03656,LUPIN,,34,YR,,F,Y,,,20200727,,HP,UG,UG,EFAVIRENZ.,Blood alkaline phosphatase increased;Off label use,180734581,OT,,,180734581,1,2020,,,,180734581,1,COVID-19
18073644,180736441,1,I,,20200720,20200727,20200727,EXP,GB-GLAXOSMITHKLINE-GB2020EME116192,GB-MYLANLABS-2020M1066335,MYLAN,,,,,M,Y,,,20200727,,CN,GB,GB,EFAVIRENZ.,Feeling abnormal;Hospitalisation;Lung cancer metastatic;Lung neoplasm malignant,180736441,HO,,,,,,,,,180736441,1,Product used for unknown indication
18073688,180736881,1,I,,20200720,20200727,20200727,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020GSK143017,VIIV,,54,YR,,M,Y,,,20200727,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,180736881,OT,,,,,,,,,180736881,1,Bipolar disorder
18073693,180736931,1,I,,20200720,20200727,20200727,EXP,,CA-GLAXOSMITHKLINE-CA2020GSK143017,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20200727,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,180736931,OT,,,,,,,,,180736931,1,Bipolar disorder
18074119,180741191,1,I,2016,20200720,20200727,20200727,EXP,,TZ-GLAXOSMITHKLINE-US2020GSK137403,GLAXOSMITHKLINE,"BACHA JM, EL?MALLAWANY NK, SLONE JS, WILKINSON JP, MEHTA PS, CAMPBELL LR. RECOMMENDATIONS FOR TREATING LIFE?THREATENING KAPOSI SARCOMA DURING PREGNANCY IN HIV?POSITIVE WOMEN IN LOW INCOME COUNTRIES. INTERNATIONAL JOURNAL OF STD AND AIDS. 2020?31 (8):724?734",31,YR,,F,Y,,,20200727,,HP,TZ,TZ,EFAVIRENZ.,Abdominal pain;Condition aggravated;Dysphagia;Dyspnoea;Exposure during pregnancy;Exposure via breast milk;Haematemesis;Haematochezia;Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma;Kaposi's sarcoma;Live birth;Lymphadenopathy;Obstructive airways disorder;Oral candidiasis;Skin lesion,180741191,LT,,,180741191,1,2016,,,,180741191,1,HIV infection
18074133,180741331,1,I,2016,20200720,20200727,20200727,EXP,,TZ-VIIV HEALTHCARE LIMITED-US2020GSK137403,VIIV,"BACHA JM, EL?MALLAWANY NK, SLONE JS, WILKINSON JP, MEHTA PS, CAMPBELL LR. RECOMMENDATIONS FOR TREATING LIFE?THREATENING KAPOSI SARCOMA DURING PREGNANCY IN HIV?POSITIVE WOMEN IN LOW INCOME COUNTRIES. INTERNATIONAL JOURNAL OF STD AND AIDS. 2020?31 (8):724?734",31,YR,,F,Y,,,20200727,,HP,TZ,TZ,EFAVIRENZ.,Abdominal pain;Condition aggravated;Dysphagia;Dyspnoea;Exposure during pregnancy;Exposure via breast milk;Haematemesis;Haematochezia;Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma;Kaposi's sarcoma;Live birth;Lymphadenopathy;Obstructive airways disorder;Oral candidiasis;Skin lesion,180741331,OT,,,180741331,1,2016,,,,180741331,1,HIV infection
18076536,180765361,1,I,202004,20200715,20200728,20200728,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-056746,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20200728,,CN,GB,GB,EFAVIRENZ.,Coronavirus infection,180765361,OT,,,,,,,,,180765361,1,Product used for unknown indication
18077162,180771621,1,I,,20200720,20200728,20200728,EXP,,FR-HETERO-HET2020FR00834,HETERO,,,,I,,Y,,,20200728,,HP,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Pachygyria,180771621,OT,,,,,,,,,180771621,1,HIV infection
18077791,180777911,1,I,200802,20200715,20200727,20200727,EXP,,US-GILEAD-2020-0484975,GILEAD,,60,YR,E,F,Y,104.31,KG,20200727,,CN,US,US,SUSTIVA,Emotional distress;Osteoporosis;Pain,180777911,OT,,,180777911,1,2004,20130629,,,180777911,1,HIV infection
18078179,180781791,1,I,,20200713,20200728,20200728,EXP,,UG-CIPLA LTD.-2020UG04969,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21 (232):1 TO 6",,,,,Y,,,20200728,,HP,UG,UG,EFAVIRENZ.,Hyperkalaemia;Hypophosphataemia,180781791,OT,,,,,,,,,180781791,1,HIV infection WHO clinical stage I
18078182,180781821,1,I,,20200713,20200728,20200728,EXP,,UG-CIPLA LTD.-2020UG04957,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21 (232):1 TO 6",,,,,Y,,,20200728,,HP,UG,UG,EFAVIRENZ;LAMIVUDINE;TENOFOVIR,Hyperkalaemia,180781821,OT,,,,,,,,,180781821,1,HIV infection WHO clinical stage II
18079395,180793951,1,I,,20200713,20200728,20200728,EXP,,UG-CIPLA LTD.-2020UG04989,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21 (232):1 TO 6",,,,,Y,,,20200728,,HP,UG,UG,EFAVIRENZ;LAMIVUDINE;TENOFOVIR,Hyperkalaemia;Hypocalcaemia,180793951,OT,,,,,,,,,180793951,1,HIV infection WHO clinical stage II
18079728,180797281,1,I,,20200720,20200728,20200728,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020GSK143033,VIIV,,,,,M,Y,,,20200728,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,180797281,DE,,,,,,,,,180797281,1,Product used for unknown indication
18079730,180797301,1,I,,20200720,20200728,20200728,EXP,,CA-GLAXOSMITHKLINE-CA2020GSK143033,GLAXOSMITHKLINE,,,,,M,Y,,,20200728,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,180797301,DE,,,,,,,,,180797301,1,Product used for unknown indication
18080239,180802391,1,I,202003,20200720,20200728,20200728,EXP,,GB-MYLANLABS-2020M1066811,MYLAN,,,,A,M,Y,,,20200728,,CN,GB,GB,EFAVIRENZ.,COVID-19;Cough;Feeling abnormal;Influenza like illness,180802391,OT,,,,,,,,,180802391,1,Product used for unknown indication
18087033,180870331,1,I,,20200720,20200729,20200729,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020GSK142975,VIIV,,54,YR,,M,Y,,,20200729,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,180870331,OT,,,,,,,,,180870331,1,Product used for unknown indication
18087039,180870391,1,I,,20200720,20200729,20200729,EXP,,CA-GLAXOSMITHKLINE-CA2020GSK142975,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20200729,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,180870391,OT,,,,,,,,,180870391,1,Product used for unknown indication
18094089,180940891,1,I,202003,20200722,20200730,20200730,EXP,,GB-MYLANLABS-2020M1067706,MYLAN,,,,A,F,Y,,,20200730,,CN,GB,GB,EFAVIRENZ.,COVID-19,180940891,OT,,,,,,,,,180940891,1,Product used for unknown indication
18095441,180954411,1,I,2016,20200723,20200730,20200730,EXP,,TZ-MYLANLABS-2020M1068658,MYLAN,"BACHA JM, EL?MALLAWANY NK, SLONE JS, WILKINSON JP, MEHTA PS, CAMPBELL LR. RECOMMENDATIONS FOR TREATING LIFE?THREATENING KAPOSI SARCOMA DURING PREGNANCY IN HIV?POSITIVE WOMEN IN LOW INCOME COUNTRIES. INT?J?STD?AIDS 2020?31(8):724?734.",31,YR,,F,Y,,,20200730,,HP,TZ,TZ,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Abdominal pain;Dysphagia;Dyspnoea;Exposure via breast milk;Haematemesis;Haematochezia;Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma;Lymphadenopathy;Maternal exposure during pregnancy;Obstructive airways disorder;Oral candidiasis,180954411,OT,,,180954411,1,2016,2016,,,180954411,1,HIV infection
18100590,181005904,4,F,,20200806,20200801,20200814,EXP,,FR-AUROBINDO-AUR-APL-2020-037112,AUROBINDO,,,,I,,Y,,,20200814,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Pachygyria,181005904,OT,,,,,,,,,181005904,1,Product used for unknown indication
18101929,181019291,1,I,202003,20200729,20200802,20200802,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-061085,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20200802,,CN,GB,GB,EFAVIRENZ.,COVID-19,181019291,OT,,,,,,,,,181019291,1,Product used for unknown indication
18102678,181026782,2,F,2012,20200831,20200803,20200918,EXP,,US-GILEAD-2020-0486585,GILEAD,,,,A,M,Y,73.47,KG,20200918,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Pain;Renal failure,181026782,OT,,,181026782,1,2011,2016,,,181026782,1,HIV infection
18109928,181099282,2,F,201002,20200831,20200804,20200918,PER,,US-GILEAD-2020-0486821,GILEAD,,56,YR,A,M,Y,53,KG,20200918,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Osteopenia;Pain,,,,,181099282,1,2006,2019,,,181099282,1,HIV infection
18110465,181104652,2,F,20130508,20200526,20200804,20200930,EXP,,US-GILEAD-2020-0486802,GILEAD,,41,YR,A,M,Y,85,KG,20200930,,CN,US,US,EFAVIRENZ.;SUSTIVA,Abdominal pain;Anhedonia;Ankle fracture;Anxiety;Chronic kidney disease;Dizziness;Emotional distress;Loss of consciousness;Pain;Pyrexia;Syncope,181104652,HO,,,181104652,1,2001,2007,,,181104652,1,HIV infection
18110954,181109541,1,I,,20200724,20200804,20200804,EXP,,US-GILEAD-2020-0488466,GILEAD,,,,A,F,Y,55.78,KG,20200804,,CN,US,US,SUSTIVA,Chronic kidney disease;Emotional distress;Pain,181109541,OT,,,181109541,1,201011,201212,,,181109541,1,HIV infection
18112162,181121621,1,I,,20200730,20200805,20200805,EXP,,FR-AUROBINDO-AUR-APL-2020-037881,AUROBINDO,SUSMAN ED. EFAVIRENZ TIED TO NEUROLOGICAL BIRTH DEFECTS... CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS. 2013,,,,,Y,,,20200805,,MD,FR,FR,Efavirenz Film Coated Tablets,Foetal exposure during pregnancy;Pachygyria,181121621,OT,,,,,,,,,181121621,1,Product used for unknown indication
18116834,181168341,1,I,,20200803,20200806,20200806,EXP,,US-ABBVIE-20K-163-3511165-00,ABBVIE,,,,I,M,Y,3.24,KG,20200806,,HP,US,US,SUSTIVA,Cystic fibrosis;Foetal exposure during pregnancy;Meconium ileus,181168341,CA,,,,,,,,,181168341,1,Maternal exposure timing unspecified
18116896,181168961,1,I,,20200511,20200805,20200805,EXP,,US-PURDUE-USA-2020-0160361,PURDUE,,,,,M,Y,,,20200804,,CN,US,US,SUSTIVA,Balance disorder;Drug dependence;Drug withdrawal syndrome;Fall;Impaired driving ability;Loss of consciousness;Overdose;Unevaluable event,181168961,OT,,,,,,,,,181168961,1,Product used for unknown indication
18117153,181171531,1,I,201909,20200731,20200805,20200805,EXP,,US-GILEAD-2020-0488858,GILEAD,,50,YR,A,F,Y,,,20200805,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident;Product use issue,181171531,OT,,,181171531,1,2007,201909,,,181171531,1,HIV infection
18119415,181194151,1,I,,20010608,20200806,20200806,EXP,,US-PFIZER INC-1343-13524,PFIZER,,,,,M,Y,3.24,KG,20200806,,HP,US,US,SUSTIVA,Cystic fibrosis pancreatic;Maternal exposure during pregnancy;Meconium ileus,181194151,OT,,,181194151,1,20000810,20000926,,,,,
18119503,181195032,2,F,20190222,20200806,20200806,20200811,EXP,,DE-PFIZER INC-2020121581,PFIZER,,36,YR,,M,Y,72,KG,20200811,,MD,DE,DE,EFAVIRENZ + EMTRICITABINE + TENOFOVIR [EFAVIRENZ;EMTRICITABINE;TENOFOV,Alcohol poisoning;Fall;Kidney rupture;Mental disorder;Off label use;Renal disorder;Retroperitoneal haematoma;Rib fracture;Splenic rupture;Toxicity to various agents,181195032,OT,,,181195032,1,20190222,20200526,,,181195032,1,Venous thrombosis
18120238,181202381,1,I,2015,20200615,20200806,20200806,EXP,,US-GILEAD-2020-0484417,GILEAD,,74,YR,E,M,Y,90.7,KG,20200806,,CN,US,US,SUSTIVA,Chronic kidney disease;Emotional distress;Pain;Renal impairment,181202381,OT,,,181202381,1,2004,2013,,,181202381,1,HIV infection
18121742,181217421,1,I,2014,20200503,20200806,20200806,EXP,,US-GILEAD-2020-0487715,GILEAD,,45,YR,A,M,Y,106.12,KG,20200806,,LW,US,US,SUSTIVA,Anxiety;Arthralgia;Back pain;Blood creatinine increased;Bone density decreased;Bone loss;Chronic kidney disease;Crying;Depressed mood;Depression;Disturbance in attention;Dysstasia;Emotional distress;Emotional poverty;HIV infection;Loss of personal independence in daily activities;Mood swings;Musculoskeletal pain;Pain;Tooth disorder;Tooth loss;Vitamin D deficiency,181217421,OT,,,181217421,1,2009,20151116,,,181217421,1,HIV infection
18122787,181227871,1,I,20191231,20200802,20200807,20200807,EXP,,GH-009507513-2008GHA000821,MERCK,"KUMBENI MT, APANGA PA, AYAMGA EA. NEXPLANON FAILURE IN A WOMAN WITH HIV INFECTION IN RURAL GHANA: A CASE REPORT. CLINICAL CASE REPORTS. 2020?1?4",37,YR,,F,Y,68,KG,20200807,,HP,GH,GH,EFAVIRENZ.,Drug interaction;Pregnancy with implant contraceptive;Treatment failure;Unintended pregnancy,181227871,OT,,,181227871,1,20171206,202002,,,181227871,1,Contraception
18122828,181228281,1,I,,20200806,20200807,20200807,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-063655,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20200807,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,181228281,OT,,,,,,,,,181228281,1,Product used for unknown indication
18130200,181302001,1,I,,20200806,20200810,20200810,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-063532,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20200810,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities;Off label use,181302001,OT,,,,,,,,,181302001,1,HIV infection
18130563,181305631,1,I,,20200804,20200810,20200810,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040221",BOEHRINGER INGELHEIM,,45,YR,,M,Y,,,20200810,,HP,CA,CA,EFAVIRENZ.,Multiple-drug resistance,181305631,OT,,,,,,,,,181305631,1,HIV infection
18130712,181307123,3,F,20150527,20200912,20200810,20200917,PER,,US-GILEAD-2020-0489352,GILEAD,,61,YR,A,M,Y,86,KG,20200917,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Osteopenia;Osteoporosis;Pain,181307123,OT,,,181307123,1,2006,20141105,,,181307123,1,HIV infection
18131515,181315151,1,I,,20200804,20200810,20200810,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040147",BOEHRINGER INGELHEIM,,52,YR,,M,Y,,,20200810,,HP,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity,181315151,OT,,,,,,,,,181315151,1,HIV infection
18131665,181316652,2,F,202003,20200728,20200810,20200813,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-060874,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20200813,,CN,GB,GB,EFAVIRENZ.,COVID-19,181316652,OT,,,,,,,,,181316652,1,Product used for unknown indication
18132499,181324991,1,I,,20200804,20200811,20200811,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040473",BOEHRINGER INGELHEIM,,52,YR,,M,Y,,,20200811,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,181324991,OT,,,,,,,,,181324991,1,HIV infection
18133234,181332341,1,I,,20200803,20200811,20200811,EXP,,TZ-AUROBINDO-AUR-APL-2020-038325,AUROBINDO,,31,YR,,F,Y,,,20200811,,HP,TZ,TZ,"Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate",Abdominal pain;Condition aggravated;Dysphagia;Dyspnoea;Exposure during pregnancy;Haematemesis;Haematochezia;Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma;Lymphadenopathy;Oral candidiasis,181332341,OT,,,,,,,,,181332341,1,HIV infection
18133299,181332992,2,F,,20200810,20200811,20200813,EXP,,FR-MYLANLABS-2020M1070646,MYLAN,,,,I,,Y,,,20200813,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Pachygyria,181332992,OT,,,,,,,,,181332992,1,HIV infection
18139381,181393811,1,I,,20200804,20200812,20200812,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-040199",BOEHRINGER INGELHEIM,,,,,,Y,,,20200812,,HP,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,181393811,OT,,,,,,,,,181393811,1,HIV infection
18142985,181429851,1,I,20100801,20200806,20200812,20200812,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-064355,BRISTOL MYERS SQUIBB,,48,YR,,F,Y,,,20200812,,CN,US,US,SUSTIVA,Arthritis;Bone density decreased,,,,,,,,,,,181429851,1,HIV infection
18147294,181472941,1,I,,20190918,20200814,20200814,EXP,,IN-MACLEODS PHARMACEUTICALS US LTD-MAC2019023105,MACLEODS,,,,,,Y,,,20200814,,MD,IN,IN,EFAVIRENZ.,Drug reaction with eosinophilia and systemic symptoms;Rash erythematous,181472941,OT,,,,,,,,,181472941,1,HIV infection
18148567,181485672,2,F,,20200914,20200813,20200921,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-063642,BRISTOL MYERS SQUIBB,,44,YR,,M,Y,,,20200921,,HP,CA,CA,SUSTIVA,Anxiety,181485672,HO,,,,,,,,,181485672,1,HIV infection
18150978,181509783,3,F,20070403,20200817,20200814,20200824,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2020160069,VIIV,,,,N,M,Y,3.2,KG,20200824,,HP,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Hydrocele,181509783,CA,,,181509783,1,20070521,20070521,,,181509783,1,Product used for unknown indication
18150985,181509853,3,F,20070403,20200817,20200814,20200824,EXP,,FR-GLAXOSMITHKLINE-FR2020160069,GLAXOSMITHKLINE,,,,N,M,Y,3.2,KG,20200824,,HP,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Hydrocele,181509853,CA,,,181509853,1,20070521,20070521,,,181509853,1,Product used for unknown indication
18154249,181542491,1,I,,20200619,20200816,20200816,EXP,,CA-ROCHE-2627259,ROCHE,,52,YR,,M,Y,,,20200817,,HP,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity,181542491,OT,,,,,,,,,181542491,1,HIV infection
18154572,181545721,1,I,,20200625,20200817,20200817,PER,,US-STRIDES ARCOLAB LIMITED-2020SP007554,STRIDES,,61,YR,,F,Y,,,20200817,,MD,US,US,EFAVIRENZ.,Alopecia,,,,,,,,,,,181545721,1,HIV infection
18155604,181556041,1,I,,20200806,20200817,20200817,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-063757,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20200817,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,181556041,OT,,,,,,,,,181556041,1,Product used for unknown indication
18155717,181557171,1,I,,20200806,20200817,20200817,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-063936,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20200817,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,181557171,OT,,,,,,,,,181557171,1,HIV infection
18155930,181559301,1,I,,20200806,20200817,20200817,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-063793,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20200817,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,181559301,OT,,,,,,,,,181559301,1,Product used for unknown indication
18156798,181567982,2,F,2005,20200921,20200817,20200928,EXP,,US-GILEAD-2020-0490398,GILEAD,,51,YR,A,F,Y,246,KG,20200928,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Depression;Emotional distress;Osteopenia;Osteoporosis;Pain;Renal impairment,181567982,OT,,,181567982,1,2005,200908,,,181567982,1,HIV infection
18157575,181575752,2,F,,20200914,20200817,20200923,EXP,,US-GILEAD-2020-0490404,GILEAD,,,,,F,Y,113.38,KG,20200923,,LW,COUNTRY NOT SPECIFIED,US,SUSTIVA,Anxiety;Bone density decreased;Depression;Emotional distress;Osteoporosis;Pain,181575752,OT,,,181575752,1,2008,2016,,,181575752,1,HIV infection
18157901,181579012,2,F,2009,20200915,20200817,20200924,EXP,,US-GILEAD-2020-0489192,GILEAD,,59,YR,A,M,Y,141.95,KG,20200924,,LW,US,US,SUSTIVA,Anxiety;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Femur fracture;Insomnia;Mental impairment;Osteoporosis;Pain,181579012,OT,,,181579012,1,2004,2009,,,181579012,1,HIV infection
18158290,181582902,2,F,20151231,20200912,20200817,20200918,EXP,,US-GILEAD-2020-0489759,GILEAD,,49,YR,A,F,Y,68.03,KG,20200918,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Pain,181582902,OT,,,181582902,1,2006,2018,,,181582902,1,HIV infection
18158546,181585462,2,F,2017,20200917,20200817,20200928,EXP,,US-GILEAD-2020-0489318,GILEAD,,,,A,M,Y,74.83,KG,20200928,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Pain,181585462,OT,,,181585462,1,2010,2013,,,181585462,1,HIV infection
18159203,181592031,1,I,,20200806,20200818,20200818,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-064977,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20200818,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,181592031,OT,,,,,,,,,181592031,1,HIV infection
18160971,181609711,1,I,2019,20200814,20200817,20200817,EXP,,LV-GILEAD-2020-0490338,GILEAD,,45,YR,A,F,Y,,,20200817,,CN,LV,LV,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Hyperhidrosis;Therapy change,181609711,OT,,,181609711,1,2019,,,,181609711,1,HIV infection
18161065,181610652,2,F,2009,20200912,20200817,20200925,EXP,,US-GILEAD-2020-0489853,GILEAD,,,,A,F,Y,69.39,KG,20200925,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Economic problem;Emotional distress;Osteoporosis;Pain,181610652,OT,,,181610652,1,200905,201603,,,181610652,1,HIV infection
18163421,181634213,3,F,2005,20200914,20200818,20200924,EXP,,US-GILEAD-2020-0490118,GILEAD,,54,YR,A,F,Y,88.44,KG,20200924,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Pain,181634213,OT,,,181634213,1,2003,2005,,,181634213,1,HIV infection
18164183,181641832,2,F,201408,20200916,20200818,20200924,EXP,,US-GILEAD-2020-0490397,GILEAD,,59,YR,A,M,Y,95.24,KG,20200924,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Emotional distress;Pain,181641832,OT,,,181641832,1,2006,201408,,,181641832,1,HIV infection
18164264,181642642,2,F,20171211,20200916,20200818,20200928,EXP,,US-GILEAD-2020-0490119,GILEAD,,64,YR,A,M,Y,87.98,KG,20200928,,LW,US,US,EFAVIRENZ.,Anhedonia;Ankle fracture;Anxiety;Bone density decreased;Emotional distress;Osteopenia;Pain,181642642,OT,,,181642642,1,2008,2018,,,181642642,1,Product used for unknown indication
18165528,181655282,2,F,20140207,20200914,20200818,20200918,PER,,US-GILEAD-2020-0489964,GILEAD,,51,YR,A,M,Y,91.16,KG,20200918,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Emotional distress;Hypokinesia;Muscular weakness;Pain;Renal impairment,,,,,181655282,1,200303,2012,,,181655282,1,Product used for unknown indication
18165600,181656002,2,F,200607,20200918,20200818,20200925,EXP,,US-GILEAD-2020-0490476,GILEAD,,26,YR,A,M,Y,94.79,KG,20200925,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;End stage renal disease;Pain,181656002,OT,,,181656002,1,200304,200603,,,181656002,1,HIV infection
18167628,181676281,1,I,,20181105,20200819,20200819,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-104537,BRISTOL MYERS SQUIBB,,44,YR,,M,Y,,,20200819,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,181676281,HO,,,,,,,,,181676281,1,HIV infection
18168279,181682793,3,F,20191111,20200827,20200819,20200831,EXP,,ZA-AUROBINDO-AUR-APL-2020-040561,AUROBINDO,,17,YR,,F,Y,,,20200831,,HP,ZA,ZA,EFAVIRENZ.,Abortion induced;Maternal exposure during pregnancy,181682793,OT,,,181682793,1,20070906,,,,181682793,1,HIV infection
18168943,181689432,2,F,2009,20200921,20200818,20200928,EXP,,US-GILEAD-2020-0489652,GILEAD,,,,A,M,Y,58.96,KG,20200928,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Bone density decreased;Emotional distress;Hip fracture;Osteoporosis;Pain;Renal impairment;Wrist fracture,181689432,OT,,,181689432,1,2006,20190617,,,181689432,1,HIV infection
18171947,181719472,2,F,200705,20200918,20200819,20200929,EXP,,US-GILEAD-2020-0490066,GILEAD,,32,YR,A,M,Y,78.9,KG,20200929,,LW,US,US,EFAVIRENZ.,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Fracture;Osteoporosis;Pain,181719472,OT,,,181719472,1,20070118,200809,,,181719472,1,Product used for unknown indication
18172232,181722322,2,F,,20200912,20200819,20200928,PER,,US-GILEAD-2020-0490163,GILEAD,,,,A,M,Y,89.34,KG,20200928,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Emotional distress;Pain,,,,,181722322,1,2001,1996,,,181722322,1,HIV infection
18172426,181724262,2,F,200808,20200919,20200820,20200928,PER,,US-GILEAD-2020-0490168,GILEAD,,,,,F,Y,99.77,KG,20200928,,CN,US,US,EFAVIRENZ.;SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Injury;Osteopenia;Pain,,,,,181724262,1,2001,201705,,,181724262,1,HIV infection
18172920,181729203,3,F,2016,20200916,20200820,20200921,EXP,,US-GILEAD-2020-0490188,GILEAD,,63,YR,A,M,Y,81.63,KG,20200921,,CN,US,US,SUSTIVA,Abdominal distension;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Dysstasia;Fracture;Gait disturbance;Pain,181729203,OT,,,181729203,1,2001,2004,,,181729203,1,HIV infection
18173335,181733352,2,F,20110712,20200918,20200819,20200928,EXP,,US-GILEAD-2020-0489972,GILEAD,,63,YR,A,M,Y,62.59,KG,20200928,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Emotional distress;Femur fracture;Hip fracture;Osteoporosis,181733352,OT,,,181733352,1,2002,20160908,,,181733352,1,HIV infection
18173426,181734262,2,F,2010,20200913,20200819,20200925,EXP,,US-GILEAD-2020-0489699,GILEAD,,60,YR,A,M,Y,74.84,KG,20200925,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Fracture;Osteoporosis;Pain;Prostate cancer,181734262,OT,,,181734262,1,20061219,20131008,,,181734262,1,HIV infection
18176884,181768841,1,I,20080625,20200615,20200820,20200820,PER,,US-GILEAD-2020-0491025,GILEAD,,58,YR,A,M,Y,111.57,KG,20200820,,CN,US,US,SUSTIVA,Osteopenia;Protein urine present,,,,,181768841,1,20060711,20190528,,,181768841,1,HIV infection
18177386,181773861,1,I,,20200817,20200820,20200820,EXP,,CA-ASTRAZENECA-2020SF04993,ASTRAZENECA,,,,,M,Y,,,20200820,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,181773861,OT,,,,,,,,,181773861,1,Product used for unknown indication
18179409,181794092,2,F,,20200413,20200821,20200911,EXP,,CA-ROCHE-2583896,ROCHE,,52,YR,,M,Y,,,20200911,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,181794092,OT,,,,,,,,,181794092,1,HIV infection
18179598,181795981,1,I,,20200817,20200820,20200820,EXP,,CA-ASTRAZENECA-2020SF04738,ASTRAZENECA,,,,,M,Y,,,20200821,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,181795981,OT,,,,,,,,,181795981,1,Product used for unknown indication
18180472,181804722,2,F,,20200911,20200821,20200922,EXP,,"FR-LANNETT COMPANY, INC.-FR-2020LAN000198",LANNETT,,,,I,M,Y,3.23,KG,20200922,,HP,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,181804722,OT,,,,,,,,,181804722,1,Product used for unknown indication
18181094,181810941,1,I,2018,20200615,20200821,20200821,PER,,US-GILEAD-2020-0491031,GILEAD,,,,A,F,Y,90.7,KG,20200821,,CN,US,US,SUSTIVA,Blood creatinine increased;Nephropathy,,,,,181810941,1,20090612,2010,,,181810941,1,HIV infection
18183207,181832073,3,F,201807,20200921,20200821,20200925,PER,,US-GILEAD-2020-0489941,GILEAD,,47,YR,A,M,Y,79.37,KG,20200925,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Fracture;Pain,181832073,OT,,,181832073,1,2004,2010,,,181832073,1,HIV infection
18184068,181840681,1,I,,20200812,20200823,20200823,EXP,E2B_03073540,CA-ACCORD-196147,ACCORD,,,,,M,Y,,,20200821,,CN,CA,CA,EFAVIRENZ.,Depression;Drug interaction,181840681,OT,,,,,,,,,181840681,1,Product used for unknown indication
18184148,181841482,2,F,2008,20200921,20200824,20200930,EXP,,US-GILEAD-2020-0491250,GILEAD,,51,YR,A,M,Y,77.1,KG,20200930,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Foot fracture;Osteoporosis;Pain;Renal impairment,181841482,OT,,,181841482,1,2006,2012,,,181841482,1,HIV infection
18184648,181846481,1,I,,20200816,20200824,20200824,EXP,,CA-TEVA-2020-CA-1817588,TEVA,,,,,M,Y,3,KG,20200824,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Brachycephaly;Conductive deafness;Congenital eyelid malformation;Congenital musculoskeletal anomaly;Congenital nose malformation;Craniosynostosis;Deafness bilateral;Deformity of orbit;Drug withdrawal syndrome neonatal;Dysmorphism;Elbow synostosis;Eyelid ptosis congenital;Foetal exposure during pregnancy;Hydronephrosis;Hypertelorism of orbit;Neonatal seizure;Skull malformation;Syndactyly;Synostosis,181846481,CA,,,,,,,,,181846481,1,Vulvovaginal candidiasis
18184896,181848961,1,I,,20200817,20200824,20200824,EXP,,CA-TEVA-2020-CA-1817636,TEVA,,,,,M,Y,,,20200824,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction,181848961,OT,,,,,,,,,181848961,1,Product used for unknown indication
18187253,181872531,1,I,,20200812,20200824,20200824,EXP,E2B_03070843,CA-ACCORD-196145,ACCORD,,,,,M,Y,,,20200824,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,181872531,DE,,,,,,,,,181872531,1,Product used for unknown indication
18190207,181902071,1,I,,20200817,20200825,20200825,EXP,,CA-TEVA-2020-CA-1817620,TEVA,,54,YR,A,M,Y,,,20200825,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,181902071,OT,,,,,,,,,181902071,1,Bipolar disorder
18191193,181911931,1,I,,20200817,20200825,20200825,EXP,,CA-TEVA-2020-CA-1817632,TEVA,,54,YR,A,M,Y,,,20200825,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,181911931,OT,,,,,,,,,181911931,1,Bipolar disorder
18192266,181922661,1,I,,20200817,20200825,20200825,EXP,,CA-TEVA-2020-CA-1817613,TEVA,,54,YR,A,M,Y,,,20200825,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,181922661,OT,,,,,,,,,181922661,1,Product used for unknown indication
18193426,181934261,1,I,,20200817,20200825,20200825,EXP,,CA-ASTRAZENECA-2020SF06106,ASTRAZENECA,,,,,M,Y,,,20200825,,CN,CA,CA,EFAVIRENZ.,Depression;Drug interaction,181934261,OT,,,,,,,,,181934261,1,Product used for unknown indication
18193433,181934331,1,I,,20200817,20200825,20200825,EXP,,CA-ASTRAZENECA-2020SF04359,ASTRAZENECA,,54,YR,,M,Y,,,20200825,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,181934331,OT,,,,,,,,,181934331,1,Bipolar disorder
18193517,181935171,1,I,,20200819,20200825,20200825,EXP,,CA-PFIZER INC-2020324083,PFIZER,,,,,,Y,,,20200825,,HP,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,181935171,OT,,,,,,,,,181935171,1,Diffuse large B-cell lymphoma
18193790,181937902,2,F,,20200827,20200825,20200828,EXP,,CA-ASTRAZENECA-2020SF06056,ASTRAZENECA,,54,YR,,M,Y,,,20200828,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,181937902,DE,,,,,,,,,181937902,1,Bipolar disorder
18193939,181939391,1,I,201406,20200711,20200825,20200825,EXP,,US-GILEAD-2020-0491422,GILEAD,,66,YR,E,M,Y,73.47,KG,20200825,,CN,US,US,SUSTIVA,Acute kidney injury;Chronic kidney disease;Emotional distress;Pain,181939391,HO,,,181939391,1,200406,201710,,,181939391,1,HIV infection
18194619,181946192,2,F,,20200825,20200825,20200902,EXP,,CA-ASTRAZENECA-2020SF06767,ASTRAZENECA,,54,YR,,M,Y,,,20200902,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,181946192,OT,,,,,,,,,181946192,1,Bipolar disorder
18194796,181947961,1,I,,20200817,20200825,20200825,EXP,,CA-ASTRAZENECA-2020SF06288,ASTRAZENECA,,,,,M,Y,,,20200825,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction,181947961,OT,,,,,,,,,181947961,1,Product used for unknown indication
18194988,181949881,1,I,,20200817,20200825,20200825,EXP,,CA-ASTRAZENECA-2020SF04813,ASTRAZENECA,,44,YR,,M,Y,,,20200825,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,181949881,HO,,,,,,,,,181949881,1,Depression
18195137,181951371,1,I,,20200817,20200825,20200825,EXP,,CA-ASTRAZENECA-2020SF06627,ASTRAZENECA,,44,YR,,M,Y,,,20200825,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,181951371,OT,,,,,,,,,181951371,2,HIV infection
18195354,181953542,2,F,2008,20200911,20200825,20200929,EXP,,US-GILEAD-2020-0490990,GILEAD,,,,A,F,Y,53.06,KG,20200929,,CN,US,US,SUSTIVA,Acute kidney injury;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Fracture;Osteoporosis,181953542,HO,,,181953542,1,2006,2016,,,181953542,1,HIV infection
18196078,181960781,1,I,,20200817,20200825,20200825,EXP,,CA-TEVA-2020-CA-1817640,TEVA,,54,YR,A,M,Y,,,20200826,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,181960781,OT,,,,,,,,,181960781,1,Bipolar disorder
18196130,181961301,1,I,,20200817,20200825,20200825,EXP,,CA-TEVA-2020-CA-1817626,TEVA,,,,,M,Y,,,20200826,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,181961301,OT,,,,,,,,,181961301,1,Product used for unknown indication
18199815,181998151,1,I,2015,20200715,20200826,20200826,EXP,,US-GILEAD-2020-0491171,GILEAD,,53,YR,A,F,Y,79.37,KG,20200826,,CN,US,US,SUSTIVA,Ankle fracture;Anxiety;Depression;Emotional distress;Fanconi syndrome acquired;Osteopenia;Pain,181998151,OT,,,181998151,1,201304,201409,,,181998151,1,HIV infection
18204112,182041121,1,I,,20200824,20200827,20200827,EXP,,CA-ASTRAZENECA-2020SF07876,ASTRAZENECA,,54,YR,,M,Y,,,20200827,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,182041121,OT,,,,,,,,,182041121,1,Bipolar disorder
18204398,182043981,1,I,,20200824,20200827,20200827,EXP,,CA-ASTRAZENECA-2020SF07439,ASTRAZENECA,,,,,M,Y,,,20200827,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,182043981,DE,,,,,,,,,182043981,1,Product used for unknown indication
18206163,182061631,1,I,201505,20200715,20200827,20200827,EXP,,US-GILEAD-2020-0491423,GILEAD,,41,YR,A,M,Y,88.89,KG,20200827,,CN,US,US,SUSTIVA,Chronic kidney disease;Emotional distress;Mobility decreased;Pain;Renal failure,182061631,OT,,,182061631,1,2012,2015,,,182061631,1,HIV infection
18207204,182072041,1,I,,20200819,20200828,20200828,EXP,,CA-TEVA-2020-CA-1818107,TEVA,,44,YR,A,M,Y,,,20200828,,HP,CA,CA,SUSTIVA,Anxiety,182072041,HO,,,,,,,,,182072041,1,Depression
18207206,182072062,2,F,,20200907,20200828,20200915,EXP,,CA-TEVA-2020-CA-1818097,TEVA,,44,YR,A,M,Y,,,20200915,,HP,CA,CA,SUSTIVA,Anxiety,182072062,HO,,,,,,,,,182072062,1,Depression
18209319,182093191,1,I,,20200824,20200828,20200828,EXP,,GB-GILEAD-2020-0492282,GILEAD,KEELEY A ET AL. ANAKINRA IN THE TREATMENT OF PROTRACTED PARADOXICAL INFLAMMATORY REACTIONS IN HIV?ASSOCIATED TUBERCULOSIS IN THE UNITED KINGDOM: A REPORT OF TWO CASES.. INTERNATIONAL JOURNAL OF STD AND AIDS.. 2020?31(8):808?82,33,YR,A,F,Y,,,20200828,,HP,GB,GB,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,182093191,LT,,,,,,,,,182093191,1,Antiretroviral therapy
18209399,182093991,1,I,,20200824,20200828,20200828,EXP,,GB-GILEAD-2020-0492283,GILEAD,KEELEY A ET AL. ANAKINRA IN THE TREATMENT OF PROTRACTED PARADOXICAL INFLAMMATORY REACTIONS IN HIV?ASSOCIATED TUBERCULOSIS IN THE UNITED KINGDOM: A REPORT OF TWO CASES.. INTERNATIONAL JOURNAL OF STD AND AIDS.. 2020?31 (8):808?812. DOI:10.1177/0956462420915394,41,YR,A,M,Y,,,20200828,,HP,GB,GB,EFAVIRENZ.,Inflammation,182093991,DS,,,,,,,,,182093991,1,Antiretroviral therapy
18209539,182095391,1,I,,20200827,20200828,20200828,EXP,,CA-ASTRAZENECA-2020SF09351,ASTRAZENECA,,54,YR,,M,Y,,,20200828,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,182095391,DE,,,,,,,,,182095391,1,Bipolar disorder
18209541,182095411,1,I,,20200827,20200828,20200828,EXP,,CA-ASTRAZENECA-2020SF09484,ASTRAZENECA,,,,,M,Y,,,20200828,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,182095411,DE,,,,,,,,,182095411,1,Product used for unknown indication
18210714,182107141,1,I,,20200824,20200829,20200829,EXP,,CA-ASTRAZENECA-2020SF07683,ASTRAZENECA,,54,YR,,M,Y,,,20200829,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,182107141,OT,,,,,,,,,182107141,1,Bipolar disorder
18210798,182107981,1,I,,20200825,20200830,20200830,EXP,,CA-ASTRAZENECA-2020SF09059,ASTRAZENECA,,54,YR,,M,Y,,,20200830,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,182107981,OT,,,,,,,,,182107981,1,Bipolar disorder
18211749,182117491,1,I,2020,20200825,20200831,20200831,PER,,US-AMGEN-USASP2020139077,AMGEN,,54,YR,A,M,Y,,,20200831,,CN,US,US,EFAVIRENZ.,Condition aggravated,,,,,182117491,1,20200129,,,,182117491,1,Product used for unknown indication
18211805,182118052,2,F,2019,20200824,20200831,20200831,EXP,,ZA-CIPLA LTD.-2020ZA06030,CIPLA,,,,,,Y,,,20200831,,HP,ZA,ZA,EFAVIRENZ.,Abortion induced;Exposure during pregnancy,182118052,OT,,,182118052,1,20070906,,,,182118052,1,HIV infection
18211868,182118681,1,I,,20200825,20200831,20200831,EXP,,CA-ASTRAZENECA-2020SF09197,ASTRAZENECA,,54,YR,,M,Y,,,20200831,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,182118681,OT,,,,,,,,,182118681,1,Product used for unknown indication
18212801,182128011,1,I,,20200823,20200831,20200831,EXP,,GB-009507513-2008GBR012191,MERCK,,,,A,F,Y,,,20200831,,CN,UG,UG,EFAVIRENZ (+) LAMIVUDINE (+) TENOFOVIR DISOPROXIL FUMARATE,Drug interaction;Pregnancy with implant contraceptive;Unintended pregnancy,182128011,OT,,,,,,,,,182128011,1,Contraception
18214486,182144861,1,I,20190710,20200819,20200831,20200831,EXP,,BY-JNJFOC-20200830007,JOHNSON AND JOHNSON,,44,YR,A,M,Y,67,KG,20200831,,MD,BY,BY,EFAVIRENZ.,Hepatitis;Platelet count decreased,182144861,OT,,,182144861,1,20190604,20190811,,,182144861,1,Tuberculosis
18214490,182144901,1,I,20200406,20200819,20200831,20200831,EXP,,BY-JNJFOC-20200830058,JOHNSON AND JOHNSON,,40,YR,A,M,Y,60,KG,20200831,,MD,BY,BY,EFAVIRENZ.,Hepatitis C;Hypersensitivity;Intentional product use issue;Off label use,182144901,OT,,,182144901,1,20190513,20200408,,,182144901,1,Tuberculosis
18214639,182146392,2,F,,20200828,20200831,20200904,EXP,,CM-VIIV HEALTHCARE LIMITED-CM2020GSK174678,VIIV,"FOKAM J, TAKOU D, SEMENGUE ENJ, TETO G, BELOUMOU G, DAMBAYA B ET AL.. FIRST CASE OF DOLUTEGRAVIR AND DARUNAVIR/R MULTI DRUG?RESISTANT HIV?1 IN CAMEROON FOLLOWING EXPOSURE TO RALTEGRAVIR: LESSONS AND IMPLICATIONS IN THE ERA OF TRANSITION TO DOLUTEGRAVIR?BASED REGIMENS. ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL. 2020?9 (1):143",,,A,M,Y,,,20200904,,HP,CM,CM,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,182146392,OT,,,182146392,1,200608,200908,,,182146392,1,HIV infection
18214646,182146462,2,F,,20200828,20200831,20200904,EXP,,CM-GLAXOSMITHKLINE-CM2020GSK174678,GLAXOSMITHKLINE,"FOKAM J, TAKOU D, SEMENGUE ENJ, TETO G, BELOUMOU G, DAMBAYA B ET AL.. FIRST CASE OF DOLUTEGRAVIR AND DARUNAVIR/R MULTI DRUG?RESISTANT HIV?1 IN CAMEROON FOLLOWING EXPOSURE TO RALTEGRAVIR: LESSONS AND IMPLICATIONS IN THE ERA OF TRANSITION TO DOLUTEGRAVIR?BASED REGIMENS. ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL. 2020?9 (1):143",,,A,M,Y,,,20200904,,HP,CM,CM,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,182146462,OT,,,182146462,1,200608,200908,,,182146462,1,HIV infection
18214744,182147441,1,I,,20200824,20200831,20200831,EXP,,CA-ASTRAZENECA-2020SF07926,ASTRAZENECA,,54,YR,,M,Y,,,20200831,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,182147441,OT,,,,,,,,,182147441,1,Bipolar disorder
18215021,182150212,2,F,2019,20200903,20200831,20200908,EXP,,US-ABBVIE-20K-163-3546537-00,ABBVIE,,91,YR,,M,Y,53.57,KG,20200908,,CN,US,US,SUSTIVA,Abdominal pain upper;Death;Depressed level of consciousness;Device dislocation;Device kink;Device occlusion;Fatigue;Heart rate decreased;Mobility decreased;Musculoskeletal stiffness;On and off phenomenon;Skin discolouration;Somnolence;Stoma complication;Stoma site discharge,182150212,DE,,,182150212,1,2017,20200821,,,182150212,1,Parkinson's disease
18215147,182151472,2,F,201009,20200715,20200831,20200925,PER,,US-GILEAD-2020-0491163,GILEAD,,60,YR,A,M,Y,95.24,KG,20200925,,CN,US,US,SUSTIVA,Acute kidney injury;Depression;Fatigue;Hypoaesthesia;Osteopenia,182151472,OT,,,182151472,1,200506,201506,,,182151472,1,HIV infection
18215605,182156051,1,I,,20200825,20200831,20200831,EXP,,CA-ASTRAZENECA-2020SF08735,ASTRAZENECA,,54,YR,,M,Y,,,20200901,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,182156051,OT,,,,,,,,,182156051,1,Bipolar disorder
18216563,182165631,1,I,,20200825,20200901,20200901,EXP,,CA-ASTRAZENECA-2020SF08373,ASTRAZENECA,,,,,M,Y,,,20200901,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,182165631,HO,,,,,,,,,182165631,1,Product used for unknown indication
18219912,182199121,1,I,,20200825,20200901,20200901,EXP,,CA-ASTRAZENECA-2020SF08718,ASTRAZENECA,,54,YR,,M,Y,,,20200902,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,182199121,OT,,,,,,,,,182199121,1,Bipolar disorder
18219955,182199551,1,I,,20200825,20200902,20200902,EXP,,CA-ASTRAZENECA-2020SF08487,ASTRAZENECA,,54,YR,,M,Y,,,20200902,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,182199551,OT,,,,,,,,,182199551,1,Bipolar disorder
18220533,182205331,1,I,,20200821,20200902,20200902,EXP,,CA-ALVOGEN-2020-ALVOGEN-114056,ALVOGEN,,,,,M,Y,,,20200902,,MD,CA,CA,SUSTIVA,Depression;Drug interaction,182205331,OT,,,,,,,,,182205331,1,Product used for unknown indication
18222336,182223361,1,I,,20200827,20200902,20200902,EXP,,CA-ASTRAZENECA-2020SF10318,ASTRAZENECA,,54,YR,,M,Y,,,20200902,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,182223361,OT,,,,,,,,,182223361,1,Bipolar disorder
18222390,182223901,1,I,,20200827,20200902,20200902,EXP,,CA-ASTRAZENECA-2020SF09174,ASTRAZENECA,,54,YR,,M,Y,,,20200902,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,182223901,OT,,,,,,,,,182223901,1,Bipolar disorder
18222401,182224011,1,I,,20200827,20200902,20200902,EXP,,CA-ASTRAZENECA-2020SF09264,ASTRAZENECA,,54,YR,,M,Y,,,20200902,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,182224011,OT,,,,,,,,,182224011,1,Bipolar disorder
18223932,182239321,1,I,,20200825,20200902,20200902,EXP,,CA-ASTRAZENECA-2020SF09077,ASTRAZENECA,,,,,M,Y,,,20200902,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction,182239321,OT,,,,,,,,,182239321,1,Product used for unknown indication
18225525,182255251,1,I,,20200821,20200903,20200903,EXP,,CA-ALVOGEN-2020-ALVOGEN-114093,ALVOGEN,,,,,M,Y,,,20200903,,MD,CA,CA,SUSTIVA,Depression;Drug interaction,182255251,OT,,,,,,,,,182255251,1,Product used for unknown indication
18225618,182256181,1,I,,20200827,20200903,20200903,EXP,,CA-ASTRAZENECA-2020SF09863,ASTRAZENECA,,54,YR,,M,Y,,,20200903,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,182256181,OT,,,,,,,,,182256181,1,Product used for unknown indication
18227744,182277441,1,I,,20200720,20200903,20200903,EXP,,CA-GLAXOSMITHKLINE-CA2020GSK176607,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20200903,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,182277441,OT,,,,,,,,,182277441,1,Bipolar disorder
18227941,182279411,1,I,,20200720,20200903,20200903,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020GSK176607,VIIV,,54,YR,,M,Y,,,20200903,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,182279411,OT,,,,,,,,,182279411,1,Bipolar disorder
18228239,182282391,1,I,,20200901,20200903,20200903,EXP,,US-PFIZER INC-2020340114,PFIZER,,19,YR,,M,Y,,,20200903,,HP,US,US,SUSTIVA,Cystic fibrosis gastrointestinal disease;Maternal exposure during pregnancy;Meconium ileus,182282391,OT,,,182282391,2,20001109,,,,182282391,1,HIV infection
18229944,182299441,1,I,20191111,20200817,20200904,20200904,EXP,,ZA-HETERO-HET2020ZA00930,HETERO,,17,YR,,F,Y,,,20200831,,HP,ZA,ZA,EFAVIRENZ.,Abortion induced;Maternal exposure during pregnancy,182299441,OT,,,182299441,1,20070906,,,,182299441,1,HIV infection
18231293,182312931,1,I,,20200827,20200904,20200904,EXP,,CA-ASTRAZENECA-2020SF09828,ASTRAZENECA,,54,YR,,M,Y,,,20200904,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,182312931,OT,,,,,,,,,182312931,1,Bipolar disorder
18231302,182313021,1,I,,20200825,20200904,20200904,EXP,,CA-ALVOGEN-2020-ALVOGEN-114123,ALVOGEN,,54,YR,,M,Y,,,20200904,,MD,CA,CA,SUSTIVA,Depression;Drug interaction,182313021,OT,,,,,,,,,182313021,1,Bipolar disorder
18232482,182324821,1,I,,20200827,20200904,20200904,EXP,,CA-ASTRAZENECA-2020SF09822,ASTRAZENECA,,,,,M,Y,,,20200904,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction,182324821,OT,,,,,,,,,182324821,1,Product used for unknown indication
18233712,182337121,1,I,,20200827,20200904,20200904,EXP,,CA-ASTRAZENECA-2020SF09979,ASTRAZENECA,,54,YR,,M,Y,,,20200904,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,182337121,OT,,,,,,,,,182337121,1,Product used for unknown indication
18233724,182337241,1,I,,20200827,20200904,20200904,EXP,,CA-ASTRAZENECA-2020SF09846,ASTRAZENECA,,,,,M,Y,,,20200904,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,182337241,OT,,,,,,,,,182337241,1,Product used for unknown indication
18233762,182337621,1,I,,20200827,20200904,20200904,EXP,,CA-ASTRAZENECA-2020SF09873,ASTRAZENECA,,,,,M,Y,,,20200904,,CN,CA,CA,EFAVIRENZ.,Depression;Drug interaction,182337621,OT,,,,,,,,,182337621,1,Product used for unknown indication
18235457,182354571,1,I,,20200903,20200905,20200905,EXP,,BW-AUROBINDO-AUR-APL-2020-046931,AUROBINDO,,42,YR,,F,Y,,,20200905,,HP,BW,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,182354571,OT,,,,,,,,,182354571,1,Product used for unknown indication
18238479,182384791,1,I,200909,20200826,20200907,20200907,EXP,,ZA-MACLEODS PHARMACEUTICALS US LTD-MAC2020027909,MACLEODS,,,,,,Y,,,20200907,,HP,ZA,ZA,EFAVIRENZ.,Diarrhoea;Drug interaction;Drug resistance;Insomnia;Treatment noncompliance;Virologic failure,182384791,OT,,,182384791,1,2007,,,,182384791,1,Antiretroviral therapy
18244282,182442821,1,I,,20200827,20200909,20200909,EXP,,ZA-LUPIN PHARMACEUTICALS INC.-2020-05601,LUPIN,,41,YR,,M,Y,,,20200909,,HP,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL SANDOZ [EFAVIRENZ;EMTRICI,Off label use,182442821,OT,,,182442821,7,2016,,,,182442821,1,COVID-19
18254907,182549071,1,I,,20200830,20200911,20200911,EXP,,CA-ALVOGEN-2020-ALVOGEN-114238,ALVOGEN,,54,YR,,M,Y,,,20200911,,MD,CA,CA,SUSTIVA,Depression;Drug interaction,182549071,OT,,,,,,,,,182549071,1,Bipolar disorder
18255854,182558541,1,I,,20200830,20200911,20200911,EXP,,CA-ALVOGEN-2020-ALVOGEN-114240,ALVOGEN,,54,YR,,M,Y,,,20200911,,MD,CA,CA,SUSTIVA,Depression;Drug interaction,182558541,OT,,,,,,,,,182558541,1,Bipolar disorder
18257744,182577441,1,I,,20200902,20200911,20200911,EXP,,US-MYLANLABS-2020M1077988,MYLAN,"SHALLIS RM, GLEESON S, AZAR MM, MALINIS M, XU ML, SEROPIAN SE, ET AL. ALLOGENEIC STEM CELL TRANSPLANTATION AND COMBINATION ANTIRETROVIRAL THERAPY: CAUTIONS, COMPLICATIONS, AND CONSIDERATIONS. LEUK?LYMPHOMA 2019?60(10):2584?2587.",44,YR,,F,Y,,,20200911,,HP,US,US,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPRO,Drug ineffective;Myelodysplastic syndrome;Thrombocytopenia,182577441,HO,,,,,,,,,182577441,1,B-cell lymphoma
18259796,182597962,2,F,,20200921,20200912,20200928,EXP,,US-DRREDDYS-USA/USA/20/0126722,DR REDDYS,"SHALLIS R, GLEESON S, AZAR M, MALINIS M, XU M, SEROPIAN S, GOWDA L, ZEIDAN A. ALLOGENEIC STEM CELL TRANSPLANTATION AND COMBINATION ANTIRETROVIRAL THERAPY: CAUTIONS, COMPLICATIONS, AND CONSIDERATIONS. LEUKEMIA AND LYMPHOMA. 2019?60(10):2584?2587. DOI:10.1080/10428194.2019.1594221",44,YR,A,F,Y,,,20200928,,HP,US,US,EFAVIRENZ AND EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Graft versus host disease;Myelodysplastic syndrome;Pneumonia haemophilus;Streptococcal infection;Thrombocytopenia,182597962,OT,,,,,,,,,182597962,1,Myelodysplastic syndrome
18261232,182612322,2,F,,20200831,20200914,20200915,EXP,,UG-CIPLA (EU) LIMITED-2020UG06367,CIPLA,"KIGGUNDU R, RHEIN J, MEYA DB, BOULWARE DR, BAHR NC.. UNMASKING CRYPTOCOCCAL MENINGITIS IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN PREGNANCY INDUCED BY HIV ANTIRETROVIRAL THERAPY WITH POSTPARTUM. MEDICAL MYCOLOGY CASE REPORTS. 2014?1 TO 9",,,,,Y,,,20200915,,HP,UG,UG,EFAVIRENZ.,Foetal exposure during pregnancy;Low birth weight baby;Neonatal respiratory distress;Premature baby,182612322,OT,,,,,,,,,,,
18261233,182612331,1,I,,20200831,20200914,20200914,EXP,,UG-CIPLA LTD.-2020UG06362,CIPLA,"KIGGUNDU R, RHEIN J, MEYA DB, BOULWARE DR, BAHR NC.. UNMASKING CRYPTOCOCCAL MENINGITIS IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN PREGNANCY INDUCED BY HIV ANTIRETROVIRAL THERAPY WITH POSTPARTUM. MEDICAL MYCOLOGY CASE REPORTS. 2014?1 TO 9",,,,,Y,,,20200914,,HP,UG,UG,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,182612331,OT,,,,,,,,,182612331,1,HIV infection
18265864,182658641,1,I,,20200903,20200915,20200915,EXP,,TH-LUPIN PHARMACEUTICALS INC.-2020-05937,LUPIN,,35,YR,,F,Y,,,20200915,,MD,TH,TH,EFAVIRENZ.,Rash maculo-papular,182658641,HO,,,,,,,,,182658641,1,Pneumocystis jirovecii pneumonia
18266591,182665911,1,I,,20200902,20200915,20200915,EXP,,US-CIPLA LTD.-2020US06593,CIPLA,,,,,,Y,,,20200915,,HP,US,US,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Myelodysplastic syndrome;Thrombocytopenia,182665911,OT,,,,,,,,,182665911,1,B-cell lymphoma
18268493,182684931,1,I,,20200910,20200915,20200915,EXP,,ZA-SA-2020SA248044,SANOFI AVENTIS,"PARRISH A, BLOCKMAN M, COLLETT G.. HAEMATURIA IN HIV ? AN INTERACTIVE WEB. CME: YOUR SA JOURNAL OF CPD. 2007?25(7):340?1",,,,,Y,,,20200915,,HP,ZA,ZA,EFAVIRENZ.,Abdominal pain lower;Drug interaction;Flank pain;Haematuria;Pallor,182684931,LT,,,,,,,,,182684931,1,Disseminated tuberculosis
18268920,182689202,2,F,20200908,20200909,20200915,20200918,PER,,US-GILEAD-2020-0494501,GILEAD,,,,A,M,Y,,,20200918,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Fatigue;Overdose,,,,,182689202,2,20200908,20200908,,,182689202,1,Product used for unknown indication
18270425,182704252,2,F,,20200921,20200915,20200928,EXP,,GB-TEVA-2020-GB-1827332,TEVA,"KEELEY AJ, PARKASH V, TUNBRIDGE A, GREIG J, COLLINI P, MCKANE W, ET AL. ANAKINRA IN THE TREATMENT OF PROTRACTED PARADOXICAL INFLAMMATORY REACTIONS IN HIV?ASSOCIATED TUBERCULOSIS IN THE UNITED KINGDOM: A REPORT OF TWO CASES. INT?J?STD?AIDS 2020?31(8):808?812.",4,DEC,A,F,Y,,,20200928,,HP,GB,GB,EFAVIRENZ.,Cataract;Inflammation;Osteoporotic fracture;Paradoxical drug reaction;Steroid diabetes;Urinary tract infection,182704252,OT,,,,,,,,,182704252,1,Immune reconstitution inflammatory syndrome associated tuberculosis
18270426,182704261,1,I,,20200907,20200915,20200915,EXP,,GB-TEVA-2020-GB-1827334,TEVA,"KEELEY AJ, PARKASH V, TUNBRIDGE A, GREIG J, COLLINI P, MCKANE W, ET AL. ANAKINRA IN THE TREATMENT OF PROTRACTED PARADOXICAL INFLAMMATORY REACTIONS IN HIV?ASSOCIATED TUBERCULOSIS IN THE UNITED KINGDOM: A REPORT OF TWO CASES. INT?J?STD?AIDS 2020?31(8):808?812.",41,YR,A,M,Y,,,20200915,,HP,GB,GB,EFAVIRENZ.,Cushingoid;Depressed mood;Inflammation;Neuropathy peripheral;Paradoxical drug reaction;Tuberculoma of central nervous system,182704261,HO,,,,,,,,,182704261,1,Tuberculoma of central nervous system
18270668,182706682,2,F,2020,20200928,20200915,20200928,EXP,FR-AFSSAPS-NT20201194,FR-GILEAD-2020-0494882,GILEAD,,64,YR,A,M,Y,,,20200928,,MD,FR,FR,EFAVIRENZ.,Acute kidney injury;Bone pain;Fanconi syndrome,182706682,OT,,,182706682,1,20110323,20200823,,,182706682,1,HIV infection
18272107,182721071,1,I,,20200907,20200916,20200916,EXP,,GB-MYLANLABS-2020M1077934,MYLAN,,,,,M,Y,,,20200916,,CN,GB,GB,EFAVIRENZ.,Feeling abnormal;Lung cancer metastatic;Lung neoplasm malignant,182721071,OT,,,,,,,,,182721071,1,Product used for unknown indication
18273618,182736181,1,I,,20200901,20200916,20200916,EXP,,CA-ALVOGEN-2020-ALVOGEN-114291,ALVOGEN,,54,YR,,M,Y,,,20200916,,MD,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,182736181,OT,,,,,,,,,182736181,1,Bipolar disorder
18273877,182738771,1,I,,20200901,20200916,20200916,EXP,,CA-ALVOGEN-2020-ALVOGEN-114314,ALVOGEN,,54,YR,,M,Y,,,20200916,,MD,CA,CA,SUSTIVA,Depression;Drug interaction,182738771,OT,,,,,,,,,182738771,1,Bipolar disorder
18275338,182753381,1,I,,20200902,20200916,20200916,EXP,,IN-GLAXOSMITHKLINE-IN2020GSK181494,GLAXOSMITHKLINE,"KODAN P, GUPTA N, RATNA S, RAMPRASAD A, RANJAN S, NISCHAL N ET AL.. PERINATAL TRANSMISSION IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION: A CROSS?SECTIONAL STUDY FROM A TERTIARY CARE CENTER IN NORTH INDIA. LE INFEZIONI IN MEDICINA. 2020?28 (2):227?230",,,,,Y,,,20200916,,HP,IN,IN,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,182753381,OT,,,,,,,,,182753381,1,HIV infection
18275339,182753391,1,I,,20200902,20200916,20200916,EXP,,IN-GLAXOSMITHKLINE-IN2020GSK181570,GLAXOSMITHKLINE,"KODAN P, GUPTA N, RATNA S, RAMPRASAD A, RANJAN S, NISCHAL N ET AL.. PERINATAL TRANSMISSION IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION: A CROSS?SECTIONAL STUDY FROM A TERTIARY CARE CENTER IN NORTH INDIA. LE INFEZIONI IN MEDICINA. 2020?28 (2):227?230",,,,,Y,,,20200916,,HP,IN,IN,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,182753391,OT,,,,,,,,,182753391,1,HIV infection
18275340,182753401,1,I,,20200902,20200916,20200916,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2020GSK181494,VIIV,"KODAN P, GUPTA N, RATNA S, RAMPRASAD A, RANJAN S, NISCHAL N ET AL.. PERINATAL TRANSMISSION IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION: A CROSS?SECTIONAL STUDY FROM A TERTIARY CARE CENTER IN NORTH INDIA. LE INFEZIONI IN MEDICINA. 2020?28 (2):227?230",,,,,Y,,,20200916,,HP,IN,IN,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,182753401,OT,,,,,,,,,182753401,1,HIV infection
18275341,182753411,1,I,,20200902,20200916,20200916,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2020GSK181570,VIIV,"KODAN P, GUPTA N, RATNA S, RAMPRASAD A, RANJAN S, NISCHAL N ET AL.. PERINATAL TRANSMISSION IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION: A CROSS?SECTIONAL STUDY FROM A TERTIARY CARE CENTER IN NORTH INDIA. LE INFEZIONI IN MEDICINA. 2020?28 (2):227?230",,,,,Y,,,20200916,,HP,IN,IN,EFAVIRENZ.,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,182753411,OT,,,,,,,,,182753411,1,HIV infection
18282249,182822491,1,I,,20200908,20200918,20200918,EXP,,US-SHILPA MEDICARE LIMITED-SML-US-2020-00280,SHILPA MEDICARE,"SHALLIS R, GLEESON S, AZAR M, MALINIS M, XU M, SEROPIAN S. ALLOGENEIC STEM CELL TRANSPLANTATION AND COMBINATION ANTIRETROVIRAL THERAPY CAUTIONS, COMPLICATIONS, AND CONSIDERATIONS. LEUKEMIA AND LYMPHOMA. 2019 APR 03?60(10):2584?2587. DOI:10.1080/10428194.2019.1594221",49,YR,A,F,Y,,,20200918,,HP,US,US,EFAVIRENZ.,Drug ineffective,182822491,OT,,,,,,,,,182822491,1,Myelodysplastic syndrome
18285068,182850681,1,I,200311,20200907,20200919,20200919,EXP,,FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-261116,RANBAXY,,36,YR,,F,Y,82,KG,20200919,,HP,NL,FR,SUSTIVA,Abdominal pain;Chills;Diarrhoea;Eyelid oedema;Lip oedema;Pyrexia;Rash;Thrombocytopenia,182850681,OT,,,182850681,1,20051201,20051202,,,182850681,1,Pyrexia
18286631,182866311,1,I,,20200911,20200921,20200921,EXP,,FR-HETERO-HET2020FR01042,HETERO,,,,,M,Y,3.2,KG,20200921,,HP,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,182866311,CA,,,182866311,1,20070403,20070521,,,182866311,1,HIV infection
18290835,182908351,1,I,,20200914,20200922,20200922,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-048232",BOEHRINGER INGELHEIM,,45,YR,A,M,Y,,,20200922,,HP,CA,CA,EFAVIRENZ.,Multiple-drug resistance,182908351,OT,,,,,,,,,182908351,1,HIV infection
18291577,182915771,1,I,2010,20190917,20200921,20200921,EXP,,US-GILEAD-2020-0495218,GILEAD,,52,YR,A,M,Y,77.1,KG,20200921,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;End stage renal disease;Osteoporosis;Pain;Renal disorder,182915771,OT,,,182915771,1,2008,201811,,,182915771,1,HIV infection
18299725,182997251,1,I,200909,20200909,20200923,20200923,EXP,,ZA-CIPLA LTD.-2020ZA06612,CIPLA,,,,,,Y,,,20200923,,PH,ZA,ZA,EFAVIRENZ.,Diarrhoea;Drug interaction;Drug resistance;Insomnia;Treatment noncompliance;Virologic failure,182997251,OT,,,182997251,1,2007,2018,,,182997251,1,HIV infection
18305146,183051462,2,F,2012,20200914,20200923,20200928,EXP,,AU-VIIV HEALTHCARE LIMITED-US2020GSK186145,VIIV,"RAJAKARUNA GK, ITALIANO CM, JOHN M, NOLAN D. CHOREA ASSOCIATED WITH PERSISTENT LOW?LEVEL VIREMIA IN A PATIENT LIVING WITH HIV: A CASE REPORT. JOURNAL OF VIRUS ERADICATION. 2020?6(1):27?29",,,A,F,Y,,,20200928,,HP,AU,AU,EFAVIRENZ.,Behaviour disorder;Central nervous system inflammation;Cerebellar syndrome;Chorea;Confusional state;Disorientation;Dysarthria;Dysdiadochokinesis;Gait disturbance;HIV-associated neurocognitive disorder;Hypophagia;Loss of personal independence in daily activities;Magnetic resonance imaging brain abnormal;Meningitis viral;Meningoencephalitis viral;Parainfluenzae virus infection;Pathogen resistance;Rhinitis;Treatment noncompliance;Viral mutation identified,183051462,HO,,,183051462,2,2012,,,,183051462,1,HIV infection
18306235,183062351,1,I,,20200917,20200924,20200924,EXP,,CA-TEVA-2020-CA-1830303,TEVA,,54,YR,A,M,Y,,,20200924,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,183062351,OT,,,,,,,,,183062351,1,HIV infection
18306813,183068131,1,I,,20200917,20200924,20200924,EXP,,CA-TEVA-2020-CA-1830320,TEVA,,54,YR,A,M,Y,,,20200924,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,183068131,OT,,,,,,,,,183068131,1,HIV infection
18310452,183104521,1,I,,20200924,20200925,20200925,EXP,,CA-ROCHE-2684583,ROCHE,,,,,M,Y,,,20200925,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction,183104521,HO,,,,,,,,,183104521,1,Product used for unknown indication
18313071,183130711,1,I,200909,20200917,20200925,20200925,EXP,,ZA-MYLANLABS-2020M1081656,MYLAN,,40,YR,,F,Y,,,20200925,,HP,ZA,ZA,EFAVIRENZ.,Diarrhoea;Drug resistance;Insomnia;Intentional dose omission;Labelled drug-drug interaction medication error;Pathogen resistance;Virologic failure,183130711,OT,,,183130711,1,2007,20091224,,,183130711,1,HIV infection
18314365,183143651,1,I,,20200915,20200925,20200925,EXP,,AU-VIIV HEALTHCARE LIMITED-AU2020186205,VIIV,,70,YR,,M,Y,,,20200925,,CN,AU,AU,EFAVIRENZ.,Acute cardiac event;Drug ineffective,183143651,OT,,,,,,,,,183143651,1,Product used for unknown indication
18314375,183143751,1,I,,20200915,20200925,20200925,EXP,,AU-GLAXOSMITHKLINE-AU2020186205,GLAXOSMITHKLINE,,70,YR,,M,Y,,,20200925,,CN,AU,AU,EFAVIRENZ.,Acute cardiac event;Drug ineffective,183143751,OT,,,,,,,,,183143751,1,Product used for unknown indication
18319433,183194331,1,I,,20200921,20200928,20200928,EXP,,CA-BAUSCH-BL-2020-027472,BAUSCH AND LOMB,,54,YR,,M,Y,,,20200928,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,183194331,OT,,,,,,,,,183194331,1,Bipolar disorder
18320424,183204241,1,I,,20200915,20200929,20200929,EXP,,IN-CIPLA LTD.-2020IN06604,CIPLA,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ?ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020?1 TO 9",,,,,Y,,,20200929,,HP,IN,IN,EFAVIRENZ.,Retinal toxicity,183204241,OT,,,,,,,,,183204241,1,HIV infection
18320586,183205861,1,I,,20200915,20200929,20200929,EXP,,IN-CIPLA LTD.-2020IN06851,CIPLA,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P.. EFAVIRENZ?ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020?1 TO 9",,,,,Y,,,20200929,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,183205861,OT,,,,,,,,,183205861,1,HIV infection
18320592,183205921,1,I,,20200915,20200929,20200929,EXP,,IN-CIPLA LTD.-2020IN06850,CIPLA,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P.. EFAVIRENZ?ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020?1 TO 9",,,,,Y,,,20200929,,HP,IN,IN,EFAVIRENZ.,Retinal toxicity,183205921,OT,,,,,,,,,183205921,1,HIV infection
18320599,183205991,1,I,,20200915,20200929,20200929,EXP,,IN-CIPLA LTD.-2020IN06844,CIPLA,"SUDHARSHAN S, KUMAR KP, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ?ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020?1 TO 10",,,,,Y,,,20200929,,HP,IN,IN,EFAVIRENZ.,Retinal toxicity,183205991,OT,,,,,,,,,183205991,1,HIV infection
18320601,183206011,1,I,,20200915,20200929,20200929,EXP,,IN-CIPLA LTD.-2020IN06847,CIPLA,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P.. EFAVIRENZ?ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020?1 TO 9",,,,,Y,,,20200929,,HP,IN,IN,EFAVIRENZ.,Retinal toxicity,183206011,OT,,,,,,,,,183206011,1,HIV infection
18321184,183211841,1,I,,20200921,20200928,20200928,EXP,,IN-GILEAD-2020-0495952,GILEAD,"RAJNISH R.K., RATHOD P.M., AGGARWAL S., AGARWAL S., KUMAR P.. BILATERAL SUB?TROCHANTERIC FEMUR FRAGILITY FRACTURES IN A PATIENT ON ANTIRETROVIRAL THERAPY: A CASE BASED DISCUSSION AND REVIEW OF LITERATURE. INTERNATIONAL JOURNAL OF BURNS + TRAUMA. 2020?10(4):121?126. DOI:2160?2026/IJBT0116707",45,YR,A,F,Y,,,20200928,,MD,IN,IN,EFAVIRENZ.,Fanconi syndrome acquired;Femur fracture;Renal disorder;Renal failure;Sepsis,183211841,HO,,,183211841,1,201408,,,,183211841,1,HIV infection
18321318,183213181,1,I,,20200921,20200928,20200928,EXP,,CA-BAUSCH-BL-2020-027500,BAUSCH AND LOMB,,54,YR,,M,Y,,,20200928,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,183213181,OT,,,,,,,,,183213181,1,Bipolar disorder
18322389,183223891,1,I,2012,20200914,20200928,20200928,EXP,,AU-GLAXOSMITHKLINE-US2020GSK186145,GLAXOSMITHKLINE,"RAJAKARUNA GK, ITALIANO CM, JOHN M, NOLAN D. CHOREA ASSOCIATED WITH PERSISTENT LOW?LEVEL VIREMIA IN A PATIENT LIVING WITH HIV: A CASE REPORT. JOURNAL OF VIRUS ERADICATION. 2020?6(1):27?29",,,A,F,Y,,,20200928,,HP,AU,AU,EFAVIRENZ.,Behaviour disorder;Central nervous system inflammation;Cerebellar syndrome;Chorea;Confusional state;Disorientation;Dysarthria;Dysdiadochokinesis;Gait disturbance;HIV-associated neurocognitive disorder;Hypophagia;Loss of personal independence in daily activities;Magnetic resonance imaging brain abnormal;Meningitis viral;Meningoencephalitis viral;Parainfluenzae virus infection;Pathogen resistance;Rhinitis;Treatment noncompliance;Viral mutation identified,183223891,OT,,,183223891,2,2012,,,,183223891,1,HIV infection
18322906,183229061,1,I,,20200914,20200928,20200928,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-075418,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20200928,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction,183229061,OT,,,,,,,,,183229061,1,Product used for unknown indication
18322908,183229081,1,I,,20200914,20200928,20200928,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-075452,BRISTOL MYERS SQUIBB,,45,YR,,M,Y,,,20200928,,HP,CA,CA,EFAVIRENZ.,Multiple-drug resistance,183229081,OT,,,,,,,,,183229081,1,HIV infection
18322942,183229421,1,I,,20200914,20200928,20200928,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-075279,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20200928,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Off label use;Prescribed overdose,183229421,OT,,,,,,,,,183229421,1,HIV infection
18323227,183232271,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079912,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183232271,1,HIV infection
18323229,183232291,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079940,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183232291,1,HIV infection
18323235,183232351,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079925,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183232351,1,HIV infection
18323238,183232381,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079922,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183232381,1,HIV infection
18323239,183232391,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079924,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183232391,1,HIV infection
18323241,183232411,1,I,,20200921,20200928,20200928,EXP,,CA-BAUSCH-BL-2020-027470,BAUSCH AND LOMB,,54,YR,,M,Y,,,20200928,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,183232411,OT,,,,,,,,,183232411,1,Bipolar disorder
18323248,183232481,1,I,,20200921,20200928,20200928,EXP,,CA-BAUSCH-BL-2020-027502,BAUSCH AND LOMB,,54,YR,,M,Y,,,20200928,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,183232481,OT,,,,,,,,,183232481,1,Bipolar disorder
18323255,183232551,1,I,,20200921,20200928,20200928,EXP,,CA-BAUSCH-BL-2020-027467,BAUSCH AND LOMB,,54,YR,,M,Y,,,20200928,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,183232551,OT,,,,,,,,,183232551,1,Bipolar disorder
18323257,183232571,1,I,,20200921,20200928,20200928,EXP,,CA-BAUSCH-BL-2020-027468,BAUSCH AND LOMB,,,,,M,Y,,,20200928,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,183232571,OT,,,,,,,,,183232571,1,Product used for unknown indication
18323302,183233021,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079921,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233021,1,HIV infection
18323305,183233051,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079918,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233051,1,HIV infection
18323306,183233061,1,I,,20200921,20200928,20200928,EXP,,CA-BAUSCH-BL-2020-027469,BAUSCH AND LOMB,,54,YR,,M,Y,,,20200928,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,183233061,OT,,,,,,,,,183233061,1,Product used for unknown indication
18323307,183233071,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079919,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233071,1,HIV infection
18323309,183233091,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079923,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233091,1,HIV infection
18323311,183233111,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079915,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233111,1,HIV infection
18323313,183233131,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079913,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233131,1,HIV infection
18323323,183233231,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079920,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233231,1,HIV infection
18323338,183233381,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079916,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233381,1,HIV infection
18323340,183233401,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079917,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233401,1,HIV infection
18323343,183233431,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079914,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183233431,1,HIV infection
18323792,183237921,1,I,,20200914,20200928,20200928,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079526,BRISTOL MYERS SQUIBB,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ?ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020?1?9",33,YR,,M,Y,,,20200928,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,183237921,OT,,,,,,,,,183237921,1,Hepatitis B
18323804,183238041,1,I,,20200914,20200928,20200928,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079528,BRISTOL MYERS SQUIBB,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ?ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020?1?9",48,YR,,F,Y,,,20200928,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,183238041,OT,,,,,,,,,183238041,1,Hepatitis B
18324197,183241971,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079958,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183241971,1,HIV infection
18324198,183241981,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079959,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183241981,1,HIV infection
18324199,183241991,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079957,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183241991,1,HIV infection
18324200,183242001,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079943,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242001,1,HIV infection
18324204,183242041,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079935,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242041,1,HIV infection
18324206,183242061,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079948,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242061,1,HIV infection
18324208,183242081,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079953,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242081,1,HIV infection
18324209,183242091,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079947,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242091,1,HIV infection
18324211,183242111,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079946,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242111,1,HIV infection
18324212,183242121,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079934,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242121,1,HIV infection
18324214,183242141,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079933,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242141,1,HIV infection
18324216,183242161,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079950,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242161,1,HIV infection
18324222,183242221,1,I,,20200914,20200928,20200928,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-077120,BRISTOL MYERS SQUIBB,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ?ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020?1?9",39,YR,,M,Y,,,20200928,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,183242221,OT,,,,,,,,,183242221,1,HIV infection
18324224,183242241,1,I,,20200914,20200928,20200928,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079529,BRISTOL MYERS SQUIBB,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ?ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020?1?9",51,YR,,M,Y,,,20200928,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,183242241,OT,,,,,,,,,183242241,1,HIV infection
18324227,183242271,1,I,,20200914,20200928,20200928,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079530,BRISTOL MYERS SQUIBB,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ?ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020?1?9",46,YR,,M,Y,,,20200928,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,183242271,OT,,,,,,,,,183242271,1,HIV infection
18324244,183242441,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079930,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242441,1,HIV infection
18324245,183242451,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079952,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242451,1,HIV infection
18324250,183242501,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079926,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242501,1,HIV infection
18324253,183242531,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079951,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242531,1,HIV infection
18324255,183242551,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079956,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242551,1,HIV infection
18324258,183242581,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079941,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242581,1,HIV infection
18324278,183242781,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079955,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242781,1,HIV infection
18324280,183242801,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079938,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242801,1,HIV infection
18324282,183242821,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079932,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242821,1,HIV infection
18324283,183242831,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079961,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242831,1,HIV infection
18324284,183242841,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079954,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242841,1,HIV infection
18324286,183242861,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079960,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242861,1,HIV infection
18324288,183242881,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-076976,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242881,1,HIV infection
18324293,183242931,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079937,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242931,1,HIV infection
18324294,183242941,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079962,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242941,1,HIV infection
18324296,183242961,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079942,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242961,1,HIV infection
18324297,183242971,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079944,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183242971,1,HIV infection
18324298,183242981,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079927,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183242981,1,HIV infection
18324300,183243001,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079931,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183243001,1,HIV infection
18324304,183243041,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079929,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183243041,1,HIV infection
18324308,183243081,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079945,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183243081,1,HIV infection
18324317,183243171,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079949,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Rash,,,,,,,,,,,183243171,1,HIV infection
18324318,183243181,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079928,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183243181,1,HIV infection
18324320,183243201,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079936,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183243201,1,HIV infection
18324356,183243561,1,I,,20200914,20200929,20200929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079939,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200929,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,183243561,1,HIV infection
18325230,183252301,1,I,,20200924,20200928,20200928,EXP,,CA-ROCHE-2684970,ROCHE,,54,YR,,M,Y,,,20200929,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,183252301,OT,,,,,,,,,183252301,1,Bipolar disorder
18326533,183265331,1,I,,20200914,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079971,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930,,HP,US,US,EFAVIRENZ.,Gastrointestinal disorder,,,,,,,,,,,183265331,1,HIV infection
18326536,183265361,1,I,,20200914,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079963,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930,,HP,US,US,EFAVIRENZ.,Hypercholesterolaemia,,,,,,,,,,,183265361,1,HIV infection
18326538,183265381,1,I,,20200914,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079970,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930,,HP,US,US,EFAVIRENZ.,Gastrointestinal disorder,,,,,,,,,,,183265381,1,HIV infection
18326548,183265481,1,I,,20200914,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079972,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930,,HP,US,US,EFAVIRENZ.,Gastrointestinal disorder,,,,,,,,,,,183265481,1,HIV infection
18326550,183265501,1,I,,20200914,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079969,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930,,HP,US,US,EFAVIRENZ.,Gastrointestinal disorder,,,,,,,,,,,183265501,1,HIV infection
18326552,183265521,1,I,,20200914,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079968,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930,,HP,US,US,EFAVIRENZ.,Gastrointestinal disorder,,,,,,,,,,,183265521,1,HIV infection
18326557,183265571,1,I,,20200914,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079964,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930,,HP,US,US,EFAVIRENZ.,Hypercholesterolaemia,,,,,,,,,,,183265571,1,HIV infection
18326558,183265581,1,I,,20200914,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079967,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930,,HP,US,US,EFAVIRENZ.,Gastrointestinal disorder,,,,,,,,,,,183265581,1,HIV infection
18327790,183277901,1,I,,20200914,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079965,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930,,HP,US,US,EFAVIRENZ.,Drug interaction,,,,,,,,,,,183277901,1,HIV infection
18327791,183277911,1,I,,20200914,20200930,20200930,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-079966,BRISTOL MYERS SQUIBB,"LEGER P, CHIRWA S, TURNER M, RICHARDSON DM, BAKER P, LEONARD M, ET AL. PHARMACOGENETICS OF EFAVIRENZ DISCONTINUATION FOR REPORTED CENTRAL NERVOUS SYMPTOMS APPEARS TO DIFFER BY RACE. PHARMACOGENETICS AND GENOMNICS. 2016?26(10):473?80",,,,,Y,,,20200930,,HP,US,US,EFAVIRENZ.,Drug interaction,,,,,,,,,,,183277911,1,HIV infection
6049025,604902521,21,F,20060216,20200916,20060519,20200928,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13375589,BRISTOL MYERS SQUIBB,,25,YR,,F,Y,56,KG,20200928,,MD,FR,FR,SUSTIVA,Abortion induced;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,604902521,HO,,,604902521,1,20050513,20050908,,,604902521,1,HIV infection
6238093,62380932,2,F,20060718,20070222,20070213,20070305,EXP,,PL-JNJFOC-20070200442,JOHNSON AND JOHNSON,,33,YR,A,F,Y,71.67,KG,20070305,,MD,PL,PL,SUSTIVA,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome,62380932,HO,62380932,HP,,,,,,,62380932,1,HIV infection
6641856,66418561,1,I,,20080506,20080516,20080516,EXP,,FR-JNJFOC-20080500998,TIBOTEC,,53,YR,A,M,Y,,,20080516,,MD,FR,FR,EFAVIRENZ.,Pancytopenia,66418561,HO,66418561,HP,,,,,,,66418561,2,HIV infection
6927327,69273277,7,F,20050813,20200911,20090304,20200914,EXP,,FR-GILEAD-2009-0020444,GILEAD,,25,YR,A,F,Y,56,KG,20200914,,HP,FR,FR,SUSTIVA,Abortion induced;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,69273277,OT,,,69273277,1,20050523,20050908,,,69273277,1,HIV infection
7117171,711717114,14,F,,20200806,20090917,20200818,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-14780902,BRISTOL MYERS SQUIBB,"PFEFFER G, COTE HCF, MONTANER JS, LI CC, JITRATKOSOL M, MEZEI MM. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY. 2009?73(1):71?2",52,YR,,M,Y,,,20200818,,MD,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,711717114,OT,,,711717114,7,200802,,,,711717114,1,HIV infection
7152253,715225312,12,F,,20200107,20091019,20200806,EXP,,CA-PFIZER INC-2009279889,PFIZER,"PFEFFER, G.. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY. 2009?73 (1):71?72",52,YR,,M,Y,,,20200806,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,715225312,OT,,,,,,,,,715225312,1,HIV infection
7302622,730262232,32,F,,20200722,20100302,20200731,EXP,,CA-MERCK-0907CAN00093,MERCK,,52,YR,,M,Y,,,20200731,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,730262232,OT,,,730262232,7,200802,,,,730262232,1,HIV infection
7680832,76808325,5,F,,20200831,20101123,20200915,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15394901,BRISTOL MYERS SQUIBB,"LAKHI N, GOVIND A. IMPLANON FAILURE IN PATIENTS ON ANTIRETROVIRAL MEDICATION: THE IMPORTANCE OF DISCLOSURE. JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE. 2010?36(3):181?2",35,YR,,F,Y,,,20200915,,MD,US,US,SUSTIVA,Abortion induced;Drug interaction;Maternal exposure during pregnancy;Pregnancy with implant contraceptive,76808325,OT,,,,,,,,,76808325,1,HIV infection
8000228,80002281,1,I,20110419,20110607,20110621,20110621,EXP,,US-JNJFOC-20110410180,TIBOTEC,,42,YR,A,F,Y,62.6,KG,20110621,,MD,US,US,EFAVIRENZ.,Acute kidney injury;Lactic acidosis;Septic shock,80002281,DS,80002281,HP,80002281,1,20080911,20110302,,,80002281,1,HIV infection
8260766,826076614,14,F,2006,20200916,20111123,20200928,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-15921299,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20200928,,MD,FR,FR,SUSTIVA,Anencephaly;Brain herniation;Congenital hydrocephalus;Encephalocele;Foetal exposure during pregnancy;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,826076614,OT,,,826076614,1,20050513,20050908,,,826076614,1,Product used for unknown indication
8299420,82994202,2,F,,20200817,20111219,20200908,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-16291882,BRISTOL MYERS SQUIBB,"PASSOS L, TALHARI C, SANTOS M, RIBEIRO?RODRIGUES R, FERREIRA LCL, TALHARI S. HISTOPLASMOSIS?ASSOCIATED IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME. ANAIS BRASILEIROS DE DERMATOLOGIA. 2011?86 (4):168?72",27,YR,,M,Y,,,20200908,,HP,BR,BR,EFAVIRENZ.,No adverse event,,,,,82994202,1,200709,,,,82994202,1,HIV infection
9109906,91099063,3,F,2005,20200624,20130222,20200705,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-17408931,BRISTOL MYERS SQUIBB,,41,YR,,F,Y,,,20200705,,MD,PT,PT,EFAVIRENZ.,Drug intolerance;Drug resistance;Fatigue;Hepatic cirrhosis;Hypertension;Nausea;Vomiting,91099063,OT,,,91099063,1,2003,2006,,,91099063,1,Antiretroviral therapy
